Table S1. Guidelines for the Clinical Application of Novel Anti-cancer Drugs (2023 Edition)

Table of Contents

Tumor drug directory of each system	
Respiratory tumor drugs	
No.	**Drug Name**
1	Gefitinib
2	Erlotinib
3	Icotinib
4	Afatinib
5	Dacomitinib
6	Osimertinib
7	Almonertinib
8	Furmonertinib
9	Befotertinib
10	Crizotinib
11	Alectinib
12	Ceritinib
13	Ensartinib
14	Brigatinib
15	Lorlatinib
16	Iruplinalkib
17	Bevacizumab
18	Endostatin
19	Anlotinib
20	Everolimus
21	Pralsetinib
22	Selpercatinib
23	Savolitinib
24	Glumetinib
25	Dabrafenib
26	Trametinib
27	Entrectinib
28	Mobocertinib
29	Nivolumab
30	Pembrolizumab
31	Durvalumab
32	Atezolizumab
33	Camrelizumab
34	Tislelizumab
35	Sintilimab
36	Ipilimumab
37	Sugemalimab

38	Toripalimab
39	Serplulimab
40	Penpulimab
41	Adebrelimab

Drugs for digestive system tumors	
No.	**Drug Name**
1	Sorafenib
2	Regorafenib
3	Lenvatinib
4	Donafenib
5	Atezolizumab
6	Sintilimab
7	Camrelizumab
8	Tislelizumab
9	Pembrolizumab
10	Toripalimab
11	Trastuzumab
12	Apatinib
13	Nivolumab
14	Disitamab Vedotin
15	Ramucirumab
16	Imatinib
17	Sunitinib
18	Avapritinib
19	Ripretinib
20	Everolimus
21	Surufatinib
22	Bevacizumab
23	Cetuximab
24	Fruquintinib
25	Envafolimab
26	Serplulimab
27	Pucotenlimab
28	Pemigatinib
29	Nimotuzumab

Hematologic tumor drugs	
No.	**Drug Name**
1	Imatinib
2	Dasatinib
3	Nilotinib
4	Olverembatinib
5	Flumatinib
6	Ibrutinib

7	Zanubrutinib
8	Orelabrutinib
9	Bortezomib
10	Carfilzomib
11	Ixazomib
12	Thalidomide
13	Lenalidomide
14	Pomalidomide
15	Daratumumab
16	Selinexor
17	Gilteritinib
18	Venetoclax
19	Ivosidenib
20	Blinatumomab
21	Sintilimab
22	Camrelizumab
23	Tislelizumab
24	Penpulimab
25	Zimberelimab
26	Rituximab
27	Ripertamab
28	Zuberitamab
29	Obinutuzumab
30	Polatuzumab Vedotin
31	Brentuximab Vedotin
32	Inotuzumab Ozogamicin
33	Chidamide
34	Linperlisib
35	Duvelisib
36	Ruxolitinib
37	Mogamulizumab
38	Siltuximab
39	Equecabtagene Autoleucel
40	Axicabtagene Ciloleucel
41	Relmacabtagene Autoleucel

Drugs for urinary system tumors	
No.	**Drug Name**
1	Sorafenib
2	Sunitinib
3	Pazopanib
4	Axitinib
5	Everolimus
6	Tislelizumab

7	Toripalimab
8	Disitamab Vedotin
9	Abiraterone
10	Apalutamide
11	Enzalutamide
12	Darolutamide
13	Rezvilutamide
14	Olaparib
15	Lenvatinib
16	Nivolumab
17	Pembrolizumab

Breast cancer drugs	
No.	**Drug Name**
1	Trastuzumab
2	Inetetamab
3	Pertuzumab
4	Lapatinib
5	Pyrotinib
6	Neratinib
7	Trastuzumab Emtansine
8	Trastuzumab Deruxtecan
9	Palbociclib
10	Abemaciclib
11	Dalpiciclib
12	Ribociclib
13	Chidamide
14	Everolimus
15	Sacituzumab Govitecan
16	Pembrolizumab

Drugs for skin tumor	
No.	**Drug Name**
1	Vemurafenib
2	Dabrafenib
3	Trametinib
4	Pembrolizumab
5	Toripalimab
6	Pucotenlimab
7	Sonidegib
8	Imatinib

Drugs for bone and soft tissue tumors	
No.	**Drug Name**
1	Everolimus
2	Denosumab

3	Anlotinib
Drugs for head and neck tumors	
No.	**Drug Name**
1	Nimotuzumab
2	Toripalimab
3	Camrelizumab
4	Sorafenib
5	Lenvatinib
6	Anlotinib
7	Nivolumab
8	Cetuximab
9	Pembrolizumab
10	Tislelizumab
11	Pralsetinib
Reproductive system tumor drugs	
No.	**Drug Name**
1	Olaparib
2	Niraparib
3	Fluzoparib
4	Pamiparib
5	Bevacizumab
6	Candonilimab
Drugs for Pansolid tumor	
No.	**Drug Name**
1	Larotrectinib
2	Entrectinib
3	Envafolimab
4	Tislelizumab
5	Serplulimab
6	Pucotenlimab

Table S2. Information on 311 Indications and Pivotal Clinical Trials of Novel Anti-cancer Drugs Approved by the National Medical Products Administration as of November 30, 2024

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
1	1	Gefitinib	1	2004	For use in locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitive mutations in the epidermal growth factor receptor (EGFR) gene	Single	Masahiro Fukuoka[1]	2011	NCT00322452	Phase III	Randomized	None	2 arms
2	2	Erlotinib	1	2006	Single-agent therapy is suitable for locally advanced or metastatic NSCLC that has progressed after at least one prior chemotherapy regimen	Multiple	Frances A. Shepherd[2]	2005	not available	Phase III	Randomized	Double-blind	2 arms
3	2	Erlotinib	2	2006	Single-agent therapy can be used for maintenance treatment in patients with locally advanced or metastatic NSCLC who are stable after four cycles of first-line platinum-based chemotherapy	Multiple	Federico Cappuzzo[3]	2010	NCT00556712	Phase III	Randomized	Double-blind	2 arms
4	2	Erlotinib	3	2017	First-line treatment for patients with locally advanced or metastatic NSCLC with sensitive mutations in the EGFR gene	Multiple	Y.-L. Wu[4]	2015	NCT01342965	Phase III	Randomized	None	2 arms
5	3	Icotinib	1	2011	First-line treatment for advanced or metastatic NSCLC with sensitive EGFR mutations, or for those previously treated with platinum-based chemotherapy	Multiple	Yuankai Shi[5]	2013	NCT01040780	Phase III	Randomized	Double-blind	2 arms
6	3	Icotinib	2	2021	Single-agent therapy is suitable for adjuvant treatment of stage II-IIIA NSCLC with sensitive EGFR mutations	Multiple	Jianxing He[6]	2021	NCT02448797	Phase III	Randomized	None	2 arms
7	4	Afatinib	1	2017	Advanced NSCLC with sensitive EGFR mutations, untreated with EGFR-TKIs(Tyrosine Kinase Inhibitors)	Multiple	Yi-Long Wu[7]	2014	NCT01121393	Phase III	Randomized	None	2 arms
8	4	Afatinib	2	2017	Advanced squamous NSCLC progressing during/after platinum chemotherapy	Multiple	Jean-Charles Soria[8]	2015	NCT01523587	Phase III	Randomized	None	2 arms
9	5	Dacomitinib	1	2019	Monotherapy for first-line treatment of advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation	Single	Yi-Long Wu[9]	2017	NCT01774721	Phase III	Randomized	None	2 arms
10	6	Osimertinib	1	2017	Indicated for adults with advanced NSCLC harboring EGFR T790M mutation, progressing after EGFR-TKIs treatment	Multiple	Min Hu[10]	2018	NCT02442349	Phase II	Nonrandomized	None	1 arm
11	6	Osimertinib	2	2019	First-line treatment for adults with advanced NSCLC harboring EGFR exon 19 deletion or exon 21 (L858R) mutation	Multiple	J.-C. Soria[11]	2018	NCT02296125	Phase III	Randomized	Double-blind	2 arms
12	6	Osimertinib	3	2021	Treatment for NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations post-surgery, with or without adjuvant chemotherapy	Multiple	Yi-Long Wu[12]	2020	NCT02511106	Phase III	Randomized	Double-blind	2 arms
13	7	Almonertinib	1	2020	Treatment for advanced NSCLC with EGFR T790M mutation, progressing after EGFR-TKIs therapy	Multiple	Shun Lu[13]	2021	NCT02981108	Phase II	Nonrandomized	None	1 arm
14	7	Almonertinib	2	2021	First-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 (L858R) mutation	Multiple	Shun Lu[14]	2022	NCT03849768	Phase III	Randomized	Double-blind	2 arms
15	8	Furmonertinib	1	2021	Treatment for advanced NSCLC with EGFR T790M mutation, progressing after EGFR-TKIs	Multiple	Yuankai Shi[15]	2021	NCT03452592	Phase IIb	Nonrandomized	None	1 arm
16	8	Furmonertinib	2	2022	First-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R mutations	Multiple	Yuankai Shi[16]	2022	NCT03787992	Phase III	Randomized	Double-blind	2 arms
17	9	Befotertinib	1	2023	For treating adults with advanced NSCLC harboring EGFR T790M mutation who have progressed on or after EGFR-TKIs therapy	Single	Shun Lu[17]	2022	NCT03861156	Phase II	Nonrandomized	None	1 arm
18	10	Crizotinib	1	2013	Treatment for ALK-positive advanced NSCLC	Multiple	Alice T. Shaw[18]	2013	NCT00932893	Phase III	Randomized	None	2 arms
19	10	Crizotinib	2	2016	Treatment for advanced NSCLC with ROS1 positivity	Multiple	Yi-Long Wu[19]	2018	NCT01945021	Phase II	Nonrandomized	None	1 arm
20	11	Alectinib	1	2018	For the treatment of patients with locally advanced or metastatic NSCLC who are ALK-positive	Single	Solange Peters[20]	2017	NCT02075840	Phase III	Randomized	None	2 arms
21	12	Ceritinib	1	2018	For ALK-positive advanced NSCLC patients progressing or intolerant to crizotinib	Multiple	Alice T Shaw[21]	2017	NCT01828112	Phase III	Randomized	None	2 arms
22	12	Ceritinib	2	2020	Monotherapy for ALK-positive advanced or metastatic NSCLC	Multiple	Jean-Charles Soria[22]	2017	NCT01828099	Phase III	Randomized	None	2 arms
23	13	Ensartinib	1	2020	For ALK-positive advanced NSCLC patients progressing or intolerant to crizotinib	Multiple	Yunpeng Yang[23]	2019	NCT03215693	Phase II	Nonrandomized	None	1 arm
24	13	Ensartinib	2	2022	Monotherapy for ALK-positive advanced or metastatic NSCLC	Multiple	Leora Horn[24]	2021	NCT02767804	Phase III	Randomized	None	2 arms

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
25	14	Brigatinib	1	2022	For the treatment of patients with locally advanced or metastatic NSCLC who are ALK-positive	Single	D. Ross Camidge[25,26]	2018/2020	NCT02737501	Phase III	Randomized	None	2 arms
26	15	Lorlatinib	1	2022	For ALK-positive advanced NSCLC previously treated with ALK TKIs	Multiple	Shun Lu[27]	2022	NCT03909971	Phase IIa	Nonrandomized	None	≥3 arms
27	15	Lorlatinib	2	2022	Monotherapy for ALK-positive advanced or metastatic NSCLC	Multiple	Alice T. Shaw[28]	2020	NCT03052608	Phase III	Randomized	None	2 arms
28	16	Iruplinalkib	1	2023	Treatment for ALK-positive advanced NSCLC progressing or intolerant to crizotinib	Multiple	Yuankai Shi[29]	2023	NCT04641754	Phase II	Nonrandomized	None	1 arm
29	16	Iruplinalkib	2	2024	Monotherapy is suitable for the treatment of ALK-positive advanced or metastatic NSCLC	Multiple	Yuankai Shi[30]	2024	NCT04632758	Phase III	Randomized	None	2 arms
30	17	Bevacizumab	1	2010	Bevacizumab with fluoropyrimidine-based chemotherapy is suitable for metastatic colorectal cancer	Multiple	J Cassidy[31]	2011	NCT00069095	Phase III	Randomized	Double-blind	≥3 arms
31	17	Bevacizumab	2	2015	Bevacizumab with platinum-based chemotherapy for first-line treatment of advanced, metastatic, or recurrent non-squamous NSCLC	Multiple	Alan Sandler[32]	2007	NCT00021060	Phase III	Randomized	None	2 arms
32	17	Bevacizumab	3	2020	Treatment for adult patients with recurrent glioblastoma	Multiple	Wolfgang Wick[33]	2017	NCT01290939	Phase III	Randomized	None	2 arms
33	17	Bevacizumab	4	2021	Combination atezolizumab treatment for patients with previously untreated, unresectable hepatocellular carcinoma	Multiple	Richard S. Finn[34]	2020	NCT03434379	Phase III	Randomized	None	2 arms
34	17	Bevacizumab	5	2021	Bevacizumab combined with carboplatin and paclitaxel for first-line treatment of stage III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer after initial surgery	Multiple	Robert A. Burger[35]	2011	NCT00262847	Phase III	Randomized	Double-blind	≥3 arms
35	17	Bevacizumab	6	2021	Bevacizumab combined with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.	Multiple	Krishnansu S. Tewari[36]	2014	NCT00803062	Phase III	Randomized	None	≥3 arms
36	18	Endostatin	1	2005	Combined with vinorelbine/cisplatin chemotherapy regimen for the treatment of newly diagnosed or relapsed stage III–IV NSCLC patients	Single	Not available	Not available	Not available	Not available	Not available	Not available	Not available
37	19	Anlotinib	1	2018	The drug is suitable for advanced NSCLC patients progressing after at least two prior chemotherapies. For EGFR mutations or ALK positivity, targeted therapy should have been used before	Multiple	Baohui Han[37]	2018	NCT02388919	Phase III	Randomized	Double-blind	2 arms
38	19	Anlotinib	2	2019	For advanced soft tissue sarcomas (alveolar soft part sarcoma, clear cell sarcoma) progressing or relapsing after one anthracycline-containing chemotherapy	Multiple	Yihebali Chi[38]	2018	NCT02449343	Phase III	Randomized	Double-blind	2 arms
39	19	Anlotinib	3	2019	Single-agent therapy for small cell lung cancer progressing or relapsing after two prior chemotherapies	Multiple	Ying Cheng[39]	2021	NCT03059797	Phase II	Randomized	Double-blind	2 arms
40	19	Anlotinib	4	2021	For the treatment of patients with symptomatic or progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma	Multiple	Dapeng Li[40]	2021	NCT02586350	Phase II	Randomized	Double-blind	2 arms
41	19	Anlotinib	5	2022	For patients with progressive, locally advanced, or metastatic radioiodine-refractory differentiated thyroid cancer	Multiple	Yihebali Chi[41]	2020	NCT02586337	Phase II	Randomized	Double-blind	2 arms
42	20	Everolimus	1	2013	Advanced renal cell carcinoma that has failed prior treatment with sunitinib or sorafenib, with data primarily based on clear cell renal carcinoma	Multiple	Robert J. Motzer[42]	2010	NCT00410124	Phase III	Randomized	Double-blind	2 arms
43	20	Everolimus	2	2014	Adult patients with unresectable, locally advanced or metastatic, well-differentiated (moderately or well-differentiated) advanced pancreatic neuroendocrine tumors	Multiple	James C. Yao[43]	2011	NCT00510068	Phase III	Randomized	Double-blind	2 arms
44	20	Everolimus	3	2014	Adult and pediatric patients with tuberous sclerosis complex-associated subependymal giant cell astrocytoma requiring therapeutic intervention but not amenable to surgical resection	Multiple	David Neal Franz[44]	2013	NCT00789828	Phase III	Randomized	Double-blind	2 arms
45	20	Everolimus	4	2016	For the treatment of adult patients with tuberous sclerosis complex-associated renal angiomyolipomas that do not require immediate surgical intervention	Multiple	John J Bissler[45]	2013	NCT00790400	Phase III	Randomized	Double-blind	2 arms
46	20	Everolimus	5	2018	Adult patients with locally advanced or metastatic, well-differentiated, progressive, non-functional gastroenteropancreatic or lung neuroendocrine tumors (NETs) that cannot be surgically resected	Multiple	James C Yao[46]	2015	NCT01524783	Phase III	Randomized	Double-blind	2 arms
47	20	Everolimus	6	2022	Everolimus with exemestane for postmenopausal women with HR-positive, HER2-negative advanced breast cancer after letrozole or anastrozole failure	Multiple	Denise A. Yardley[47] & M. Piccart[48]	2013/2014	NCT00863655	Phase III	Randomized	Double-blind	2 arms

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
48	21	Pralsetinib	1	2021	Treatment for adult patients with locally advanced or metastatic NSCLC with RET gene fusion positive	Multiple	Justin F Gainor[49]	2021	NCT03037385	PhaseI/II	Nonrandomized	None	1 arm
49	21	Pralsetinib	2	2022	For adults and pediatric patients ≥12 years with advanced/metastatic RET-mutant MTC or RET fusion-positive thyroid cancer, requiring systemic therapy and refractory to radioactive iodine (if applicable)	Multiple	Vivek Subbiah[50]	2021	NCT03037385	PhaseI/II	Nonrandomized	None	1 arm
50	22	Selpercatinib	1	2022	For the treatment of adult patients with locally advanced or metastatic RET-positive NSCLC	Multiple	A. Drilon[51]	2020	NCT03157128	PhaseI/II	Nonrandomized	None	1 arm
51	22	Selpercatinib	2	2022	For adults and pediatric patients ≥12 years with advanced/metastatic RET-mutant MTC or RET fusion-positive thyroid cancer, requiring systemic therapy and refractory to radioactive iodine (if applicable)	Multiple	L.J. Wirth[52]	2020	NCT03157128	PhaseI/II	Nonrandomized	None	1 arm
52	23	Savolitinib	1	2021	For adults with advanced metastatic NSCLC with MET exon 14 mutation who progressed or are intolerant to platinum-based chemotherapy	Single	Shun Lu[53]	2021	NCT02897479	Phase II	Nonrandomized	None	1 arm
53	24	Glumetinib	1	2023	For the treatment of locally advanced or metastatic NSCLC with MET exon 14 skipping mutation	Single	Yongfeng Yu[54]	2023	NCT04270591	Phase Ib/II	Nonrandomized	None	1 arm
54	25	Dabrafenib	1	2019	Dabrafenib combined with trametinib is used to treat patients with unresectable or metastatic melanoma with BRAF V600E/K mutations	Multiple	Georgina V Long[55,56]	2014/2015	NCT01584648	Phase III	Randomized	Double-blind	2 arms
55	25	Dabrafenib	2	2020/3/6	Dabrafenib combined with trametinib is suitable for adjuvant treatment in patients with stage III melanoma with BRAF V600E/K mutations after complete resection	Multiple	G.V. Long[57]	2017	NCT01682083	Phase III	Randomized	Double-blind	2 arms
56	25	Dabrafenib	3	2022	Dabrafenib combined with trametinib is used to treat patients with metastatic NSCLC with BRAF V600 mutations	Multiple	David Planchard[58–60]	2016/2016/2017	NCT01336634	Phase II	Nonrandomized	None	1 arm
57	26	Trametinib	1	2019	Trametinib combined with dabrafenib is used to treat patients with unresectable or metastatic melanoma with BRAF V600E/K mutations	Multiple	Georgina V Long[55,56]	2014/2015	NCT01584648	Phase III	Randomized	Double-blind	2 arms
58	26	Trametinib	2	2020	Trametinib combined with dabrafenib is suitable for adjuvant treatment in patients with completely resected stage III melanoma with BRAF V600E/K mutations	Multiple	G.V. Long[57]	2017	NCT01682083	Phase III	Randomized	Double-blind	2 arms
59	26	Trametinib	3	2022	Trametinib combined with dabrafenib is used to treat patients with metastatic NSCLC with BRAF V600 mutations	Multiple	David Planchard[58–60]	2016/2016/2017	NCT01336634	Phase II	Nonrandomized	None	1 arm
60	27	Entrectinib	1	2022	Indicated for adults and pediatric patients ≥12 years with solid tumors meeting the following criteria: Diagnosed with NTRK gene fusions (excluding acquired resistance mutations); Locally advanced, metastatic, or surgically resectable with severe complications; No satisfactory alternative treatments or failure of prior therapies.	Multiple	Robert C Doebele[61]	2019	NCT02097810 &NCT02568267	PhaseI & II	Nonrandomized	None	1 arm
61	27	Entrectinib	2	2022	Indicated for adult patients with locally advanced or metastatic ROS1-positive NSCLC	Multiple	Alexander Drilon[62]	2019	NCT02097810 &NCT02568267	PhaseI & II	Nonrandomized	None	1 arm
62	27	Entrectinib	3	2024	Indicated for adults and pediatric patients ≥1 month of age with solid tumors meeting the following criteria: Diagnosed with NTRK gene fusions (excluding acquired resistance mutations); Locally advanced, metastatic, or surgically resectable with severe complications; No satisfactory alternative treatments or failure of prior therapies.	Multiple	Ami V. Desai[63]	2022	NCT02650401 &NCT04589845	PhaseI/II & II	Nonrandomized	None	1 arm
63	28	Mobocertinib	1	2023	For adults with advanced NSCLC harboring EGFR exon 20 insertion mutation who progressed during or after platinum-based chemotherapy	Single	Caicun Zhou[64]	2021	NCT02716116	PhaseI & II	Nonrandomized	None	1 arm
64	29	Nivolumab	1	2018	Indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC that is EGFR mutation-negative and ALK-negative, who have experienced disease progression or intolerance after prior platinum-based chemotherapy	Multiple	Yi-Long Wu[65]	2019	NCT02613507	Phase III	Randomized	None	2 arms
65	29	Nivolumab	2	2019	Indicated as monotherapy for recurrent or metastatic SCCHN patients with PD-L1-expressing tumors (≥1%) and disease progression on or after platinum-based therapy	Multiple	Robert L. Ferris[66,67]	2016/2018	NCT02105636	Phase III	Randomized	None	2 arms
66	29	Nivolumab	3	2020	Patients with advanced or recurrent gastric or gastroesophageal junction adenocarcinoma who have received two or more prior systemic treatment regimens	Multiple	Yoon-Koo Kang[68] & Li-Tzong Chen[69]	2017/2020	NCT02267343	Phase III	Randomized	Double-blind	2 arms

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
67	29	Nivolumab	4	2021	Nivolumab combined with ipilimumab for adult patients with unresectable, previously untreated non-epithelioid malignant pleural mesothelioma	Multiple	Paul Baas[70]	2021	NCT02899299	Phase III	Randomized	None	≥3 arms
68	29	Nivolumab	5	2021	Nivolumab with fluoropyrimidine and platinum chemotherapy is for first-line treatment of advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma	Multiple	Yelena Y Janjigian[71]	2021	NCT02872116	Phase III	Randomized	None	≥3 arms
69	29	Nivolumab	6	2022	Nivolumab combined with fluoropyrimidine and platinum-based chemotherapy is suitable for first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma	Multiple	Y. Doki[72]	2022	NCT03143153	Phase III	Randomized	None	≥3 arms
70	29	Nivolumab	7	2022	Adjuvant treatment for patients with esophageal or gastroesophageal junction cancer who have residual pathology after neoadjuvant chemoradiotherapy and complete surgical resection	Multiple	R.J. Kelly[73]	2021	NCT02743494	Phase III	Randomized	Double-blind	2 arms
71	29	Nivolumab	8	2023	Nivolumab with platinum-based chemotherapy is for neoadjuvant treatment of resectable NSCLC (tumor ≥4 cm or lymph node positive) in adults	Multiple	P.M. Forde[74]	2022	NCT02998528	Phase III	Randomized	None	2 arms
72	29	Nivolumab	9	2023	For adjuvant treatment of patients with urothelial carcinoma at high risk of recurrence after radical cystectomy	Multiple	D.F. Bajorin[75]	2021	NCT02632409	Phase III	Randomized	Double-blind	2 arms
73	29	Nivolumab	10	2024	For first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)	Multiple	T. Andre[76]	2024	NCT04008030	Phase III	Randomized	None	2 arms
74	29	Nivolumab	11	2024	Nivolumab combined with cisplatin and gemcitabine for first-line treatment in adult patients with unresectable or metastatic urothelial carcinoma	Multiple	M.S. van der Heijden[77]	2023	NCT03036098	Phase III	Randomized	None	2 arms
75	30	Pembrolizumab	1	2018	For the treatment of unresectable or metastatic melanoma after failure of first-line therapy	Multiple	Lu Si[78]	2019	NCT02821000	Phaselb	Nonrandomized	None	1 arm
76	30	Pembrolizumab	2	2019	Pembrolizumab with pemetrexed and platinum chemotherapy is for first-line treatment of metastatic non-squamous NSCLC with EGFR and ALK-negative mutations	Multiple	L. Gandhi[79]	2018	NCT02578680	Phase III	Randomized	Double-blind	2 arms
77	30	Pembrolizumab	3	2019	Pembrolizumab is indicated as first-line monotherapy for EGFR-negative, ALK-negative, locally advanced or metastatic NSCLC with PD-L1 ≥1%, as approved by the National Medical Products Administration	Multiple	Tony S K Mok[80]	2019	NCT02220894	Phase III	Randomized	None	2 arms
78	30	Pembrolizumab	4	2019	Pembrolizumab combined with carboplatin and paclitaxel is suitable for first-line treatment of patients with metastatic squamous NSCLC	Multiple	L. Paz-Ares[81]	2018	NCT02775435	Phase III	Randomized	Double-blind	2 arms
79	30	Pembrolizumab	5	2020	Pembrolizumab monotherapy is for advanced or metastatic esophageal squamous cell carcinoma with PD-L1 CPS ≥10 in patients who failed first-line treatment, as approved by the National Medical Products Administration	Multiple	Takashi Kojima[82]	2020	NCT02564263	Phase III	Randomized	None	2 arms
80	30	Pembrolizumab	6	2020	Pembrolizumab monotherapy is for first-line treatment of metastatic or unresectable recurrent HNSCC with PD-L1 CPS ≥20, as assessed by a validated test	Multiple	Barbara Burtness[83]	2019	NCT02358031	Phase III	Randomized	None	≥3 arms
81	30	Pembrolizumab	7	2021	Pembrolizumab monotherapy is for first-line treatment of unresectable or metastatic MSI-H or dMMR CRC with wild-type KRAS, NRAS, and BRAF genes	Multiple	T. André[84]	2020	NCT02563002	Phase III	Randomized	None	2 arms
82	30	Pembrolizumab	8	2021	Pembrolizumab combined with platinum-based and fluoropyrimidine chemotherapy for first-line treatment of locally advanced unresectable or metastatic esophageal/gastroesophageal junction cancer	Multiple	Jong-Mu Sun[85]	2021	NCT03189719	Phase III	Randomized	Double-blind	2 arms
83	30	Pembrolizumab	9	2022	Pembrolizumab monotherapy for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib or chemotherapy containing oxaliplatin	Multiple	Shukui Qin[86]	2022	NCT03062358	Phase III	Randomized	Double-blind	2 arms
84	30	Pembrolizumab	10	2022	Pembrolizumab combined with chemotherapy as neoadjuvant treatment, followed by pembrolizumab monotherapy as adjuvant treatment for early high-risk PD-L1-positive (CPS ≥20) triple-negative breast cancer (TNBC)	Multiple	P. Schmid[87,88]	2020/2022	NCT03036488	Phase III	Randomized	Double-blind	2 arms
85	30	Pembrolizumab	11	2023	Monotherapy for adult patients with advanced unresectable or metastatic solid tumors with high microsatellite instability (MSI-H) or defective mismatch repair (dMMR), including colorectal cancer progressing after fluoropyrimidines, oxaliplatin, and irinotecan, and other solid tumors with no satisfactory treatment options	Multiple	Dung T. Le[89] & Aurelien Marabelle[90]	2020/2020	NCT02460198 &NCT02628067	Phase II	Nonrandomized	None	1 arm

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
86	30	Pembrolizumab	12	2023	Pembrolizumab with fluoropyrimidine and platinum-based chemotherapy for first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric/gastroesophageal junction adenocarcinoma	Multiple	Sun Young Rha[91]	2023	NCT03675737	Phase III	Randomized	Double-blind	2 arms
87	30	Pembrolizumab	13	2024	Pembrolizumab combined with gemcitabine and cisplatin for first-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC)	Multiple	Robin Kate Kelley[92]	2023	NCT04003636	Phase III	Randomized	Double-blind	2 arms
88	30	Pembrolizumab	14	2024	Pembrolizumab with trastuzumab, fluoropyrimidine, and platinum-based chemotherapy for first-line treatment of HER2-positive gastric/gastroesophageal junction adenocarcinoma with PD-L1 expression (CPS ≥1)	Multiple	Yelena Y. Janjigian[93]	2024	NCT03615326	Phase III	Randomized	Double-blind	2 arms
89	31	Durvalumab	1	2019	Treatment for unresectable stage III NSCLC patients without progression after platinum-based chemotherapy and concurrent radiotherapy	Multiple	S.J. Antonia[94]	2017	NCT02125461	Phase III	Randomized	Double-blind	2 arms
90	31	Durvalumab	2	2021	Duvaliumab combined with etoposide and carboplatin or cisplatin as first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC)	Multiple	Luis Paz-Ares[95]	2019	NCT03043872	Phase III	Randomized	None	≥3 arms
91	31	Durvalumab	3	2023	Durvalumab combined with gemcitabine and cisplatin for the first-line treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC)	Multiple	Do-Youn Oh[96]	2022	NCT03875235	Phase III	Randomized	Double-blind	2 arms
92	32	Atezolizumab	1	2020	Atezolizumab combined with carboplatin and etoposide for first-line treatment of ES-SCLC patients	Multiple	L. Horn[97]	2018	NCT02763579	Phase III	Randomized	Double-blind	2 arms
93	32	Atezolizumab	2	2020	Atezolizumab combined with bevacizumab treatment for patients with previously untreated, unresectable hepatocellular carcinoma	Multiple	Richard S. Finn[98]	2020	NCT03434379	Phase III	Randomized	None	2 arms
94	32	Atezolizumab	3	2021	First-line monotherapy for metastatic EGFR- and ALK-negative NSCLC, with PD-L1 positive in ≥50% of tumor cells (TC≥50%) or immune cells covering ≥10% of the tumor (IC≥10%)	Multiple	Roy S. Herbst[99]	2020	NCT02409342	Phase III	Randomized	None	2 arms
95	32	Atezolizumab	4	2021	Atezolizumab with pemetrexed and platinum-based chemotherapy for first-line treatment of metastatic EGFR- and ALK-negative non-squamous NSCLC	Multiple	Makoto Nishio[100]	2020	NCT02657434	Phase III	Randomized	None	2 arms
96	32	Atezolizumab	5	2022	Atezolizumab monotherapy for adjuvant treatment of stage II-IIIA NSCLC with PD-L1 TC ≥1% after surgery and platinum-based chemotherapy	Multiple	Enriqueta Felip[101]	2021	NCT02486718	Phase III	Randomized	None	2 arms
97	33	Camrelizumab	1	2019	Treatment of patients with relapsed or refractory classical Hodgkin lymphoma who have received at least second-line systemic chemotherapy with a single agent	Multiple	Yuqin Song[102]	2019	NCT03155425	Phase II	Nonrandomized	None	1 arm
98	33	Camrelizumab	2	2020	For the treatment of advanced hepatocellular carcinoma patients who have previously received sorafenib treatment and/or systemic chemotherapy containing oxaliplatin	Multiple	Shukui Qin[103]	2020	NCT02989922	Phase II	Randomized	None	2 arms
99	33	Camrelizumab	3	2020	Monotherapy for the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma who have experienced disease progression or intolerance to prior first-line chemotherapy	Multiple	Jing Huang[104]	2020	NCT03099382	Phase III	Randomized	None	2 arms
100	33	Camrelizumab	4	2020	Camrelizumab combined with pemetrexed and carboplatin is suitable for first-line treatment of EGFR-negative, ALK-negative, locally advanced or metastatic non-squamous NSCLC that is not amenable to surgery	Multiple	Caicun Zhou[105]	2020	NCT03134872	Phase III	Randomized	None	2 arms
101	33	Camrelizumab	5	2021	For the treatment of advanced nasopharyngeal carcinoma patients who have experienced disease progression or intolerance after second-line or above chemotherapy	Multiple	Yunpeng Yang[106]	2021	NCT03558191	Phase II	Nonrandomized	None	1 arm
102	33	Camrelizumab	6	2021	Camrelizumab combined with cisplatin and gemcitabine for first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma	Multiple	Yunpeng Yang[107]	2021	NCT03707509	Phase III	Randomized	Double-blind	2 arms
103	33	Camrelizumab	7	2021	Camrelizumab combined with paclitaxel and carboplatin is a first-line treatment for locally advanced or metastatic squamous NSCLC	Multiple	Shengxiang Ren[108]	2021	NCT03668496	Phase III	Randomized	Double-blind	2 arms
104	33	Camrelizumab	8	2021	Camrelizumab combined with paclitaxel and cisplatin for first-line treatment of patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma	Multiple	Huiyan Luo[109]	2021	NCT03691090	Phase III	Randomized	Double-blind	2 arms

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
105	33	Camrelizumab	9	2023	Camrelizumab combined with apatinib mesylate for first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma	Multiple	Shukui Qin[110]	2023	NCT03764293	Phase III	Randomized	None	2 arms
106	34	Tislelizumab	1	2019	For the treatment of relapsed or refractory classical Hodgkin lymphoma in patients who have received at least second-line systemic chemotherapy	Multiple	Yuqin Song[111]	2019	NCT03209973	Phase II	Nonrandomized	None	1 arm
107	34	Tislelizumab	2	2020	Treatment for locally advanced or metastatic urothelial carcinoma with high PD-L1 expression after platinum-based chemotherapy failure or pr[1]ogression within 12 months of neoadjuvant/adjuvant chemotherapy	Multiple	Dingwei Ye[112]	2020	NCT04004221	Phase II	Nonrandomized	None	1 arm
108	34	Tislelizumab	3	2021	Tislelizumab combined with paclitaxel and carboplatin is a first-line treatment for unresectable locally advanced or metastatic squamous NSCLC	Multiple	Jie Wang[113]	2021	NCT03594747	Phase III	Randomized	None	≥3 arms
109	34	Tislelizumab	4	2021	Tislelizumab with pemetrexed and platinum is a first-line treatment for EGFR-negative, ALK-negative, unresectable advanced or metastatic non-squamous NSCLC	Multiple	Shun Lu[114]	2021	NCT03663205	Phase III	Randomized	None	2 arms
110	34	Tislelizumab	5	2021	Indicated for the treatment of hepatocellular carcinoma in patients who have received at least one systemic therapy	Multiple	Zhenggang Ren[115]	2022	NCT03419897	Phase II	Nonrandomized	None	1 arm
111	34	Tislelizumab	6	2021	Monotherapy is indicated for adults with EGFR and ALK-negative, platinum-treated, locally advanced or metastatic NSCLC (non-squamous or squamous) with disease progression or intolerance	Multiple	Caicun Zhou[116]	2022	NCT03358875	Phase III	Randomized	None	2 arms
112	34	Tislelizumab	7	2022	For adult patients with unresectable or metastatic advanced solid tumors, including MSI-H or dMMR, with progression after treatment with fluoropyrimidines, oxaliplatin, and irinotecan for colorectal cancer, or other advanced solid tumors with no satisfactory treatment options	Multiple	Jian Li[117]	2024	NCT03736889	Phase II	Nonrandomized	None	1 arm
113	34	Tislelizumab	8	2022	For the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma who have progressed or are intolerant to first-line standard chemotherapy	Multiple	Lin Shen[118]	2022	NCT03430843	Phase III	Randomized	None	2 arms
114	34	Tislelizumab	9	2022	Tislelizumab combined with gemcitabine and cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma	Multiple	Yunpeng Yang[119]	2023	NCT03924986	Phase III	Randomized	Double-blind	2 arms
115	34	Tislelizumab	10	2023	Tislelizumab combined with fluoropyrimidine and platinum-based chemotherapy for the first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression	Multiple	Miao-Zhen Qiu[120]	2024	NCT03777657	Phase III	Randomized	Double-blind	2 arms
116	34	Tislelizumab	11	2023	Tislelizumab combined with paclitaxel and platinum-based drugs or fluoropyrimidine and platinum-based drugs for first-line treatment of unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma	Multiple	Jianming Xu[121]	2023	NCT03783442	Phase III	Randomized	Double-blind	2 arms
117	34	Tislelizumab	12	2023	Tislelizumab monotherapy is suitable for the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma	Multiple	Shukui Qin[122]	2023	NCT03412773	Phase III	Randomized	None	2 arms
118	34	Tislelizumab	13	2024	Tislelizumab combined with etoposide and platinum-based chemotherapy for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)	Multiple	Ying Cheng[123]	2024	NCT04005716	Phase III	Randomized	Double-blind	2 arms
119	34	Tislelizumab	14	2024	Tislelizumab combined with platinum-based chemotherapy as neoadjuvant therapy, followed by monotherapy, for resectable stage II or IIIA NSCLC	Multiple	Dongsheng Yue[124]	2024	NCT04379635	Phase III	Randomized	Double-blind	2 arms
120	35	Sintilimab	1	2018	Treatment of patients with relapsed or refractory classical Hodgkin lymphoma who have received at least second-line systemic chemotherapy with single-agent therapy	Multiple	Yuankai Shi[125]	2019	NCT03114683	Phase II	Nonrandomized	None	1 arm
121	35	Sintilimab	2	2020	Sintilimab combined with paclitaxel and cisplatin or fluorouracil and cisplatin for first-line treatment of unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma	Multiple	Zhihao Lu[126]	2022	NCT03748134	Phase III	Randomized	Double-blind	2 arms
122	35	Sintilimab	3	2021	Sintilimab with pemetrexed and platinum-based chemotherapy is a first-line treatment for EGFR and ALK-negative, locally advanced or metastatic non-squamous NSCLC not amenable to surgery	Multiple	Yunpeng Yang[127]	2020	NCT03607539	Phase III	Randomized	Double-blind	2 arms
123	35	Sintilimab	4	2021	Sintilimab with gemcitabine and platinum-based chemotherapy is a first-line treatment for unresectable locally advanced or metastatic squamous NSCLC	Multiple	Caicun Zhou[128]	2021	NCT03629925	Phase III	Randomized	Double-blind	2 arms

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
124	35	Sintilimab	5	2021	Sintilimab combined with bevacizumab (Daoyoutong®) for the first-line treatment of patients with previously untreated, unresectable or metastatic hepatocellular carcinoma	Multiple	Zhenggang Ren[129]	2021	NCT03794440	PhaseII/III	Randomized	None	2 arms
125	35	Sintilimab	6	2022	Sintilimab combined with fluoropyrimidine and platinum-based chemotherapy for the first-line treatment of unresectable locally advanced, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma	Multiple	Jianming Xu[130]	2023	NCT03745170	Phase III	Randomized	Double-blind	2 arms
126	35	Sintilimab	7	2023	Sintilimab with bevacizumab, pemetrexed, and cisplatin is for patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have failed EGFR-TKI treatment	Multiple	Shun Lu[131]	2023	NCT03802240	Phase III	Randomized	Double-blind	≥3 arms
127	36	Ipilimumab	1	2021	Ipilimumab combined with nivolumab for adult patients with unresectable, previously untreated non-epithelioid malignant pleural mesothelioma	Multiple	Paul Baas[70]	2021	NCT02899299	Phase III	Randomized	None	2 arms
128	36	Ipilimumab	2	2024	For the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)	Multiple	T. Andre[76]	2024	NCT04008030	Phase III	Randomized	None	2 arms
129	37	Sugemalimab	1	2021	Sugemalimab with pemetrexed and carboplatin for first-line treatment of metastatic EGFR-negative, ALK-negative non-squamous NSCLC; with paclitaxel and carboplatin for metastatic squamous NSCLC	Multiple	Caicun Zhou[132]	2022	NCT03789604	Phase III	Randomized	Double-blind	2 arms
130	37	Sugemalimab	2	2022	Indicated for the treatment of patients with unresectable stage III non-small NSCLC who have not experienced disease progression after platinum-based concurrent or sequential chemoradiotherapy	Multiple	Qing Zhou[133]	2022	NCT03728556	Phase III	Randomized	Double-blind	2 arms
131	37	Sugemalimab	3	2023	Single drug for the treatment of adult patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL)	Multiple	Huiqiang Huang[134]	2023	NCT03595657	Phase II	Nonrandomized	None	1 arm
132	37	Sugemalimab	4	2023	Sugemalimab combined with fluoropyrimidine and platinum-based chemotherapy drugs for the first-line treatment of unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC)	Multiple	Jin Li[135]	2024	NCT04187352	Phase III	Randomized	Double-blind	2 arms
133	37	Sugemalimab	5	2024	Sugemalimab with fluoropyrimidine and platinum chemotherapy for first-line treatment of unresectable advanced or metastatic gastric and gastroesophageal junction adenocarcinoma with PD-L1 (CPS ≥ 5)	Multiple	X. Zhang[136]	2023	NCT03802591	Phase III	Randomized	Double-blind	2 arms
134	38	Toripalimab	1	2018	Toripalimab is used for the treatment of patients with unresectable or metastatic melanoma who have failed prior systemic therapy	Multiple	Bixia Tang[137]	2020	NCT03013101	Phase II	Nonrandomized	None	1 arm
135	38	Toripalimab	2	2021	Toripalimab is suitable for the treatment of locally advanced or metastatic urothelial carcinoma that has progressed within 12 months after failure of platinum-based chemotherapy, including neoadjuvant or adjuvant chemotherapy	Multiple	Xinan Sheng[138]	2021	NCT03113266	Phase II	Nonrandomized	None	1 arm
136	38	Toripalimab	3	2021	For the treatment of patients with recurrent/metastatic nasopharyngeal carcinoma who have failed second-line or above systemic therapy	Multiple	Feng-Hua Wang[139]	2020	NCT02915432	PhaseIb/II	Nonrandomized	None	1 arm
137	38	Toripalimab	4	2021	Toripalimab combined with cisplatin and gemcitabine for first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma	Multiple	Hai-Qiang Mai[140]	2021	NCT03581786	Phase III	Randomized	Double-blind	2 arms
138	38	Toripalimab	5	2022	Toripalimab combined with paclitaxel and cisplatin is suitable for first-line treatment of unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma	Multiple	Zi-Xian Wang[141]	2022	NCT03829969	Phase III	Randomized	Double-blind	2 arms
139	38	Toripalimab	6	2022	Toripalimab with pemetrexed and platinum for first-line treatment of advanced or metastatic EGFR- and ALK-negative non-squamous NSCLC	Multiple	Zhijie Wang[142]	2022	NCT03856411	Phase III	Randomized	Double-blind	2 arms
140	38	Toripalimab	7	2023	Toripalimab with chemotherapy for perioperative treatment, followed by adjuvant monotherapy, for resectable stage IIIA-IIIB NSCLC	Multiple	Shun Lu[143]	2024	NCT04158440	Phase III	Randomized	Double-blind	2 arms
141	38	Toripalimab	8	2024	Toripalimab combined with axitinib for first-line treatment of patients with intermediate or high-risk, unresectable or metastatic renal cell carcinoma	Multiple	X. Q. Yan[144]	2023	NCT04394975	Phase III	Randomized	None	2 arms
142	38	Toripalimab	9	2024	Toripalimab combined with etoposide and platinum is indicated for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)	Multiple	Y. Cheng[145]	2023	NCT04012606	Phase III	Randomized	Double-blind	2 arms

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
143	38	Toripalimab	10	2024	Toripalimab combined with paclitaxel for injection (albumin-bound) is indicated for first-line treatment of recurrent or metastatic PD-L1-positive (CPS ≥ 1) triple-negative breast cancer (TNBC) as assessed by a validated test	Multiple	Zefei Jiang[146]	2024	NCT03777579	Phase III	Randomized	Double-blind	2 arms
144	39	Serplulimab	1	2022	For adults with unresectable or metastatic MSI-H solid tumors: colorectal cancer after fluoropyrimidines, oxaliplatin, and irinotecan; gastric cancer after two prior therapies; other solid tumors after one prior therapy, with no alternative options	Multiple	Shukui Qin[147]	2022	NCT03941574	Phase II	Nonrandomized	None	1 arm
145	39	Serplulimab	2	2022	Serplulimab combined with carboplatin and albumin-bound paclitaxel is indicated for the first-line treatment of unresectable locally advanced or metastatic squamous NSCLC	Multiple	Caicun Zhou[148]	2024	NCT04033354	Phase III	Randomized	Double-blind	2 arms
146	39	Serplulimab	3	2023	Serplulimab combined with carboplatin and etoposide is suitable for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)	Multiple	Ying Cheng[149]	2022	NCT04063163	Phase III	Randomized	Double-blind	2 arms
147	39	Serplulimab	4	2023	Serplulimab combined with fluoropyrimidine and platinum drugs for the first-line treatment of PD-L1 positive, unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (ESCC)	Multiple	Yan Song[150]	2023	NCT03958890	Phase III	Randomized	Double-blind	2 arms
148	40	Penpulimab	1	2021	Indicated for adult patients with relapsed or refractory classical Hodgkin lymphoma who have received at least two lines of systemic chemotherapy	Multiple	Yuqin Song[151]	2022	NCT03722147	PhaseI/II	Nonrandomized	None	1 arm
149	40	Penpulimab	2	2023	Penpulimab combined with paclitaxel and carboplatin is indicated for first-line treatment of locally advanced or metastatic squamous NSCLC	Multiple	Hua Zhong[152]	2024	NCT03866993	Phase III	Randomized	Double-blind	2 arms
150	40	Penpulimab	3	2024	For the treatment of adult patients with recurrent/metastatic nasopharyngeal cancer who have failed prior second-line or higher systemic therapy	Multiple	Xiaozhong Chen[153]	2024	NCT03866967	Phase II	Nonrandomized	None	1 arm
151	41	Adebrelimab	1	2023	Combined with carboplatin and etoposide for first-line treatment of patients with extensive-stage small cell lung cancer	Single	Jie Wang[154]	2022	NCT03711305	Phase III	Randomized	Double-blind	2 arms
152	42	Sorafenib	1	2006	For the treatment of unresectable advanced renal cell carcinoma	Multiple	Bernard Escudier[155,156]	2007/2009	NCT00073307	Phase III	Randomized	Double-blind	2 arms
153	42	Sorafenib	2	2008	For the treatment of unresectable or metastatic hepatocellular carcinoma	Multiple	Josep M. Llovet[157]	2008	NCT00105443	Phase III	Randomized	Double-blind	2 arms
154	42	Sorafenib	3	2017	For the treatment of locally recurrent or metastatic progressive radioiodine-refractory differentiated thyroid cancer	Multiple	Marcia S Brose[158]	2014	NCT00984282	Phase III	Randomized	Double-blind	2 arms
155	43	Regorafenib	1	2017	For metastatic colorectal cancer (mCRC) patients previously treated with fluoropyrimidines, oxaliplatin, and irinotecan, and those unsuitable for or previously treated with anti-VEGF or anti-EGFR (RAS wild-type) therapy	Multiple	Axel Grothey[159]	2013	NCT01103323	Phase III	Randomized	Double-blind	2 arms
156	43	Regorafenib	2	2017	Indicated for locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) patients who have previously received imatinib mesylate and sunitinib malate treatment	Multiple	George D Demetri[160]	2021	NCT01271712	Phase III	Randomized	Double-blind	2 arms
157	43	Regorafenib	3	2017	Indicated for hepatocellular carcinoma (HCC) patients who have previously received sorafenib treatment	Multiple	Jordi Bruix[161]	2016	NCT01774344	Phase III	Randomized	Double-blind	2 arms
158	44	Lenvatinib	1	2018	Monotherapy is indicated for unresectable hepatocellular carcinoma patients who have not previously received systemic treatment	Multiple	Masatoshi Kudo[162]	2018	NCT01761266	Phase III	Randomized	None	2 arms
159	44	Lenvatinib	2	2020	Indicated for patients with progressive, locally advanced, or metastatic radioiodine-refractory differentiated thyroid cancer	Multiple	Martin Schlumberger[163]	2015	NCT01321554	Phase III	Randomized	Double-blind	2 arms
160	45	Donafenib	1	2021	Indicated for unresectable hepatocellular carcinoma patients who have not previously received systemic treatment	Multiple	Shukui Qin[164]	2021	NCT02645981	Phase III	Randomized	None	2 arms
161	45	Donafenib	2	2022	Indicated for patients with progressive, locally advanced, or metastatic radioiodine-refractory differentiated thyroid cancer	Multiple	Yansong Lin[165]	2023	NCT03602495	Phase III	Randomized	Double-blind	2 arms
162	46	Trastuzumab	1	2002	Indicated for HER2-overexpressing metastatic breast cancer: in combination with paclitaxel or docetaxel, for metastatic breast cancer patients who have not received chemotherapy	Multiple	DENNIS J. SLAMON[166]	2001	not available	Phase III	Randomized	None	2 arms

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
163	46	Trastuzumab	2	2002	Indicated for HER2-overexpressing metastatic breast cancer: as a monotherapy for metastatic breast cancer patients who have received one or more prior chemotherapy regimens	Multiple	not available	not available	not available	Phase III	Nonrandomized	None	1 arm
164	46	Trastuzumab	3	2002	Indicated for HER2-positive early breast cancer	Multiple	Edith A. Perez[167]	2011	not available	Phase III	Randomized	None	2 arms
165	46	Trastuzumab	4	2012	Trastuzumab with capecitabine or 5-FU and cisplatin for HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma patients without prior metastatic treatment	Multiple	Yung-Jue Bang[168]	2010	NCT01041404	Phase III	Randomized	None	2 arms
166	47	Apatinib	1	2014	Monotherapy is indicated for advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma patients who have progressed or relapsed after receiving at least two prior lines of systemic chemotherapy	Multiple	Jin Li[169]	2016	NCT01512745	Phase III	Randomized	Double-blind	2 arms
167	47	Apatinib	2	2020	Monotherapy for patients with advanced hepatocellular carcinoma who have failed or were intolerant to at least one prior line of systemic therapy	Multiple	Shukui Qin[170]	2021	NCT02329860	Phase III	Randomized	Double-blind	2 arms
168	47	Apatinib	3	2023	Apatinib combined with carrelizumab injection for first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma	Multiple	Shukui Qin[110]	2023	NCT03764293	Phase III	Randomized	None	2 arms
169	48	Disitamab Vedotin	1	2021	For patients with HER2 overexpressing locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two prior systemic chemotherapies	Multiple	Zhi Peng[171]	2021	NCT03556345	Phase II	Nonrandomized	None	1 arm
170	48	Disitamab Vedotin	2	2021	Indicated for patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-based chemotherapy and have HER2 overexpression	Multiple	Xinan Sheng[172]	2023	NCT03809013 &NCT03507166	Phase II	Nonrandomized	None	1 arm
171	48	Disitamab Vedotin	3	2024	Disitamab Vedotin combined with toripalimab injection is indicated for perioperative treatment of muscle-invasive bladder cancer	Multiple	Xinan Sheng[173]	2024	NCT05297552	Phase II	Nonrandomized	None	1 arm
172	49	Ramucirumab	1	2022	Ramucirumab combined with paclitaxel for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma patients who have disease progression during or after fluoropyrimidine- or platinum-containing chemotherapy	Multiple	Hansjochen Wilke[174]	2014	NCT01170663	Phase III	Randomized	Double-blind	2 arms
173	49	Ramucirumab	2	2022	Monotherapy for the treatment of hepatocellular carcinoma patients who have previously received sorafenib treatment and have an alpha-fetoprotein level of ≥400ng/mL	Multiple	Andrew X Zhu[175]	2019	NCT02435433	Phase III	Randomized	Double-blind	2 arms
174	50	Imatinib	1	2002	Indicated for the treatment of chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML)	Multiple	Stephen G. O'Brien[176]	2003	not available	Phase III	Randomized	None	2 arms
175	50	Imatinib	2	2002	Indicated for the treatment of accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML)	Multiple	Moshe Talpaz[177]	2002	not available	Phase II	Nonrandomized	None	2 arms
176	50	Imatinib	3	2002	Indicated for the treatment of blast crisis Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML)	Multiple	Charles L. Sawyers[178]	2003	not available	Phase II	Nonrandomized	None	2 arms
177	50	Imatinib	4	2003	Indicated for the treatment of adult patients with unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST)	Multiple	GEORGE D. DEMETR[179]	2002	not available	Phase II	Randomized	None	2 arms
178	50	Imatinib	5	not available	Imatinib combined with chemotherapy is indicated for the treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in pediatric patients	Multiple	Kirk R. Schultz[180]	2009	not available	Phase III	Nonrandomized	None	≥3 arms
179	50	Imatinib	6	not available	Indicated for the treatment of relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adult patients	Multiple	Barbara Wassmann[181]	2004	not available	Phase II	not available	None	≥3 arms
180	50	Imatinib	7	not available	Indicated for the treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα fusion kinase	Multiple	MichaelC.Heinrich[182]	2008	not available	Phase II	Nonrandomized	None	1 arm
181	50	Imatinib	8	not available	Indicated for the treatment of adult patients with myelodysplastic syndromes/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements	Multiple	MichaelC.Heinrich[182]	2008	not available	Phase II	Nonrandomized	None	1 arm

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
182	50	Imatinib	9	not available	Indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM) without D816V c-Kit gene mutation or with unknown c-Kit gene mutation	Multiple	MichaelC.Heinrich[182]	2008	not available	Phase II	Nonrandomized	None	1 arm
183	50	Imatinib	10	2010	Indicated for the treatment of unresectable, recurrent, or metastatic dermatofibrosarcoma protuberans (DFSP)	Multiple	MichaelC.Heinrich[182]	2008	not available	Phase II	Nonrandomized	None	1 arm
184	50	Imatinib	11	not available	Indicated for adjuvant treatment of adult patients with Kit (CD117)-positive GIST who have a significant risk of recurrence after surgical resection. Patients with very low and low recurrence risk should not receive this adjuvant treatment	Multiple	Ronald P. DeMatteo[183]	2009	NCT00041197	Phase III	Randomized	Double-blind	2 arms
185	51	Sunitinib	1	2007	For advanced renal cell carcinoma (RCC) that cannot be treated with surgery	Multiple	Robert J. Motzer[184]	2007	NCT00083889	Phase III	Randomized	None	2 arms
186	51	Sunitinib	2	2007	Indicated for gastrointestinal stromal tumors (GIST) in patients who have failed or are intolerant to imatinib mesylate treatment	Multiple	George D Demetri[185]	2006	NCT00075218	Phase III	Randomized	Double-blind	2 arms
187	51	Sunitinib	3	2013	Indicated for adult patients with unresectable, metastatic, well-differentiated, advanced pancreatic neuroendocrine tumors (pNET)	Multiple	Eric Raymond[186]	2011	NCT00428597	Phase III	Randomized	Double-blind	2 arms
188	52	Avapritinib	1	2021	For the treatment of adult patients with unresectable or metastatic GIST harboring PDGFRA exon 18 (including D842V) mutations	Single	Michael C Heinrich[187]	2020	NCT02508532	Phase I	Nonrandomized	None	1 arm
189	53	Ripretinib	1	2021	For the treatment of adult patients with advanced GIST who have received three or more tyrosine kinase inhibitors, including imatinib	Single	Jean-Yves Blay[188]	2020	NCT03353753	Phase III	Randomized	Double-blind	2 arms
190	54	Surufatinib	1	2020	For the treatment of unresectable advanced or metastatic non-pancreatic G1/G2 non-functional neuroendocrine tumors	Single	Jianming Xu[189]	2020	NCT02588170	Phase III	Randomized	Double-blind	2 arms
191	55	Cetuximab	1	2019	For RAS wild-type metastatic colorectal cancer: combined with FOLFOX or FOLFIRI for first-line treatment, and with irinotecan after irinotecan-based therapy failure	Multiple	Shukui Qin[190]	2018	NCT01228734	Phase III	Randomized	None	2 arms
192	55	Cetuximab	2	2020	Cetuximab combined with platinum-based chemotherapy and fluoropyrimidine is indicated for first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma	Multiple	Jan B. Vermorken[191]	2008	NCT00122460	Phase III	Randomized	None	2 arms
193	55	Cetuximab	3	2022	Indicated for the treatment of head and neck squamous cell carcinoma: in combination with radiation therapy for locally advanced disease	Multiple	James A. Bonner[192]	2006	NCT00004227	Phase III	Randomized	None	2 arms
194	56	Fruquintinib	1	2018	Monotherapy for mCRC patients who have received chemotherapy and are unsuitable for anti-VEGF or anti-EGFR (RAS wild-type) therapies	Single	Jin Li[193]	2018	NCT02314819	Phase III	Randomized	Double-blind	2 arms
195	57	Envafolimab	1	2021	For the treatment of adult patients with unresectable or metastatic MSI-H/dMMR advanced solid tumors, including: Advanced colorectal cancer that progressed after fluoropyrimidine, oxaliplatin, and irinotecan treatment; Other advanced solid tumors that progressed with no alternative options	Single	Jian Li[194]	2021	NCT03667170	Phase II	Nonrandomized	None	1 arm
196	58	Larotrectinib	1	2022	For adult and pediatric patients with solid tumors confirmed to have non-resistant NTRK fusions, who have locally advanced/metastatic disease or high surgical risk, and no satisfactory alternative treatment	Single	David S Hong[195]	2018	NCT02122913/NCT02637687/NCT02576431	Phase I/II	Nonrandomized	None	1 arm
197	59	Pucotenlimab	1	2022	For unresectable or metastatic MSI-H or dMMR advanced solid tumors: including advanced colorectal cancer patients with progression after fluoropyrimidines, oxaliplatin, and irinotecan, and other advanced solid tumors with progression after at least one prior treatment and no satisfactory alternatives	Multiple	Bo Zhang[196]	2023	NCT03704246	Phase II	Nonrandomized	None	1 arm
198	59	Pucotenlimab	2	2022	Indicated for unresectable or metastatic melanoma patients who have failed prior systemic therapy	Multiple	Chuanliang Cui[197]	2023	NCT04749485	Phase II	Nonrandomized	None	1 arm
199	60	Pemigatinib	1	2022	For adult patients with advanced cholangiocarcinoma who have received systemic therapy and tested positive for FGFR2 fusions/rearrangements	Single	Ghassan K Abou-Alfa[198]	2020	NCT02924376	Phase II	Nonrandomized	None	1 arm

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
200	61	Dasatinib	1	2011	For the treatment of adult patients with Ph+ CML in the chronic, accelerated, or blast phase who are resistant or intolerant to imatinib	Single	Neil P. Shah[199-201]	2008/2014/2016	NCT00123474	Phase III	Randomized	None	≥3 arms
201	62	Nilotinib	1	2009	Indicated for adult patients with chronic or accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) who are resistant or intolerant to prior treatment, including imatinib	Multiple	Hagop M. Kantarjian[202]	2010	NCT00109707	Phase II	Nonrandomized	None	2 arms
202	62	Nilotinib	2	2016	Indicated for adult patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML)	Multiple	Giuseppe Saglio[203] & Hagop M Kantarjian[204]	2010/2011	NCT00471497	Phase III	Randomized	None	≥3 arms
203	62	Nilotinib	3	2019	Indicated for the treatment of chronic myelogenous leukemia in children aged 2 years and older	Multiple	Nobuko Hijiya[205]	2019	NCT01844765	Phase II	Nonrandomized	None	2 arms
204	63	Olverembatinib	1	2021	Indicated for adult patients with chronic or accelerated phase chronic myelogenous leukemia (CML) who are resistant to any tyrosine kinase inhibitor and diagnosed with T315I mutation using a validated testing method	Multiple	Qian Jiang[206]	2022	NCT03883087 &NCT03883100	Phase II	Nonrandomized	None	1 arm
205	63	Olverembatinib	2	2023	Indicated for adult patients with chronic phase chronic myelogenous leukemia (CML) who are resistant to and/or intolerant of first- and second-generation tyrosine kinase inhibitors	Multiple	Qian Jiang[206]	2022	NCT04126681	Phase II	Randomized	None	2 arms
206	64	Flumatinib	1	2019	For the treatment of adult patients with Ph+ CML in the chronic phase	Single	Li Zhang[207]	2020	NCT02204644	Phase III	Randomized	None	2 arms
207	65	Ibrutinib	1	2017	Indicated as monotherapy for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy	Multiple	Martin Dreyling[208]	2015	NCT01646021	Phase III	Randomized	None	2 arms
208	65	Ibrutinib	2	2017	Indicated as monotherapy for the treatment of treatment-naïve and relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients	Multiple	J.C. Byrd[209]	2014	NCT01578707	Phase III	Randomized	None	2 arms
209	65	Ibrutinib	3	2018	Indicated as monotherapy for the treatment of Waldenström's macroglobulinemia patients who have received at least one prior therapy, or as first-line treatment for patients with Waldenström's macroglobulinemia who are not suitable for chemotherapy or immunotherapy	Multiple	Steven P. Treon[210]	2015	NCT01614821	Phase II	Nonrandomized	None	1 arm
210	65	Ibrutinib	4	2018	Ibrutinib combined with rituximab is indicated for the treatment of patients with Waldenström's macroglobulinemia	Multiple	M.A. Dimopoulos[211]	2018	NCT02165397	Phase III	Randomized	Double-blind	2 arms
211	66	Zanubrutinib	1	2020	Indicated for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy	Multiple	Yuqin Song[212]	2020	NCT03206970	Phase II	Nonrandomized	None	1 arm
212	66	Zanubrutinib	2	2020	Indicated for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy	Multiple	Wei Xu[213]	2020	NCT03206918	Phase II	Nonrandomized	None	1 arm
213	66	Zanubrutinib	3	2021	Indicated for adult patients with Waldenström's macroglobulinemia (WM) who have received at least one prior therapy	Multiple	Gang An[214]	2021	NCT03332173	Phase II	Nonrandomized	None	1 arm
214	66	Zanubrutinib	4	2023	Indicated as monotherapy for treatment-naïve adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)	Multiple	Constantine S Tam[215]	2022	NCT03336333	Phase III	Randomized	None	2 arms
215	67	Orelabrutinib	1	2020	Indicated for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy	Multiple	Li-Juan Deng[216]	2023	NCT03494179	Phase II	Randomized	None	2 arms
216	67	Orelabrutinib	2	2020	Indicated for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy	Multiple	Wei Xu[217]	2022	NCT03493217	Phase II	Nonrandomized	None	1 arm
217	67	Orelabrutinib	3	2023	Indicated for adult patients with marginal zone lymphoma (MZL) who have received at least one prior therapy	Multiple	Lijuan Deng[218]	2023	NCT03797456	Phase II	Nonrandomized	None	1 arm
218	68	Bortezomib	1	2005	Bortezomib + melphalan + prednisone (MP regimen) for untreated multiple myeloma patients ineligible for high-dose chemotherapy and stem cell transplantation	Multiple	APEX trial[219]	2003	NCT00048230	Phase III	Randomized	None	2 arms
219	68	Bortezomib	2	2005	Indicated for the treatment of relapsed multiple myeloma patients who have received at least one prior therapy	Multiple	Jesús F. San Miguel[220]	2008	NCT00111319	Phase III	Randomized	None	2 arms

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
220	68	Bortezomib	3	2009	Indicated for the treatment of relapsed or refractory mantle cell lymphoma (MCL) patients who have received at least one prior therapy	Multiple	Richard I. Fisher[221]	2006	NCT00063713	Phase II	Nonrandomized	None	1 arm
221	68	Bortezomib	4	2018	Bortezomib, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, is indicated for the treatment of previously untreated adult patients with mantle cell lymphoma (MCL) who are not candidates for hematopoietic stem cell transplantation	Multiple	Tadeusz Robak[222]	2015	NCT00722137	Phase III	Randomized	None	2 arms
222	69	Carfilzomib	1	2021	With dexamethasone for adults with relapsed/refractory multiple myeloma after two or more treatments	Single	Juan Du[223]	2021	NCT03029234	Phase III	Nonrandomized	None	1 arm
223	70	Ixazomib	1	2018	With lenalidomide and dexamethasone for adults with multiple myeloma after at least one prior treatment	Single	P. Moreau[224]	2016	NCT01564537	Phase III	Randomized	Double-blind	2 arms
224	71	Lenalidomide	1	2013	Lenalidomide in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy	Multiple	Donna M. Weber[225]	2007	NCT00056160	Phase III	Randomized	Double-blind	2 arms
225	71	Lenalidomide	2	2017	Lenalidomide in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have not received prior treatment and are not candidates for transplantation	Multiple	Lotfi Benboubker[226]	2014	NCT00689936	Phase III	Randomized	None	≥3 arms
226	71	Lenalidomide	3	2020	Lenalidomide in combination with rituximab is indicated for the treatment of adult patients with follicular lymphoma grades 1–3a who have received prior treatment	Multiple	John P. Leonard[227]	2019	NCT01938001	Phase III	Randomized	Double-blind	2 arms
227	72	Pomalidomide	1	2020	Pomalidomide + dexamethasone for adults with relapsed/refractory multiple myeloma after ≥2 treatments and progression within 60 days	Single	Jesus San Miguel[228]	2013	NCT01311687	Phase III	Randomized	None	2 arms
228	73	Daratumumab	1	2019	Monotherapy is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received treatment including proteasome inhibitors and immunomodulatory agents, with disease progression at the last treatment	Multiple	Sagar Lonial[229]	2016	NCT01985126	Phase II	Randomized	None	1 arm
229	73	Daratumumab	2	2021	Daratumumab combined with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, is indicated for the treatment of adult patients with multiple myeloma who have previously received at least one line of therapy	Multiple	Antonio Palumbo[230]	2019	NCT02136134	Phase III	Randomized	None	2 arms
230	73	Daratumumab	3	2021	Daratumumab combined with lenalidomide and dexamethasone, or with bortezomib, melphalan, and prednisone, is indicated for the treatment of newly diagnosed multiple myeloma adult patients who are not candidates for autologous stem cell transplantation	Multiple	Maria-Victoria Mateos[231]	2019	NCT02195479	Phase III	Randomized	None	2 arms
231	74	Selinexor	1	2021	With dexamethasone for adults with relapsed/refractory multiple myeloma resistant to proteasome inhibitor, immunomodulator, and anti-CD38 antibody	Single	Dan T. Vogl[232]	2018	NCT02336815	Phase II	Nonrandomized	None	1 arm
232	75	Gilteritinib	1	2021	For adults with relapsed/refractory AML confirmed to have FLT3 mutation by validated testing	Single	A.E. Perl[233]	2019	NCT02421939	Phase III	Randomized	None	2 arms
233	76	Venetoclax	1	2020	With azacitidine for newly diagnosed AML adults ineligible for intensive induction chemotherapy due to comorbidities or age ≥75	Single	C.D. DiNardo[234]	2020	NCT02993523	Phase III	Randomized	Double-blind	2 arms
234	77	Ivosidenib	1	2022	For adults with relapsed/refractory AML with an IDH1 mutation	Single	Kelly J. Norsworthy[235]	2019	NCT02074839	Phase II	Nonrandomized	None	1 arm
235	78	Blinatumomab	1	2020	Indicated for the treatment of adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia	Multiple	Hagop Kantarjian[236]	2017	NCT02013167	Phase III	Randomized	None	2 arms
236	78	Blinatumomab	2	2022	Indicated for the treatment of pediatric patients with relapsed or refractory CD19-positive precursor B-cell acute lymphoblastic leukemia	Multiple	Franco Locatelli[237]	2021	NCT02393859	Phase III	Randomized	None	2 arms
237	79	Zimberelimab	1	2021	Indicated for adult patients with relapsed or refractory classic Hodgkin lymphoma who have received at least two lines of systemic chemotherapy	Multiple	Ningjing Lin[238]	2021	NCT03655483	Phase II	Nonrandomized	None	1 arm
238	79	Zimberelimab	2	2023	Indicated for patients with relapsed or metastatic cervical cancer who have failed platinum-based chemotherapy and are PD-L1 positive (CPS≥1)	Multiple	Lingfang Xia[239]	2023	NCT03972722	Phase II	Nonrandomized	None	1 arm

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
239	80	Rituximab	1	2000	Indicated for previously untreated CD20-positive stage III-IV follicular non-Hodgkin lymphoma patients, to be used in combination with chemotherapy	Multiple	Gilles Salles[240]	2011	NCT00140582	Phase III	Randomized	None	2 arms
240	80	Rituximab	2	2000	Indicated for the treatment of relapsed or chemotherapy-resistant follicular lymphoma	Multiple	Marinus H. J. van Oers[241]	2006	NCT00004179	Phase III	Randomized	None	2 arms
241	80	Rituximab	3	2000	CD20-positive diffuse large B-cell lymphoma (DLBCL) should be treated in combination with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) for 8 cycles	Multiple	Annalisa Chiappella[242]	2017	NCT00499018	Phase III	Randomized	None	2 arms
242	80	Rituximab	4	2019	Monotherapy is used for maintenance treatment of follicular lymphoma patients who have achieved complete or partial remission after rituximab combined with chemotherapy	Multiple	Gilles Salles[240]	2011	NCT00140582	Phase III	Randomized	None	2 arms
243	80	Rituximab	5	2019	Rituximab combined with fludarabine and cyclophosphamide (FC) is used for the treatment of previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL) patients	Multiple	M Hallek[243]	2010	NCT00281918	Phase III	Randomized	None	2 arms
244	81	Ripertamab	1	2022	For newly diagnosed adults with CD20+ DLBCL and IPI 0-2, in combination with standard CHOP chemotherapy	Single	YuankaiShi[244]	2022	NCT02772822	Phase III	Randomized	Single-blind	2 arms
245	82	Zuberitamab	1	2023	For adults with CD20+ diffuse large B-cell lymphoma, in combination with standard CHOP chemotherapy	Single	Not Available	Not Available	NCT03485118	Phase III	Randomized	Double-blind	2 arms
246	83	Obinutuzumab	1	2021	In combination with chemotherapy for newly diagnosed stage II with large tumors, stage III, or stage IV follicular lymphoma, followed by obinutuzumab maintenance after partial remission	Single	R. Marcus[245]	2017	NCT01332968	Phase III	Randomized	None	2 arms
247	84	Polatuzumab Vedotin	1	2023	Polatuzumab Vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone is indicated for the treatment of previously untreated adult patients with diffuse large B-cell lymphoma (DLBCL)	Multiple	H. Tilly[246]	2021	NCT03274492	Phase III	Randomized	Double-blind	2 arms
248	84	Polatuzumab Vedotin	2	2023	Polatuzumab Vedotin combined with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for hematopoietic stem cell transplantation. Conditional approval was based on complete response rates and duration of response for relapsed or refractory DLBCL	Multiple	Laurie H. Sehn[247,248]	2019/2020	NCT02257567	Phase II	Randomized	None	2 arms
249	85	Brentuximab Vedotin	1	2020	Indicated for the treatment of adult patients with CD30-positive lymphoma: relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)	Multiple	Barbara Pro[249]	2017	NCT00866047	Phase II	Nonrandomized	None	1 arm
250	85	Brentuximab Vedotin	2	2020	Indicated for the treatment of adult patients with CD30-positive lymphoma: relapsed or refractory classical Hodgkin lymphoma (cHL)	Multiple	Robert Chen[250]	2016	NCT00848926	Phase II	Nonrandomized	None	1 arm
251	85	Brentuximab Vedotin	3	2021	Indicated for adult patients with CD30-positive primary cutaneous anaplastic large cell lymphoma (pcALCL) or mycosis fungoides (MF) who have previously received systemic therapy	Multiple	H Miles Prince[251]	2017	NCT01578499	Phase III	Randomized	None	2 arms
252	86	Inotuzumab Ozogamicin	1	2021	For adults with relapsed/refractory precursor B-cell acute lymphoblastic leukemia	Single	Hagop M. Kantarjian[252]	2016	NCT01564784	Phase III	Randomized	None	2 arms
253	87	Chidamide	1	2014	Indicated for adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who have received at least one prior systemic chemotherapy	Multiple	Y. Shi[253]	2015	NCT05833724	Phase II	Nonrandomized	None	1 arm
254	87	Chidamide	2	2019	Chidamide + aromatase inhibitors is indicated for postmenopausal HR-positive, HER2-negative locally advanced or metastatic breast cancer patients with recurrence or progression after endocrine therapy	Multiple	Zefei Jiang[254]	2019	NCT02482753	Phase III	Randomized	Double-blind	2 arms
255	88	Linperlisib	1	2022	For adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies	Single	Tingyu Wang[255]	2023	NCT04370405	Phase II	Nonrandomized	None	1 arm
256	89	Duvelisib	1	2022	For adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies	Single	Not Available	Not Available	NCT01882803	Phase II	Nonrandomized	None	1 arm
257	90	Ruxolitinib	1	2017	For adults with intermediate- or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF), to treat disease-related splenomegaly or symptoms	Single	Ruben A. Mesa[256]	2013	NCT00952289	Phase III	Randomized	Double-blind	2 arms

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
258	91	Mogamulizumab	1	2022	Indicated for relapsed/refractory Sézary syndrome or advanced (Stage III/IV) mycosis fungoides in adults who have received systemic therapy	Single	Youn H Kim[257]	2018	NCT01728805	Phase III	Randomized	None	2 arms
259	92	Siltuximab	1	2021	Indicated for the treatment of adult patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative	Single	Frits van Rhee[258]	2014	NCT01024036	Phase II	Randomized	Double-blind	2 arms
260	93	Pazopanib	1	2017	For first-line and post-cytokine therapy treatment of advanced renal cell carcinoma (RCC)	Single	Cora N. Sternberg[259]	2010	NCT00334282	Phase III	Randomized	Double-blind	2 arms
261	94	Axitinib	1	2015	For adult patients with advanced renal cell carcinoma (RCC) who have progressed following prior treatment with one tyrosine kinase inhibitor (TKI) or cytokine therapy	Single	Brian I Rini[260]	2011	NCT00678392	Phase III	Randomized	None	2 arms
262	95	Abiraterone	1	2015	Abiraterone, in combination with prednisone or prednisolone, is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC)	Multiple	Johann S. de Bono[261]	2011	NCT00638690	Phase III	Randomized	Double-blind	2 arms
263	95	Abiraterone	2	2018	Abiraterone acetate, in combination with prednisone or prednisolone, is indicated for the treatment of newly diagnosed high-risk metastatic endocrine-sensitive prostate cancer, including patients who have not received endocrine therapy or have received endocrine therapy for no more than 3 months	Multiple	Karim Fizazi[262]	2017	NCT01715285	Phase III	Randomized	Double-blind	2 arms
264	96	Apalutamide	1	2019	Indicated for the treatment of adult patients with high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC)	Multiple	Matthew R. Smith[263]	2018	NCT01946204	Phase III	Randomized	Double-blind	2 arms
265	96	Apalutamide	2	2020	Indicated for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC)	Multiple	Kim N. Chi[264]	2019	NCT02489318	Phase III	Randomized	Double-blind	2 arms
266	97	Enzalutamide	1	2019	Indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic and have not received chemotherapy after failure of androgen deprivation therapy	Multiple	T.M. Beer[265]	2014	NCT01212991	Phase III	Randomized	Double-blind	2 arms
267	97	Enzalutamide	2	2020	Indicated for adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis	Multiple	Maha Hussain[266]	2018	NCT02003924	Phase III	Randomized	Double-blind	2 arms
268	97	Enzalutamide	3	2024	Indicated for metastatic hormone-sensitive prostate cancer (mHSPC)	Multiple	Andrew J. Armstrong[267]	2019	NCT02677896	Phase III	Randomized	Double-blind	2 arms
269	98	Darolutamide	1	2021	Indicated for the treatment of adult patients with high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC)	Multiple	Karim Fizazi[268]	2019	NCT02200614	Phase III	Randomized	Double-blind	2 arms
270	98	Darolutamide	2	2023	Darolutamide in combination with docetaxel is indicated for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC)	Multiple	Matthew R. Smith[269]	2022	NCT02799602	Phase III	Randomized	Double-blind	2 arms
271	99	Rezvilutamide	1	2022	Indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with high tumor burden	Single	Weijie Gu[270]	2022	NCT03520478	Phase III	Randomized	None	2 arms
272	100	Olaparib	1	2018	Monotherapy is indicated for the maintenance treatment of adult patients with platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have achieved complete or partial response after platinum-based chemotherapy	Multiple	Eric Pujade-Lauraine[271]	2017	NCT01874353	Phase III	Randomized	Double-blind	2 arms
273	100	Olaparib	2	2019	Indicated for the maintenance treatment of adult patients with germline or somatic BRCA-mutated advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have achieved complete or partial response after first-line platinum-based chemotherapy	Multiple	K. Moore[272]	2018	NCT01844986	Phase III	Randomized	Double-blind	2 arms
274	100	Olaparib	3	2021	Indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who carry germline or somatic BRCA mutations (gBRCAm or sBRCAm) and have previously failed treatment, including with a novel endocrine therapy	Multiple	J. de Bono[273]	2020	NCT02987543	Phase III	Randomized	None	2 arms
275	100	Olaparib	4	2022	Olaparib in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who are homologous recombination repair-deficient (HRD-positive) and have achieved a complete or partial response to first-line platinum-based chemotherapy combined with bevacizumab	Multiple	I. Ray-Coquard[274]	2019	NCT02477644	Phase III	Randomized	Double-blind	2 arms

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
276	101	Trastuzumab Emtansine	1	2020	Adjuvant treatment for breast cancer: Monotherapy is indicated for HER2-positive early breast cancer patients who have residual invasive disease after receiving neoadjuvant therapy with taxane combined with trastuzumab	Multiple	G. von Minckwitz[275]	2018	NCT01772472	Phase III	Randomized	None	2 arms
277	101	Trastuzumab Emtansine	2	2021	Metastatic breast cancer treatment: Monotherapy is indicated for HER2-positive, unresectable locally advanced or metastatic breast cancer patients who have received treatment with taxane and trastuzumab. The patient should meet one of the following conditions: previously received treatment for locally advanced or metastatic breast cancer, or experienced disease recurrence within 6 months after adjuvant treatment or during the course of adjuvant therapy	Multiple	Sunil Verma[276]	2012	NCT00829166	Phase III	Randomized	None	2 arms
278	102	Pertuzumab	1	2018	Indicated for adjuvant treatment in HER2-positive early breast cancer patients with high recurrence risk, in combination with trastuzumab and chemotherapy	Multiple	Gunter von Minckwitz[277]	2017	NCT01358877	Phase III	Randomized	Double-blind	2 arms
279	102	Pertuzumab	2	2019	Indicated for neoadjuvant treatment in HER2-positive, locally advanced, inflammatory, or early breast cancer patients (with tumors >2 cm or lymph node-positive), in combination with trastuzumab and chemotherapy, as part of the overall treatment plan for early breast cancer	Multiple	Zhimin Shao[278]	2019	NCT02586025	Phase III	Randomized	Double-blind	2 arms
280	102	Pertuzumab	3	2019	Pertuzumab, in combination with trastuzumab and docetaxel, is indicated for HER2-positive patients with metastatic disease who have not previously received HER2-targeted treatment or chemotherapy for metastatic or unresectable locally recurrent breast cancer	Multiple	Sandra M. Swain[279]	2015	NCT00567190	Phase III	Randomized	Double-blind	2 arms
281	103	Trastuzumab Deruxtecan	1	2023	Monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received one or more HER2-targeted therapies	Multiple	J. Cortés[280]	2022	NCT03529110	Phase III	Randomized	None	2 arms
282	103	Trastuzumab Deruxtecan	2	2023	Monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC1+ or IHC2+/ISH-) breast cancer who have previously received at least one systemic therapy during the metastatic disease phase, or who experienced disease recurrence within 6 months after adjuvant chemotherapy or during the course of adjuvant chemotherapy	Multiple	S. Modi[281]	2022	NCT03734029	Phase III	Randomized	None	2 arms
283	104	Inetetamab	1	2020	Indicated for the treatment of HER2-positive metastatic breast cancer (MBC) in combination with vinorelbine in patients who have previously received one or more prior chemotherapy regimens	Single	Bian Li[282]	2020	Not Available	Phase III	Randomized	None	2 arms
284	105	Lapatinib	1	2013	For HER2-overexpressing advanced or metastatic breast cancer (MBC), in combination with capecitabine, previously treated with anthracyclines, taxanes, and trastuzumab	Single	Charles E. Geyer[283]	2006	NCT00078572	Phase III	Randomized	None	2 arms
285	106	Pyrotinib	1	2018	Pyrotinib in combination with capecitabine is indicated for the treatment of HER2-positive, recurrent or metastatic breast cancer patients who have not received or have previously received trastuzumab. Prior to the use of pyrotinib, patients should have received anthracycline or taxane-based chemotherapy	Multiple	Fei Ma[284]	2019	NCT02422199	Phase II	Randomized	None	2 arms
286	106	Pyrotinib	2	2022	Pyrotinib in combination with trastuzumab and docetaxel is indicated for neoadjuvant treatment of HER2-positive early or locally advanced breast cancer patients	Multiple	Jiong Wu[285]	2022	NCT03588091	Phase III	Randomized	Double-blind	2 arms
287	106	Pyrotinib	3	2023	Pyrotinib in combination with trastuzumab and docetaxel is indicated for the treatment of HER2-positive, advanced-stage, recurrent or metastatic breast cancer patients who have not previously received anti-HER2 therapy	Multiple	Fei Ma[286]	2023	NCT03863223	Phase III	Randomized	Double-blind	2 arms
288	107	Neratinib	1	2020	For adult patients with HER2-positive early breast cancer, following enhanced adjuvant therapy after trastuzumab-based treatment	Single	Miguel Martin[287]	2017	NCT00878709	Phase III	Randomized	Double-blind	2 arms
289	108	Palbociclib	1	2018	For HR+/HER2- locally advanced or metastatic breast cancer (MBC) in postmenopausal women, in combination with an aromatase inhibitor (AI) as first-line endocrine therapy	Single	Richard S. Finn[288]	2016	NCT01740427	Phase III	Randomized	Double-blind	2 arms
290	109	Abemaciclib	1	2020	Abemaciclib in combination with aromatase inhibitors is indicated as initial endocrine therapy for postmenopausal HR-positive, HER2-negative, locally advanced or metastatic breast cancer patients	Multiple	Stephen Johnston[289]	2019	NCT02246621	Phase III	Randomized	Double-blind	2 arms
291	109	Abemaciclib	2	2020	Abemaciclib in combination with fulvestrant is indicated for HR-positive, HER2-negative, locally advanced or metastatic breast cancer patients who have progressed after previous endocrine therapy	Multiple	George W. Sledge[290]	2019	NCT02107703	Phase III	Randomized	Double-blind	2 arms

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
292	109	Abemaciclib	3	2021	Abemaciclib in combination with endocrine therapy (tamoxifen or aromatase inhibitors) is indicated for adjuvant treatment of HR-positive, HER2-negative, lymph node-positive, high-risk early breast cancer adult patients with Ki-67 ≥ 20%	Multiple	Stephen R. D. Johnston[291]	2020	NCT03155997	Phase III	Randomized	None	2 arms
293	110	Dalpiciclib	1	2021	Dalpiciclib in combination with fulvestrant is indicated for patients who have experienced disease progression after prior endocrine therapy	Multiple	Binghe Xu[292]	2021	NCT03927456	Phase III	Randomized	Double-blind	2 arms
294	110	Dalpiciclib	2	2023	Indicated for patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer: to be used in combination with an aromatase inhibitor as initial endocrine therapy.	Multiple	Pin Zhang[293]	2023	NCT03966898	Phase III	Randomized	Double-blind	2 arms
295	111	Ribociclib	1	2023	Indicated for use in combination with an aromatase inhibitor as initial endocrine therapy for premenopausal or perimenopausal women with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer. When using endocrine therapy, it should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist	Multiple	Debu Tripathy[294]	2018	NCT02278120	Phase III	Randomized	Double-blind	2 arms
296	111	Ribociclib	2	2023	Indicated for use in postmenopausal women with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine therapy	Multiple	Gabriel N. Hortobagyi[295,296]	2018/2022	NCT01958021	Phase III	Randomized	Double-blind	2 arms
297	112	Sacituzumab Govitecan	1	2022	Indicated for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic therapies, with at least one for metastatic disease	Single	A. Bardia[297]	2019	NCT01631552	Phase II	Nonrandomized	None	1 arm
298	113	Vemurafenib	1	2017	Indicated for the treatment of unresectable or metastatic melanoma with BRAF V600 mutation-positive status	Single	Paul B. Chapman[298] & Grant A McArthur[299]	2011/2014	NCT01006980	Phase III	Randomized	None	2 arms
299	114	Sonidegib	1	2021	Indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) who are not candidates for surgery or radiation, or who have recurrent disease following surgery or radiation therapy	Single	J.T. Lear[300]	2017	NCT01327053	Phase II	Randomized	Double-blind	2 arms
300	115	Denosumab	1	2019	Indicated for the treatment of unresectable or surgically resectable bone giant cell tumors that could cause severe functional impairment, including adult patients and adolescents with skeletal maturity (defined as at least one mature long bone and body weight ≥ 45kg)	Multiple	Sant Chawla[301]	2013	NCT00680992	Phase II	Nonrandomized	None	1 arm
301	115	Denosumab	2	2020	Indicated for the prevention of bone-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma	Multiple	Alison T. Stopeck[302] & Noopur Raje[303]	2010/2018	NCT00321464 &NCT01345019	Phase III	Randomized	Double-blind	2 arms
302	116	Nimotuzumab	1	2008	Nimotuzumab in combination with radiotherapy is indicated for the treatment of stage III-IV nasopharyngeal carcinoma with positive EGFR gene expression	Multiple	Not Available	Not Available	not available	Phase II	Randomized	None	2 arms
303	116	Nimotuzumab	2	2023	Nimotuzumab in combination with gemcitabine is indicated for the treatment of K-Ras wild-type locally advanced or metastatic pancreatic cancer	Multiple	B. Schultheis[304]	2017	NCT00561990	PhaseIIb/IIIa	Randomized	Double-blind	2 arms
304	116	Nimotuzumab	3	2024	Nimotuzumab in combination with concurrent chemoradiotherapy is indicated for the treatment of locally advanced head and neck squamous cell carcinoma	Multiple	Vijay Maruti Patil[305]	2019	not available	Phase III	Randomized	None	2 arms
305	117	Niraparib	1	2019	Indicated for the maintenance treatment of adult patients with platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, following platinum-based chemotherapy achieving a complete or partial response	Multiple	M.R. Mirza[306]	2016	NCT01847274	Phase III	Randomized	Double-blind	2 arms
306	117	Niraparib	2	2020	Indicated for the maintenance treatment of adult patients with advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have achieved a complete or partial response after first-line platinum-based chemotherapy	Multiple	A. González-Martín[307]	2019	NCT02655016	Phase III	Randomized	Double-blind	2 arms
307	118	Fluzoparib	1	2020	Indicated for the treatment of platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with germline BRCA mutations who have received at least second-line chemotherapy	Multiple	N. Li[308]	2019	NCT03509636	PhaseIb	Nonrandomized	None	1 arm

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	Initial Pivotal Study (first author)	Publication Year	NCT	Clinical trial phase	Allocation	Masking	Arms
308	118	Fluzoparib	2	2021	Indicated for maintenance treatment of platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in adult patients who have achieved a complete or partial response after platinum-based chemotherapy	Multiple	Ning Li[309]	2022	NCT03863860	Phase III	Randomized	Double-blind	2 arms
309	119	Pamiparib	1	2021	Indicated for the treatment of patients with relapsed, advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer harboring a germline BRCA mutation, who have received two or more prior lines of chemotherapy	Single	Xiaohua Wu[310]	2022	NCT03333915	PhaseI/II	Nonrandomized	None	1 arm
310	120	Candonilimab	1	2022	Indicated for the treatment of recurrent or metastatic cervical cancer in patients who have previously failed platinum-based chemotherapy	Multiple	Not Available	Not Available	NCT04380805	PhaseIb/II	Nonrandomized	None	1 arm
311	120	Candonilimab	2	2024	Candonilimab in combination with XELOX (oxaliplatin and capecitabine) is indicated for first-line treatment of unresectable locally advanced, recurrent, or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma	Multiple	Jiafu Ji[311]	2024	NCT05008783	Phase III	Randomized	Double-blind	2 arms

REFERENCES

1. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS). *JCO*. 2011;29(21):2866-2874. doi:10.1200/JCO.2010.33.4235
2. Shepherd FA, Hirsh V, Smylie M, Findlay B, Santabárbara P. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer. *N Engl J Med*. 2005;353(2):123-132. doi:10.1056/NEJMoa050753
3. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. *The Lancet Oncology*. 2010;11(6):521-529. doi:10.1016/S1470-2045(10)70112-1
4. Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. *Annals of Oncology*. 2015;26(9):1883-1889. doi:10.1093/annonc/mdv270
5. Shi Y, Li Z, Liu X. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. *The Lancet Oncology*. 2013;14(10):953-961. doi:10.1016/S1470-2045(13)70355-3
6. He J, Su C, Liang W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. *The Lancet Respiratory Medicine*. 2021;9(9):1021-1029. doi:10.1016/S2213-2600(21)00134-X
7. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. *The Lancet Oncology*. 2014;15(2):213-222. doi:10.1016/S1470-2045(13)70604-1
8. Soria JC, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. *The Lancet Oncology*. 2015;16(8):897-907. doi:10.1016/S1470-2045(15)00006-6
9. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. *The Lancet Oncology*. 2017;18(11):1454-1466. doi:10.1016/S1470-2045(17)30608-3
10. Hu M, Wu YL, Zhu X, et al. Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial. *JCO*. 2018;36(15_suppl):9077-9077. doi:10.1200/JCO.2018.36.15_suppl.9077
11. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated *EGFR* -Mutated Advanced Non–Small-Cell Lung Cancer. *N Engl J Med*. 2018;378(2):113-125. doi:10.1056/NEJMoa1713137
12. Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected *EGFR* -Mutated Non–Small-Cell Lung Cancer. *N Engl J Med*. 2020;383(18):1711-1723. doi:10.1056/NEJMoa2027071
13. Lu S, Wang Q, Zhang G, et al. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. *Journal of Thoracic Oncology*. 2022;17(3):411-422. doi:10.1016/j.jtho.2021.10.024
14. Lu S, Dong X, Jian H, et al. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With *EGFR* Exon 19 Deletion or L858R Mutations. *JCO*. 2022;40(27):3162-3171. doi:10.1200/JCO.21.02641
15. Shi Y, Hu X, Zhang S, et al. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. *The Lancet Respiratory Medicine*. 2021;9(8):829-839. doi:10.1016/S2213-2600(20)30455-0
16. Shi Y, Chen G, Wang X, et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. *The Lancet Respiratory Medicine*. 2022;10(11):1019-1028. doi:10.1016/S2213-2600(22)00168-0
17. Lu S, Zhang Y, Zhang G, et al. Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study. *Journal of Thoracic Oncology*. 2022;17(10):1192-1204. doi:10.1016/j.jtho.2022.06.002
18. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus Chemotherapy in Advanced *ALK* -Positive Lung Cancer. *N Engl J Med*. 2013;368(25):2385-2394. doi:10.1056/NEJMoa1214886

19. Wu YL, Yang JCH, Kim DW, et al. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer. *JCO*. 2018;36(14):1405-1411. doi:10.1200/JCO.2017.75.5587

20. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated *ALK* -Positive Non–Small-Cell Lung Cancer. *N Engl J Med*. 2017;377(9):829-838. doi:10.1056/NEJMoa1704795

21. Shaw AT, Kim TM, Crinò L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. *The Lancet Oncology*. 2017;18(7):874-886. doi:10.1016/S1470-2045(17)30339-X

22. Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. *The Lancet*. 2017;389(10072):917-929. doi:10.1016/S0140-6736(17)30123-X

23. Yang Y, Zhou J, Zhou J, et al. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. *The Lancet Respiratory Medicine*. 2020;8(1):45-53. doi:10.1016/S2213-2600(19)30252-8

24. Horn L, Wang Z, Wu G, et al. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer: A Randomized Clinical Trial. *JAMA Oncol*. 2021;7(11):1617. doi:10.1001/jamaoncol.2021.3523

25. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in *ALK* -Positive Non–Small-Cell Lung Cancer. *N Engl J Med*. 2018;379(21):2027-2039. doi:10.1056/NEJMoa1810171

26. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. *JCO*. 2020;38(31):3592-3603. doi:10.1200/JCO.20.00505

27. Lu S, Zhou Q, Liu X, et al. Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China. *Journal of Thoracic Oncology*. 2022;17(6):816-826. doi:10.1016/j.jtho.2022.02.014

28. Shaw AT, Bauer TM, De Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced *ALK* -Positive Lung Cancer. *N Engl J Med*. 2020;383(21):2018-2029. doi:10.1056/NEJMoa2027187

29. Shi Y, Chen J, Zhang H, et al. Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT). *BMC Med*. 2023;21(1):72. doi:10.1186/s12916-023-02738-5

30. Shi Y, Chen J, Yang R, et al. Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE). *Journal of Thoracic Oncology*. 2024;19(6):912-927. doi:10.1016/j.jtho.2024.01.013

31. Cassidy J, Clarke S, Díaz-Rubio E, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. *Br J Cancer*. 2011;105(1):58-64. doi:10.1038/bjc.2011.201

32. Sandler A, Schiller JH, Johnson DH. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer. *N Engl J Med*. 2006;355:2542-2550.

33. Wick W, Gorlia T, Bendszus M, et al. Lomustine and Bevacizumab in Progressive Glioblastoma. *N Engl J Med*. 2017;377(20):1954-1963. doi:10.1056/NEJMoa1707358

34. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N Engl J Med*. 2020;382(20):1894-1905. doi:10.1056/NEJMoa1915745

35. Burger RA, Fleming GF, Mannel RS, Greer BE, Liang SX. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. *N Engl J Med*. 2011;365:2473-2483.

36. Tewari KS, Sill MW, Long HJ, et al. Improved Survival with Bevacizumab in Advanced Cervical Cancer. *N Engl J Med*. 2014;370(8):734-743. doi:10.1056/NEJMoa1309748

37. Han B, Li K, Wang Q, et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. *JAMA Oncol*. 2018;4(11):1569. doi:10.1001/jamaoncol.2018.3039

38. Chi Y, Yao Y, Wang S, et al. Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial. *JCO*. 2018;36(15_suppl):11503-11503. doi:10.1200/JCO.2018.36.15_suppl.11503

39. Cheng Y, Wang Q, Li K, et al. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. *Br J Cancer*. 2021;125(3):366-371. doi:10.1038/s41416-021-01356-3

40. Li D, Chi Y, Chen X, et al. Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial. *Clinical Cancer Research*. 2021;27(13):3567-3575. doi:10.1158/1078-0432.CCR-20-2950

41. Chi Y, Zheng X, Zhang Y, et al. Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial. *Clinical Cancer Research*. 2023;29(20):4047-4056. doi:10.1158/1078-0432.CCR-22-3406

42. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. *Cancer*. 2010;116(18):4256-4265. doi:10.1002/cncr.25219

43. Yao JC, Shah MH, Ito T, et al. Everolimus for Advanced Pancreatic Neuroendocrine Tumors. *N Engl J Med*. 2011;364(6):514-523. doi:10.1056/NEJMoa1009290

44. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. *The Lancet*. 2013;381(9861):125-132. doi:10.1016/S0140-6736(12)61134-9

45. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. *The Lancet*. 2013;381(9869):817-824. doi:10.1016/S0140-6736(12)61767-X

46. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. *The Lancet*. 2016;387(10022):968-977. doi:10.1016/S0140-6736(15)00817-X

47. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. *Adv Ther*. 2013;30(10):870-884. doi:10.1007/s12325-013-0060-1

48. Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. *Annals of Oncology*. 2014;25(12):2357-2362. doi:10.1093/annonc/mdu456

49. Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. *The Lancet Oncology*. 2021;22(7):959-969. doi:10.1016/S1470-2045(21)00247-3

50. Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. *The Lancet Diabetes & Endocrinology*. 2021;9(8):491-501. doi:10.1016/S2213-8587(21)00120-0

51. Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of Selpercatinib in *RET* Fusion–Positive Non–Small-Cell Lung Cancer. *N Engl J Med*. 2020;383(9):813-824. doi:10.1056/NEJMoa2005653

52. Wirth LJ, Sherman E, Robinson B, et al. Efficacy of Selpercatinib in *RET* -Altered Thyroid Cancers. *N Engl J Med*. 2020;383(9):825-835. doi:10.1056/NEJMoa2005651

53. Lu S, Fang J, Li X, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. *The Lancet Respiratory Medicine*. 2021;9(10):1154-1164. doi:10.1016/S2213-2600(21)00084-9

54. Yu Y, Zhou J, Li X, et al. Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial. *eClinicalMedicine*. 2023;59:101952. doi:10.1016/j.eclinm.2023.101952

55. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. *N Engl J Med*. 2014;371(20):1877-1888. doi:10.1056/NEJMoa1406037

56. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *The Lancet*. 2015;386(9992):444-451. doi:10.1016/S0140-6736(15)60898-4

57. Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III *BRAF* -Mutated Melanoma. *N Engl J Med*. 2017;377(19):1813-1823. doi:10.1056/NEJMoa1708539

58. Planchard D, Kim TM, Mazieres J, et al. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. *The Lancet Oncology*. 2016;17(5):642-650. doi:10.1016/S1470-2045(16)00077-2

59. Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. *The Lancet Oncology*. 2016;17(7):984-993. doi:10.1016/S1470-2045(16)30146-2

60. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. *The Lancet Oncology*. 2017;18(10):1307-1316. doi:10.1016/S1470-2045(17)30679-4

61. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. *The Lancet Oncology*. 2020;21(2):271-282. doi:10.1016/S1470-2045(19)30691-6

62. Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. *The Lancet Oncology*. 2020;21(2):261-270. doi:10.1016/S1470-2045(19)30690-4

63. Desai AV, Robinson GW, Gauvain K, et al. Entrectinib in children and young adults with solid or primary CNS tumors harboring *NTRK* , *ROS1* , or *ALK* aberrations (STARTRK-NG). *Neuro-Oncology*. 2022;24(10):1776-1789. doi:10.1093/neuonc/noac087

64. Zhou C, Ramalingam SS, Kim TM, et al. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With *EGFR* Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. *JAMA Oncol*. 2021;7(12):e214761. doi:10.1001/jamaoncol.2021.4761

65. Wu YL, Lu S, Cheng Y, et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. *Journal of Thoracic Oncology*. 2019;14(5):867-875. doi:10.1016/j.jtho.2019.01.006

66. Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med*. 2016;375(19):1856-1867. doi:10.1056/NEJMoa1602252

67. Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. *Oral Oncology*. 2018;81:45-51. doi:10.1016/j.oraloncology.2018.04.008

68. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet*. 2017;390(10111):2461-2471. doi:10.1016/S0140-6736(17)31827-5

69. Chen LT, Satoh T, Ryu MH, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. *Gastric Cancer*. 2020;23(3):510-519. doi:10.1007/s10120-019-01034-7

70. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. *The Lancet*. 2021;397(10272):375-386. doi:10.1016/S0140-6736(20)32714-8

71. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *The Lancet*. 2021;398(10294):27-40. doi:10.1016/S0140-6736(21)00797-2

72. Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. *N Engl J Med*. 2022;386(5):449-462. doi:10.1056/NEJMoa2111380

73. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. *N Engl J Med*. 2021;384(13):1191-1203. doi:10.1056/NEJMoa2032125

74. Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. *N Engl J Med*. 2022;386(21):1973-1985. doi:10.1056/NEJMoa2202170

75. Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. *N Engl J Med*. 2021;384(22):2102-2114. doi:10.1056/NEJMoa2034442

76. André T, Elez E, Van Cutsem E, et al. Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer. *N Engl J Med*. 2024;391(21):2014-2026. doi:10.1056/NEJMoa2402141

77. Van Der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma. *N Engl J Med*. 2023;389(19):1778-1789. doi:10.1056/NEJMoa2309863

78. Si L, Zhang X, Shu Y, et al. A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). *Translational Oncology*. 2019;12(6):828-835. doi:10.1016/j.tranon.2019.02.007

79. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. *N Engl J Med*. 2018;378(22):2078-2092. doi:10.1056/NEJMoa1801005

80. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. *The Lancet*. 2019;393(10183):1819-1830. doi:10.1016/S0140-6736(18)32409-7

81. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. *N Engl J Med*. 2018;379(21):2040-2051. doi:10.1056/NEJMoa1810865

82. Kojima T, Shah MA, Muro K, et al. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. *JCO*. 2020;38(35):4138-4148. doi:10.1200/JCO.20.01888

83. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *The Lancet*. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7

84. André T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. *N Engl J Med*. 2020;383(23):2207-2218. doi:10.1056/NEJMoa2017699

85. Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. *The Lancet*. 2021;398(10302):759-771. doi:10.1016/S0140-6736(21)01234-4

86. Qin S, Chen Z, Fang W, et al. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. *JCO*. 2023;41(7):1434-1443. doi:10.1200/JCO.22.00620

87. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. *N Engl J Med*. 2020;382(9):810-821. doi:10.1056/NEJMoa1910549

88. Schmid P, Cortes J, Dent R, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. *N Engl J Med*. 2022;386(6):556-567. doi:10.1056/NEJMoa2112651

89. Le DT, Kim TW, Van Cutsem E, et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164. *JCO*. 2020;38(1):11-19. doi:10.1200/JCO.19.02107

90. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. *JCO*. 2020;38(1):1-10. doi:10.1200/JCO.19.02105

91. Rha SY, Oh DY, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. *The Lancet Oncology*. 2023;24(11):1181-1195. doi:10.1016/S1470-2045(23)00515-6

92. Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet*. 2023;401(10391):1853-1865. doi:10.1016/S0140-6736(23)00727-4

93. Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab in HER2-Positive Gastric Cancer. *N Engl J Med*. 2024;391(14):1360-1362. doi:10.1056/NEJMc2408121

94. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. *N Engl J Med*. 2017;377(20):1919-1929. doi:10.1056/NEJMoa1709937

95. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *The Lancet*. 2019;394(10212):1929-1939. doi:10.1016/S0140-6736(19)32222-6

96. Oh DY, Ruth He A, Qin S, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. *NEJM Evidence*. 2022;1(8). doi:10.1056/EVIDoa2200015

97. Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *N Engl J Med*. 2018;379(23):2220-2229. doi:10.1056/NEJMoa1809064

98. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N Engl J Med*. 2020;382(20):1894-1905. doi:10.1056/NEJMoa1915745

99. Herbst RS, Giaccone G, De Marinis F, et al. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC. *N Engl J Med*. 2020;383(14):1328-1339. doi:10.1056/NEJMoa1917346

100. Nishio M, Barlesi F, West H, et al. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. *Journal of Thoracic Oncology*. 2021;16(4):653-664. doi:10.1016/j.jtho.2020.11.025

101. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. *The Lancet*. 2021;398(10308):1344-1357. doi:10.1016/S0140-6736(21)02098-5

102. Song Y, Wu J, Chen X, et al. A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. *Clinical Cancer Research*. 2019;25(24):7363-7369. doi:10.1158/1078-0432.CCR-19-1680

103. Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. *The Lancet Oncology*. 2020;21(4):571-580. doi:10.1016/S1470-2045(20)30011-5

104. Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. *The Lancet Oncology*. 2020;21(6):832-842. doi:10.1016/S1470-2045(20)30110-8

105. Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. *The Lancet Respiratory Medicine*. 2021;9(3):305-314. doi:10.1016/S2213-2600(20)30365-9

106. Yang Y, Zhou T, Chen X, et al. Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study). *J Immunother Cancer*. 2021;9(12):e003790. doi:10.1136/jitc-2021-003790

107. Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. *The Lancet Oncology*. 2021;22(8):1162-1174. doi:10.1016/S1470-2045(21)00302-8

108. Ren S, Chen J, Xu X, et al. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. *Journal of Thoracic Oncology*. 2022;17(4):544-557. doi:10.1016/j.jtho.2021.11.018

109. Luo H, Lu J, Bai Y, et al. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. *JAMA*. 2021;326(10):916. doi:10.1001/jama.2021.12836

110. Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. *The Lancet*. 2023;402(10408):1133-1146. doi:10.1016/S0140-6736(23)00961-3

111. Song Y, Gao Q, Zhang H, et al. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. *Leukemia*. 2020;34(2):533-542. doi:10.1038/s41375-019-0545-2

112. Ye D, Liu J, Zhou A, et al. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. *Cancer Science*. 2021;112(1):305-313. doi:10.1111/cas.14681

113. Wang J, Lu S, Yu X, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncol*. 2021;7(5):709. doi:10.1001/jamaoncol.2021.0366

114. Lu S, Wang J, Yu Y, et al. Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. *Journal of Thoracic Oncology*. 2021;16(9):1512-1522. doi:10.1016/j.jtho.2021.05.005

115. Ren Z, Ducreux M, Abou-Alfa GK, et al. Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial. *Liver Cancer*. 2023;12(1):72-84. doi:10.1159/000527175

116. Zhou C, Huang D, Fan Y, et al. Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial. *Journal of Thoracic Oncology*. 2023;18(1):93-105. doi:10.1016/j.jtho.2022.09.217

117. Li J, Xu Y, Zang A, et al. Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/ mismatch repair-deficient solid tumors. *Chin J Cancer Res*. 2024;36(3).

118. Shen L, Kato K, Kim SB, et al. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. *JCO*. 2022;40(26):3065-3076. doi:10.1200/JCO.21.01926

119. Yang Y, Pan J, Wang H, et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). *Cancer Cell*. 2023;41(6):1061-1072.e4. doi:10.1016/j.ccell.2023.04.014

120. Qiu MZ, Oh DY, Kato K, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. *BMJ*. Published online May 28, 2024:e078876. doi:10.1136/bmj-2023-078876

121. Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. *The Lancet Oncology*. 2023;24(5):483-495. doi:10.1016/S1470-2045(23)00108-0

122. Qin S, Kudo M, Meyer T, et al. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. *JAMA Oncol*. 2023;9(12):1651. doi:10.1001/jamaoncol.2023.4003

123. Cheng Y, Fan Y, Zhao Y, et al. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. *Journal of Thoracic Oncology*. 2024;19(7):1073-1085. doi:10.1016/j.jtho.2024.03.008

124. Yue D, Wang W, Liu H, et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial. *The Lancet Respiratory Medicine*. 2025;13(2):119-129. doi:10.1016/S2213-2600(24)00269-8

125. Shi Y, Su H, Song Y, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. *The Lancet Haematology*. 2019;6(1):e12-e19. doi:10.1016/S2352-3026(18)30192-3

126. Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. *BMJ*. Published online April 19, 2022:e068714. doi:10.1136/bmj-2021-068714

127. Yang Y, Wang Z, Fang J, et al. Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). *Journal of Thoracic Oncology*. 2020;15(10):1636-1646. doi:10.1016/j.jtho.2020.07.014

128. Zhou C, Wu L, Fan Y, et al. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). *Journal of Thoracic Oncology*. 2021;16(9):1501-1511. doi:10.1016/j.jtho.2021.04.011

129. Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. *The Lancet Oncology*. 2021;22(7):977-990. doi:10.1016/S1470-2045(21)00252-7

130. Xu J, Jiang H, Pan Y, et al. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial. *JAMA*. 2023;330(21):2064. doi:10.1001/jama.2023.19918

131. Lu S, Wu L, Jian H, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. *The Lancet Respiratory Medicine*. 2023;11(7):624-636. doi:10.1016/S2213-2600(23)00135-2

132. Zhou C, Wang Z, Sun Y, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. *The Lancet Oncology*. 2022;23(2):220-233. doi:10.1016/S1470-2045(21)00650-1

133. Zhou Q, Chen M, Jiang O, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. *The Lancet Oncology*. 2022;23(2):209-219. doi:10.1016/S1470-2045(21)00630-6

134. Huang H, Tao R, Hao S, et al. Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study. *JCO*. 2023;41(16):3032-3041. doi:10.1200/JCO.22.02367

135. Li J, Chen Z, Bai Y, et al. First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. *Nat Med*. 2024;30(3):740-748. doi:10.1038/s41591-024-02797-y

136. Zhang X, Wang J, Wang G, et al. LBA79 GEMSTONE-303: Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. *Annals of Oncology*. 2023;34:S1319. doi:10.1016/j.annonc.2023.10.080

137. Tang B, Chi Z, Chen Y, et al. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial. *Clinical Cancer Research*. 2020;26(16):4250-4259. doi:10.1158/1078-0432.CCR-19-3922

138. Sheng X, Chen H, Hu B, et al. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03. *Clinical Cancer Research*. 2022;28(3):489-497. doi:10.1158/1078-0432.CCR-21-2210

139. Wang FH, Wei XL, Feng J, et al. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). *JCO*. 2021;39(7):704-712. doi:10.1200/JCO.20.02712

140. Mai HQ, Chen QY, Chen D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. *Nat Med*. 2021;27(9):1536-1543. doi:10.1038/s41591-021-01444-0

141. Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. *Cancer Cell*. 2022;40(3):277-288.e3. doi:10.1016/j.ccell.2022.02.007

142. Wang Z, Wu L, Li B, et al. Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01). *JCO*. 2023;41(3):651-663. doi:10.1200/JCO.22.00727

143. Lu S, Zhang W, Wu L, et al. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. *JAMA*. 2024;331(3):201. doi:10.1001/jama.2023.24735

144. Yan XQ, Ye MJ, Zou Q, et al. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. *Annals of Oncology*. 2024;35(2):190-199. doi:10.1016/j.annonc.2023.09.3108

145. Cheng Y, Liu Y, Zhang W, et al. LBA93 EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC). *Annals of Oncology*. 2023;34:S1334. doi:10.1016/j.annonc.2023.10.096

146. Jiang Z, Ouyang Q, Sun T, et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. *Nat Med*. 2024;30(1):249-256. doi:10.1038/s41591-023-02677-x

147. Qin S, Li J, Zhong H, et al. Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial. *Br J Cancer*. 2022;127(12):2241-2248. doi:10.1038/s41416-022-02001-3

148. Zhou C, Hu Y, Arkania E, et al. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004). *Cancer Cell*. 2024;42(2):198-208.e3. doi:10.1016/j.ccell.2023.12.004

149. Cheng Y, Han L, Wu L, et al. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. *JAMA*. 2022;328(12):1223. doi:10.1001/jama.2022.16464

150. Song Y, Zhang B, Xin D, et al. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. *Nat Med*. 2023;29(2):473-482. doi:10.1038/s41591-022-02179-2

151. Song Y, Zhou K, Jin C, et al. Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). *Front Oncol*. 2022;12:925236. doi:10.3389/fonc.2022.925236

152. Zhong H, Sun S, Chen J, et al. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. *The Lancet Respiratory Medicine*. 2024;12(5):355-365. doi:10.1016/S2213-2600(23)00431-9

153. Chen X, Wang W, Zou Q, et al. Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study. *Sig Transduct Target Ther*. 2024;9(1):148. doi:10.1038/s41392-024-01865-6

154. Wang J, Zhou C, Yao W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*. 2022;23(6):739-747. doi:10.1016/S1470-2045(22)00224-8

155. Escudier B, Szczylik C, Negrier S, et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. *N Engl J Med*. 2007;356:125- - 34.

156. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. *JCO*. 2009;27(20):3312-3318. doi:10.1200/JCO.2008.19.5511

157. Llovet JM, Hilgard P, de Oliveira AC, et al. Sorafenib in Advanced Hepatocellular Carcinoma. *N Engl J Med*. 2008;359:378-390.

158. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. *The Lancet*. 2014;384(9940):319-328. doi:10.1016/S0140-6736(14)60421-9

159. Grothey A, Cutsem EV, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *The Lancet*. 2013;381(9863):303-312. doi:10.1016/S0140-6736(12)61900-X

160. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *The Lancet*. 2013;381(9863):295-302. doi:10.1016/S0140-6736(12)61857-1

161. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet*. 2017;389(10064):56-66. doi:10.1016/S0140-6736(16)32453-9

162. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *The Lancet*. 2018;391(10126):1163-1173. doi:10.1016/S0140-6736(18)30207-1

163. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. *N Engl J Med*. 2015;372(7):621-630. doi:10.1056/NEJMoa1406470

164. Qin S, Bi F, Gu S, et al. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. *JCO*. 2021;39(27):3002-3011. doi:10.1200/JCO.21.00163

165. Lin Y, Qin S, Yang H, et al. Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer. *Clinical Cancer Research*. 2023;29(15):2791-2799. doi:10.1158/1078-0432.CCR-22-3613

166. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. *N Engl J Med*. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101

167. Perez EA, Romond EH, Suman VJ, et al. Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31. *JCO*. 2011;29(25):3366-3373. doi:10.1200/JCO.2011.35.0868

168. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *The Lancet*. 2010;376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X

169. Li J, Qin S, Xu J, et al. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. *JCO*. 2016;34(13):1448-1454. doi:10.1200/JCO.2015.63.5995

170. Qin S, Li Q, Gu S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. *The Lancet Gastroenterology & Hepatology*. 2021;6(7):559-568. doi:10.1016/S2468-1253(21)00109-6

171. Peng Z, Liu T, Wei J, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. *Cancer Communications*. 2021;41(11):1173-1182. doi:10.1002/cac2.12214

172. Sheng X, Wang L, He Z, et al. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials. *JCO*. 2024;42(12):1391-1402. doi:10.1200/JCO.22.02912

173. Sheng X, Yang K, Ji Y, et al. Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression. *JCO*. 2024;42(16_suppl):4568-4568. doi:10.1200/JCO.2024.42.16_suppl.4568

174. Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *The Lancet Oncology*. 2014;15(11):1224-1235. doi:10.1016/S1470-2045(14)70420-6

175. Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*. 2019;20(2):282-296. doi:10.1016/S1470-2045(18)30937-9

176. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. *N Engl J Med*. 2003;348(11):994-1004. doi:10.1056/NEJMoa022457

177. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. *Blood*. 2002;99(6):1928-1937. doi:10.1182/blood.V99.6.1928

178. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at the 43rd Annual Meeting of The American Society of Hematology, Orlando, FL, December 11, 2001. *Blood*. 2002;99(10):3530-3539. doi:10.1182/blood.V99.10.3530

179. Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. *N Engl J Med*. 2002;347(7):472-480. doi:10.1056/NEJMoa020461

180. Schultz KR, Bowman WP, Aledo A, et al. Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. *JCO*. 2009;27(31):5175-5181. doi:10.1200/JCO.2008.21.2514

181. Wassmann B, Pfeifer H, Scheuring UJ, et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. *Blood*. 2004;103(4):1495-1498. doi:10.1182/blood-2003-01-0154

182. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases. *Clinical Cancer Research*. 2008;14(9):2717-2725. doi:10.1158/1078-0432.CCR-07-4575

183. DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. *The Lancet*. 2009;373(9669):1097-1104. doi:10.1016/S0140-6736(09)60500-6

184. Motzer Robert J., Hutson Thomas E., Tomczak Piotr, et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. *N Engl J Med*. 2007;356(2):115-124. doi:10.1056/NEJMoa065044

185. Demetri GD, Oosterom AT van, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *The Lancet*. 2006;368(9544):1329-1338. doi:10.1016/S0140-6736(06)69446-4

186. Raymond Eric, Dahan Laetitia, Raoul Jean-Luc, et al. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. *N Engl J Med*. 2011;364(6):501-513. doi:10.1056/NEJMoa1003825

187. Heinrich MC, Jones RL, Von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. *The Lancet Oncology*. 2020;21(7):935-946. doi:10.1016/S1470-2045(20)30269-2

188. Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. *The Lancet Oncology*. 2020;21(7):923-934. doi:10.1016/S1470-2045(20)30168-6

189. Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. *The Lancet Oncology*. 2020;21(11):1500-1512. doi:10.1016/S1470-2045(20)30496-4

190. Qin S, Li J, Wang L, et al. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With *RAS* Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. *JCO*. 2018;36(30):3031-3039. doi:10.1200/JCO.2018.78.3183

191. Vermorken JB, Mesia R, Rivera F, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. *N Engl J Med*. 2008;359(11):1116-1127. doi:10.1056/NEJMoa0802656

192. Bonner James A., Harari Paul M., Giralt Jordi, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med*. 2006;354(6):567-578. doi:10.1056/NEJMoa053422

193. Li J, Qin S, Xu RH, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. *JAMA*. 2018;319(24):2486. doi:10.1001/jama.2018.7855

194. Li J, Deng Y, Zhang W, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. *J Hematol Oncol*. 2021;14(1):95. doi:10.1186/s13045-021-01095-1

195. Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. *The Lancet Oncology*. 2020;21(4):531-540. doi:10.1016/S1470-2045(19)30856-3

196. Zhang B, Song Y, Luo S, et al. Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. *Cell Reports Medicine*. 2023;4(12):101301. doi:10.1016/j.xcrm.2023.101301

197. Cui C, Chen Y, Luo Z, et al. Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study. *BMC Cancer*. 2023;23(1):121. doi:10.1186/s12885-022-10473-y

198. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. *The Lancet Oncology*. 2020;21(5):671-684. doi:10.1016/S1470-2045(20)30109-1

199. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia. *JCO*. 2008;26(19):3204-3212. doi:10.1200/JCO.2007.14.9260

200. Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. *Blood*. 2014;123(15):2317-2324. doi:10.1182/blood-2013-10-532341

201. Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. *American J Hematol*. 2016;91(9):869-874. doi:10.1002/ajh.24423

202. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. *Blood*. 2011;117(4):1141-1145. doi:10.1182/blood-2010-03-277152

203. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. *N Engl J Med*. 2010;362(24):2251-2259. doi:10.1056/NEJMoa0912614

204. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. *The Lancet Oncology*. 2011;12(9):841-851. doi:10.1016/S1470-2045(11)70201-7

205. Hijiya N, Maschan A, Rizzari C, et al. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia. *Blood*. 2019;134(23):2036-2045. doi:10.1182/blood.2019000069

206. Jiang Q, Li Z, Qin Y, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. *J Hematol Oncol*. 2022;15(1):113. doi:10.1186/s13045-022-01334-z

207. Zhang L, Meng L, Liu B, et al. Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study. *Clinical Cancer Research*. 2021;27(1):70-77. doi:10.1158/1078-0432.CCR-20-1600

208. Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. *The Lancet*. 2016;387(10020):770-778. doi:10.1016/S0140-6736(15)00667-4

209. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. *N Engl J Med*. 2014;371(3):213-223. doi:10.1056/NEJMoa1400376

210. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in Previously Treated Waldenström's Macroglobulinemia. *N Engl J Med*. 2015;372(15):1430-1440. doi:10.1056/NEJMoa1501548

211. Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. *N Engl J Med*. 2018;378(25):2399-2410. doi:10.1056/NEJMoa1802917

212. Song Y, Zhou K, Zou D, et al. Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. *Clinical Cancer Research*. 2020;26(16):4216-4224. doi:10.1158/1078-0432.CCR-19-3703

213. Xu W, Yang S, Zhou K, et al. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. *J Hematol Oncol*. 2020;13(1):48. doi:10.1186/s13045-020-00884-4

214. An G, Zhou D, Cheng S, et al. A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. *Clinical Cancer Research*. 2021;27(20):5492-5501. doi:10.1158/1078-0432.CCR-21-0539

215. Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. *The Lancet Oncology*. 2022;23(8):1031-1043. doi:10.1016/S1470-2045(22)00293-5

216. Deng LJ, Zhou KS, Liu LH, et al. Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study. *Blood Advances*. 2023;7(16):4349-4357. doi:10.1182/bloodadvances.2022009168

217. Xu W, Zhou K, Wang T, et al. Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. *American J Hematol*. 2023;98(4):571-579. doi:10.1002/ajh.26826

218. Deng L, Li Z, Zhang H, et al. Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study. *American J Hematol*. 2023;98(11):1742-1750. doi:10.1002/ajh.27064

219. APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant multiple myeloma. *Clin Adv Hematol Oncol*. 2003;1(3):190.

220. San Miguel Jesús F., Schlag Rudolf, Khuageva Nuriet K., et al. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. *N Engl J Med*. 2008;359(9):906-917. doi:10.1056/NEJMoa0801479

221. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma. *JCO*. 2006;24(30):4867-4874. doi:10.1200/JCO.2006.07.9665

222. Robak T, Huang H, Jin J, et al. Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma. *N Engl J Med*. 2015;372(10):944-953. doi:10.1056/NEJMoa1412096

223. Du J, Fang B, Li J, et al. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China. *Int J Hematol*. 2021;113(3):422-429. doi:10.1007/s12185-020-03044-z

224. Moreau P, Masszi T, Grzasko N, et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med*. 2016;374(17):1621-1634. doi:10.1056/NEJMoa1516282

225. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. *N Engl J Med*. 2007;357(21):2133-2142. doi:10.1056/NEJMoa070596

226. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. *N Engl J Med*. 2014;371(10):906-917. doi:10.1056/NEJMoa1402551

227. Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. *JCO*. 2019;37(14):1188-1199. doi:10.1200/JCO.19.00010

228. Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. *The Lancet Oncology*. 2013;14(11):1055-1066. doi:10.1016/S1470-2045(13)70380-2

229. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. *The Lancet*. 2016;387(10027):1551-1560. doi:10.1016/S0140-6736(15)01120-4

230. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. *N Engl J Med*. 2016;375(8):754-766. doi:10.1056/NEJMoa1606038

231. Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. *The Lancet*. 2020;395(10218):132-141. doi:10.1016/S0140-6736(19)32956-3

232. Vogl DT, Dingli D, Cornell RF, et al. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. *JCO*. 2018;36(9):859-866. doi:10.1200/JCO.2017.75.5207

233. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory *FLT3* -Mutated AML. *N Engl J Med*. 2019;381(18):1728-1740. doi:10.1056/NEJMoa1902688

234. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. *N Engl J Med*. 2020;383(7):617-629. doi:10.1056/NEJMoa2012971

235. Norsworthy KJ, Luo L, Hsu V, et al. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation. *Clinical Cancer Research*. 2019;25(11):3205-3209. doi:10.1158/1078-0432.CCR-18-3749

236. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. *N Engl J Med*. 2017;376(9):836-847. doi:10.1056/NEJMoa1609783

237. Locatelli F, Zugmaier G, Rizzari C, et al. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. *JAMA*. 2021;325(9):843. doi:10.1001/jama.2021.0987

238. Lin N, Zhang M, Bai H, et al. Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study. *European Journal of Cancer*. 2022;164:117-126. doi:10.1016/j.ejca.2021.07.021

239. Xia L, Wang J, Wang C, et al. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study. *International Journal of Gynecological Cancer*. 2023;33(12):1861-1868. doi:10.1136/ijgc-2023-004705

240. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. *The Lancet*. 2011;377(9759):42-51. doi:10.1016/S0140-6736(10)62175-7

241. Van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. *Blood*. 2006;108(10):3295-3301. doi:10.1182/blood-2006-05-021113

242. Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. *The Lancet Oncology*. 2017;18(8):1076-1088. doi:10.1016/S1470-2045(17)30444-8

243. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. *The Lancet*. 2010;376(9747):1164-1174. doi:10.1016/S0140-6736(10)61381-5

244. Shi Y, Zhang Q, Hong X, et al. Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera ®) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial. *Hematological Oncology*. 2022;40(5):930-940. doi:10.1002/hon.3054

245. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. *N Engl J Med*. 2017;377(14):1331-1344. doi:10.1056/NEJMoa1614598

246. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. *N Engl J Med*. 2022;386(4):351-363. doi:10.1056/NEJMoa2115304

247. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *JCO*. 2020;38(2):155-165. doi:10.1200/JCO.19.00172

248. Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. *Blood Advances*. 2022;6(2):533-543. doi:10.1182/bloodadvances.2021005794

249. Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. *Blood*. 2017;130(25):2709-2717. doi:10.1182/blood-2017-05-780049

250. Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. *Blood*. 2016;128(12):1562-1566. doi:10.1182/blood-2016-02-699850

251. Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. *The Lancet*. 2017;390(10094):555-566. doi:10.1016/S0140-6736(17)31266-7

252. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. *N Engl J Med*. 2016;375(8):740-753. doi:10.1056/NEJMoa1509277

253. Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. *Annals of Oncology*. 2015;26(8):1766-1771. doi:10.1093/annonc/mdv237

254. Jiang Z, Li W, Hu X, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*. 2019;20(6):806-815. doi:10.1016/S1470-2045(19)30164-0

255. Wang T, Sun X, Qiu L, et al. The Oral PI3Kd Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial. *CLINICAL CANCER RESEARCH*.

256. Mesa RA, Gotlib J, Gupta V, et al. Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial. *JCO*. 2013;31(10):1285-1292. doi:10.1200/JCO.2012.44.4489

257. Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. *The Lancet Oncology*. 2018;19(9):1192-1204. doi:10.1016/S1470-2045(18)30379-6

258. Van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. *The Lancet Oncology*. 2014;15(9):966-974. doi:10.1016/S1470-2045(14)70319-5

259. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. *JCO*. 2010;28(6):1061-1068. doi:10.1200/JCO.2009.23.9764

260. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *The Lancet*. 2011;378(9807):1931-1939. doi:10.1016/S0140-6736(11)61613-9

261. de Bono Johann S., Logothetis Christopher J., Molina Arturo, et al. Abiraterone and Increased Survival in Metastatic Prostate Cancer. *N Engl J Med*. 2011;364(21):1995-2005. doi:10.1056/NEJMoa1014618

262. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. *N Engl J Med*. 2017;377(4):352-360. doi:10.1056/NEJMoa1704174

263. Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. *N Engl J Med*. 2018;378(15):1408-1418. doi:10.1056/NEJMoa1715546

264. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. *N Engl J Med*. 2019;381(1):13-24. doi:10.1056/NEJMoa1903307

265. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. *N Engl J Med*. 2014;371(5):424-433. doi:10.1056/NEJMoa1405095

266. Hussain M, Fizazi K, Saad F, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med*. 2018;378(26):2465-2474. doi:10.1056/NEJMoa1800536

267. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. *JCO*. 2019;37(32):2974-2986. doi:10.1200/JCO.19.00799

268. Fizazi K, Shore N, Tammela TL, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med*. 2019;380(13):1235-1246. doi:10.1056/NEJMoa1815671

269. Smith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. *N Engl J Med*. 2022;386(12):1132-1142. doi:10.1056/NEJMoa2119115

270. Gu W, Han W, Luo H, et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. *The Lancet Oncology*. 2022;23(10):1249-1260. doi:10.1016/S1470-2045(22)00507-1

271. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. *The Lancet Oncology*. 2017;18(9):1274-1284. doi:10.1016/S1470-2045(17)30469-2

272. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med*. 2018;379(26):2495-2505. doi:10.1056/NEJMoa1810858

273. De Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med*. 2020;382(22):2091-2102. doi:10.1056/NEJMoa1911440

274. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. *N Engl J Med*. 2019;381(25):2416-2428. doi:10.1056/NEJMoa1911361

275. Von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. *N Engl J Med*. 2019;380(7):617-628. doi:10.1056/NEJMoa1814017

276. Verma S, Miles D, Gianni L, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. *N Engl J Med*. 2012;367(19):1783-1791. doi:10.1056/NEJMoa1209124

277. Von Minckwitz G, Procter M, De Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. *N Engl J Med*. 2017;377(2):122-131. doi:10.1056/NEJMoa1703643

278. Shao Z, Pang D, Yang H, et al. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. *JAMA Oncol*. 2020;6(3):e193692. doi:10.1001/jamaoncol.2019.3692

279. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. *N Engl J Med*. 2015;372(8):724-734. doi:10.1056/NEJMoa1413513

280. Cortés J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. *N Engl J Med*. 2022;386(12):1143-1154. doi:10.1056/NEJMoa2115022

281. Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. *N Engl J Med*. 2022;387(1):9-20. doi:10.1056/NEJMoa2203690

282. Bian L, Xu BH, Di LJ, et al. Phase III randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study. *Natl Med J China*. 2020;100(30):2351-2357. doi:10.3760/cma.j.cn112137-20200116-00105

283. Geyer Charles E., Forster John, Lindquist Deborah, et al. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. *New England Journal of Medicine*. 2006;355(26):2733-2743. doi:10.1056/NEJMoa064320

284. Ma F, Ouyang Q, Li W, et al. Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. *JCO*. 2019;37(29):2610-2619. doi:10.1200/JCO.19.00108

285. Wu J, Jiang Z, Liu Z, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. *BMC Med*. 2022;20(1):498. doi:10.1186/s12916-022-02708-3

286. Ma F, Yan M, Li W, et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. *BMJ*. Published online October 31, 2023:e076065. doi:10.1136/bmj-2023-076065

287. Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*. 2017;18(12):1688-1700. doi:10.1016/S1470-2045(17)30717-9

288. Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. *N Engl J Med*. 2016;375(20):1925-1936. doi:10.1056/NEJMoa1607303

289. Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. *npj Breast Cancer*. 2019;5(1):5. doi:10.1038/s41523-018-0097-z

290. Sledge GW, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial. *JAMA Oncol*. 2020;6(1):116. doi:10.1001/jamaoncol.2019.4782

291. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE). *JCO*. 2020;38(34):3987-3998. doi:10.1200/JCO.20.02514

292. Xu B, Zhang Q, Zhang P, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. *Nat Med*. 2021;27(11):1904-1909. doi:10.1038/s41591-021-01562-9

293. Zhang P, Zhang Q, Tong Z, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*. 2023;24(6):646-657. doi:10.1016/S1470-2045(23)00172-9

294. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. *The Lancet Oncology*. 2018;19(7):904-915. doi:10.1016/S1470-2045(18)30292-4

295. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. *Annals of Oncology*. 2018;29(7):1541-1547. doi:10.1093/annonc/mdy155

296. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. *N Engl J Med*. 2022;386(10):942-950. doi:10.1056/NEJMoa2114663

297. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. *N Engl J Med*. 2019;380(8):741-751. doi:10.1056/NEJMoa1814213

298. Chapman PB, Hauschild A, Robert C, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. *N Engl J Med*. 2011;364(26):2507-2516. doi:10.1056/NEJMoa1103782

299. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *The Lancet Oncology*. 2014;15(3):323-332. doi:10.1016/S1470-2045(14)70012-9

300. Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. *Acad Dermatol Venereol*. 2018;32(3):372-381. doi:10.1111/jdv.14542

301. Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. *The Lancet Oncology*. 2013;14(9):901-908. doi:10.1016/S1470-2045(13)70277-8

302. Stopeck AT, Lipton A, Body JJ, et al. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. *JCO*. 2010;28(35):5132-5139. doi:10.1200/JCO.2010.29.7101

303. Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. *The Lancet Oncology*. 2018;19(3):370-381. doi:10.1016/S1470-2045(18)30072-X

304. Schultheis B, Reuter D, Ebert MP, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. *Annals of Oncology*. 2017;28(10):2429-2435. doi:10.1093/annonc/mdx343

305. Patil VM, Noronha V, Joshi A, et al. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. *Cancer*. 2019;125(18):3184-3197. doi:10.1002/cncr.32179

306. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. *N Engl J Med*. 2016;375(22):2154-2164. doi:10.1056/NEJMoa1611310

307. González-Martín A, Pothuri B, Vergote I, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med*. 2019;381(25):2391-2402. doi:10.1056/NEJMoa1910962

308. Li N, Bu H, Liu J, et al. Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer. *Gynecologic Oncology*. 2020;159:159. doi:10.1016/j.ygyno.2020.05.229

309. Li N, Zhang Y, Wang J, et al. Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. *JCO*. 2022;40(22):2436-2446. doi:10.1200/JCO.21.01511

310. Wu X, Zhu J, Wang J, et al. Pamiparib Monotherapy for Patients with Germline *BRCA1/2* -Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study. *Clinical Cancer Research*. 2022;28(4):653-661. doi:10.1158/1078-0432.CCR-21-1186

311. Shen L, Zhang Y, Li Z, et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. *Nat Med*. Published online January 22, 2025. doi:10.1038/s41591-024-03450-4

Table S3. Information on 265 Indications and Pivotal Clinical Trials of Novel Multi-indication Anti-cancer Drugs Approved by the National Medical Products Administration as of November 30, 2024

No.	Generic name	Delivery route	Product type	Mechanism of action	Origin country	Exclusive production	Indication	Classification of Indications	Cancer type	Biomarker	Treatment type	Reimbursed	Year of indication approval	Approval type	Clinical trial	Phase of treatment	Line	Clinical trial phase	Allocation	Masking	Arms	Primary Outcome
1	Erlotinib	Po	small molecule	Targeted agents	Import	No	Single-agent therapy is suitable for locally advanced or metastatic NSCLC that has progressed after at least one prior chemotherapy regimen	NSCLC	Solid	No	Combination	Yes	2006	not available	not available	Advanced-stage Treatment	2-Line& 3-Line	Phase III	Randomized	Double-blind	2 arms	OS
2	Erlotinib	Po	small molecule	Targeted agents	Import	No	Single-agent therapy can be used for maintenance treatment in patients with locally advanced or metastatic NSCLC who are stable after four cycles of first-line platinum-based chemotherapy	NSCLC	Solid	No	Combination	Yes	2006	not available	NCT00556712	Advanced-stage Treatment	/	Phase III	Randomized	Double-blind	2 arms	PFS
3	Erlotinib	Po	small molecule	Targeted agents	Import	No	First-line treatment for patients with locally advanced or metastatic NSCLC with sensitive mutations in the EGFR gene	NSCLC	Solid	Yes	Combination	Yes	2017	Standard approval	NCT01342965	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
4	Icotinib	Po	small molecule	Targeted agents	Domestic	Yes	First-line treatment for advanced or metastatic NSCLC with sensitive EGFR mutations, or for those previously treated with platinum-based chemotherapy	NSCLC	Solid	Yes	Combination	Yes	2011	Special approval	NCT01040780	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
5	Icotinib	Po	small molecule	Targeted agents	Domestic	Yes	Single-agent therapy is suitable for adjuvant treatment of stage II-IIIA NSCLC with sensitive EGFR mutations	NSCLC	Solid	Yes	Combination	Yes	2021	Priority approval	NCT02448797	Adjuvant Therapy	/	Phase III	Randomized	None	2 arms	DFS
6	Afatinib	Po	small molecule	Targeted agents	Import	No	Advanced NSCLC with sensitive EGFR mutations, untreated with EGFR TKIs	NSCLC	Solid	Yes	Combination	Yes	2017	Special approval	NCT01121393	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
7	Afatinib	Po	small molecule	Targeted agents	Import	No	Advanced squamous NSCLC progressing during/after platinum chemotherapy	NSCLC	Solid	No	Combination	Yes	2017	Special approval	NCT01523587	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	PFS
8	Osimertinib	Po	small molecule	Targeted agents	Import	No	Indicated for adults with advanced NSCLC harboring EGFR T790M mutation, progressing after EGFR TKI treatment	NSCLC	Solid	Yes	Combination	Yes	2017	Special approval	NCT02442349	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
9	Osimertinib	Po	small molecule	Targeted agents	Import	No	First-line treatment for adults with advanced NSCLC harboring EGFR exon 19 deletion or exon 21 (L858R) mutation	NSCLC	Solid	Yes	Combination	Yes	2019	Priority approval	NCT02296125	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
10	Osimertinib	Po	small molecule	Targeted agents	Import	No	Treatment for NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations post-surgery, with or without adjuvant chemotherapy	NSCLC	Solid	Yes	Combination	Yes	2021	Priority approval	NCT02511106	Adjuvant Therapy	/	Phase III	Randomized	Double-blind	2 arms	DFS

No.	Generic name	Delivery route	Product type	Mechanism of action	Origin country	Exclusive production	Indication	Classification of Indications	Cancer type	Biomarker	Treatment type	Reimbursed	Year of indication approval	Approval type	Clinical trial	Phase of treatment	Line	Clinical trial phase	Allocation	Masking	Arms	Primary Outcome
11	Almonertinib	Po	small molecule	Targeted agents	Domestic	Yes	Treatment for advanced NSCLC with EGFR T790M mutation, progressing after EGFR-TKI therapy	NSCLC	Solid	Yes	Combination	Yes	2020	Special approval	NCT02981108	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
12	Almonertinib	Po	small molecule	Targeted agents	Domestic	Yes	First-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 (L858R) mutation	NSCLC	Solid	Yes	Combination	Yes	2021	Breakthrough approval	NCT03849768	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
13	Furmonertinib	Po	small molecule	Targeted agents	Domestic	Yes	Treatment for advanced NSCLC with EGFR T790M mutation, progressing after EGFR-TKI	NSCLC	Solid	Yes	Combination	Yes	2021	Conditional approval	NCT03452592	Advanced-stage Treatment	2-Line	Phase IIb	Nonrandomized	None	1 arm	ORR
14	Furmonertinib	Po	small molecule	Targeted agents	Domestic	Yes	First-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R mutations	NSCLC	Solid	Yes	Combination	Yes	2022	Breakthrough approval	NCT03787992	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
15	Crizotinib	Po	small molecule	Targeted agents	Import	Yes	Treatment for ALK-positive advanced NSCLC	NSCLC	Solid	No	Combination	Yes	2013	Special approval	NCT00932893	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
16	Crizotinib	Po	small molecule	Targeted agents	Import	Yes	Treatment for advanced NSCLC with ROS1 positivity	NSCLC	Solid	Yes	Combination	Yes	2016	not available	NCT01945021	Advanced-stage Treatment	1-Line	Phase II	Nonrandomized	None	1 arm	ORR
17	Ceritinib	Po	small molecule	Targeted agents	Import	No	For ALK-positive advanced NSCLC patients progressing or intolerant to crizotinib	NSCLC	Solid	Yes	Combination	No	2018	Priority approval	NCT01828112	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	PFS
18	Ceritinib	Po	small molecule	Targeted agents	Import	No	Monotherapy for ALK-positive advanced or metastatic NSCLC	NSCLC	Solid	Yes	Combination	Yes	2020	Standard approval	NCT01828099	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
19	Ensartinib	Po	small molecule	Targeted agents	Domestic	Yes	For ALK-positive advanced NSCLC patients progressing or intolerant to crizotinib	NSCLC	Solid	Yes	Combination	No	2020	Priority approval	NCT03215693	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
20	Ensartinib	Po	small molecule	Targeted agents	Domestic	Yes	Monotherapy for ALK-positive advanced or metastatic NSCLC	NSCLC	Solid	Yes	Combination	Yes	2022	Priority approval	NCT02767804	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
21	Lorlatinib	Po	small molecule	Targeted agents	Import	Yes	For ALK-positive advanced NSCLC previously treated with ALK TKIs	NSCLC	Solid	Yes	Combination	No	2022	Conditional approval	NCT03909971	Advanced-stage Treatment	2-Line	Phase IIa	Nonrandomized	None	≥3 arms	ORR
22	Lorlatinib	Po	small molecule	Targeted agents	Import	Yes	Monotherapy for ALK-positive advanced or metastatic NSCLC	NSCLC	Solid	Yes	Combination	Yes	2022	Standard approval	NCT03052608	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
23	Iruplinalkib	Po	small molecule	Targeted agents	Domestic	Yes	Treatment for ALK-positive advanced NSCLC progressing or intolerant to crizotinib	NSCLC	Solid	Yes	Combination	No	2023	Standard approval	NCT04641754	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	PFS
24	Iruplinalkib	Po	small molecule	Targeted agents	Domestic	Yes	Monotherapy is suitable for the treatment of ALK-positive advanced or metastatic NSCLC	NSCLC	Solid	Yes	Combination	Yes	2024	Standard approval	NCT04632758	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
25	Bevacizumab	Iv	monoclonal antibody	Targeted agents	Import	No	Bevacizumab with fluoropyrimidine-based chemotherapy is suitable for metastatic colorectal cancer	CRC	Solid	No	Combination	Yes	2010	not available	NCT00069095	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	≥3 arms	PFS
26	Bevacizumab	Iv	monoclonal antibody	Targeted agents	Import	No	Bevacizumab with platinum-based chemotherapy for first-line treatment of advanced, metastatic, or recurrent non-squamous NSCLC	NSCLC	Solid	No	Combination	Yes	2015	not available	NCT00021060	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS
27	Bevacizumab	Iv	monoclonal antibody	Targeted agents	Import	No	Treatment for adult patients with recurrent glioblastoma	Glioma	Solid	No	Combination	Yes	2020	Standard approval	NCT01290939	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	OS
28	Bevacizumab	Iv	monoclonal antibody	Targeted agents	Import	No	Combination atezolizumab treatment for patients with previously untreated, unresectable hepatocellular carcinoma	HCC	Solid	No	Combination	Yes	2021	Priority approval	NCT03434379	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS
29	Bevacizumab	Iv	monoclonal antibody	Targeted agents	Import	No	Bevacizumab combined with carboplatin and paclitaxel for first-line treatment of stage III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer after initial surgery	OC&TC&PC	Solid	No	Combination	Yes	2021	Standard approval	NCT00262847	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	≥3 arms	PFS
30	Bevacizumab	Iv	monoclonal antibody	Targeted agents	Import	No	Bevacizumab combined with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.	CC	Solid	No	Combination	Yes	2021	Standard approval	NCT00803062	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	≥3 arms	OS

No.	Generic name	Delivery route	Product type	Mechanism of action	Origin country	Exclusive production	Indication	Classification of Indications	Cancer type	Biomarker	Treatment type	Reimbursed	Year of indication approval	Approval type	Clinical trial	Phase of treatment	Line	Clinical trial phase	Allocation	Masking	Arms	Primary Outcome
31	Anlotinib	Po	small molecule	Targeted agents	Domestic	Yes	The drug is suitable for advanced NSCLC patients progressing after at least two prior chemotherapies. For EGFR mutations or ALK positivity, targeted therapy should have been used before	NSCLC	Solid	Yes	Combination	Yes	2018	Special approval	NCT02388919	Advanced-stage Treatment	≥3-Line	Phase III	Randomized	Double-blind	2 arms	OS
32	Anlotinib	Po	small molecule	Targeted agents	Domestic	Yes	For advanced soft tissue sarcomas (alveolar soft part sarcoma, clear cell sarcoma) progressing or relapsing after one anthracycline-containing chemotherapy	BSTT	Solid	No	Combination	Yes	2019	Special approval	NCT02449343	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	pFS
33	Anlotinib	Po	small molecule	Targeted agents	Domestic	Yes	Single-agent therapy for small cell lung cancer progressing or relapsing after two prior chemotherapies	SCLC	Solid	No	Combination	Yes	2019	Special approval	NCT03059797	Advanced-stage Treatment	≥3-Line	Phase II	Randomized	Double-blind	2 arms	PFS
34	Anlotinib	Po	small molecule	Targeted agents	Domestic	Yes	For the treatment of patients with symptomatic or progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma	TC	Solid	No	Combination	Yes	2021	Priority approval	NCT02586350	Advanced-stage Treatment	1-Line	Phase II	Randomized	Double-blind	2 arms	PFS
35	Anlotinib	Po	small molecule	Targeted agents	Domestic	Yes	For patients with progressive, locally advanced, or metastatic radioiodine-refractory differentiated thyroid cancer	TC	Solid	No	Combination	Yes	2022	Standard approval	NCT02586337	Advanced-stage Treatment	1-Line	Phase II	Randomized	Double-blind	2 arms	PFS
36	Everolimus	Po	small molecule	Targeted agents	Import	No	Advanced renal cell carcinoma that has failed prior treatment with sunitinib or sorafenib, with data primarily based on clear cell renal carcinoma	RCC	Solid	No	Combination	Yes	2013	Special approval	NCT00410124	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	PFS
37	Everolimus	Po	small molecule	Targeted agents	Import	No	Adult patients with unresectable, locally advanced or metastatic, well-differentiated (moderately or well-differentiated) advanced pancreatic neuroendocrine tumors	NET	Solid	No	Combination	Yes	2014	not available	NCT00510068	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	PFS
38	Everolimus	Po	small molecule	Targeted agents	Import	No	Adult and pediatric patients with tuberous sclerosis complex-associated subependymal giant cell astrocytoma requiring therapeutic intervention but not amenable to surgical resection	TSC	Solid	No	Combination	Yes	2014	not available	NCT00789828	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	RR
39	Everolimus	Po	small molecule	Targeted agents	Import	No	For the treatment of adult patients with tuberous sclerosis complex-associated renal angiomyolipomas that do not require immediate surgical intervention	TSC	Solid	No	Combination	Yes	2016	not available	NCT00790400	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	ORR
40	Everolimus	Po	small molecule	Targeted agents	Import	No	Adult patients with locally advanced or metastatic, well-differentiated, progressive, non-functional gastroenteropancreatic or lung neuroendocrine tumors (NETs) that cannot be surgically resected	NET	Solid	No	Combination	Yes	2018	not available	NCT01524783	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	PFS
41	Everolimus	Po	small molecule	Targeted agents	Import	No	Everolimus with exemestane for postmenopausal women with HR-positive, HER2-negative advanced breast cancer after letrozole or anastrozole failure	BC	Solid	Yes	Combination	Yes	2022	Standard approval	NCT00863655	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	PFS
42	Pralsetinib	Po	small molecule	Targeted agents	Import	Yes	Treatment for adult patients with locally advanced or metastatic NSCLC with RET gene fusion positive	NSCLC	Solid	Yes	Combination	No	2021	Conditional approval	NCT03037385	Advanced-stage Treatment	1-Line	PhaseI/II	Nonrandomized	None	1 arm	ORR
43	Pralsetinib	Po	small molecule	Targeted agents	Import	Yes	For adults and pediatric patients ≥12 years with advanced/metastatic RET-mutant MTC or RET fusion-positive thyroid cancer, requiring systemic therapy and refractory to radioactive iodine (if applicable)	TC	Solid	Yes	Combination	No	2022	Conditional approval	NCT03037385	Advanced-stage Treatment	2-Line & 3-Line	PhaseI/II	Nonrandomized	None	1 arm	ORR
44	Selpercatinib	Po	small molecule	Targeted agents	Import	Yes	For the treatment of adult patients with locally advanced or metastatic RET-positive NSCLC	NSCLC	Solid	Yes	Combination	No	2022	Conditional approval	NCT03157128	Advanced-stage Treatment	1-Line	PhaseI/II	Nonrandomized	None	1 arm	ORR
45	Selpercatinib	Po	small molecule	Targeted agents	Import	Yes	For adults and pediatric patients ≥12 years with advanced/metastatic RET-mutant MTC or RET fusion-positive thyroid cancer, requiring systemic therapy and refractory to radioactive iodine (if applicable)	TC	Solid	Yes	Combination	No	2022	Conditional approval	NCT03157128	Advanced-stage Treatment	2-Line & 3-Line	PhaseI/II	Nonrandomized	None	1 arm	ORR
46	Dabrafenib	Po	small molecule	Targeted agents	Import	Yes	Dabrafenib combined with trametinib is used to treat patients with unresectable or metastatic melanoma with BRAF V600E/K mutations	MEL	Solid	Yes	Combination	Yes	2019	Priority approval	NCT01584648	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
47	Dabrafenib	Po	small molecule	Targeted agents	Import	Yes	Dabrafenib combined with trametinib is suitable for adjuvant treatment in patients with stage III melanoma with BRAF V600E/K mutations after complete resection	MEL	Solid	Yes	Combination	Yes	2020/3/6	Priority approval	NCT01682083	Adjuvant Therapy	/	Phase III	Randomized	Double-blind	2 arms	RFS
48	Dabrafenib	Po	small molecule	Targeted agents	Import	Yes	Dabrafenib combined with trametinib is used to treat patients with metastatic NSCLC with BRAF V600 mutations	NSCLC	Solid	Yes	Combination	Yes	2022	Conditional approval	NCT01336634	Advanced-stage Treatment	1-Line	Phase II	Nonrandomized	None	1 arm	ORR
49	Trametinib	Po	small molecule	Targeted agents	Import	Yes	Trametinib combined with dabrafenib is used to treat patients with unresectable or metastatic melanoma with BRAF V600E/K mutations	MEL	Solid	Yes	Combination	Yes	2019	Priority approval	NCT01584648	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
50	Trametinib	Po	small molecule	Targeted agents	Import	Yes	Trametinib combined with dabrafenib is suitable for adjuvant treatment in patients with completely resected stage III melanoma with BRAF V600E/K mutations	MEL	Solid	Yes	Combination	Yes	2020	Priority approval	NCT01682083	Adjuvant Therapy	/	Phase III	Randomized	Double-blind	2 arms	RFS

No.	Generic name	Delivery route	Product type	Mechanism of action	Origin country	Exclusive production	Indication	Classification of Indications	Cancer type	Biomarker	Treatment type	Reimbursed	Year of indication approval	Approval type	Clinical trial	Phase of treatment	Line	Clinical trial phase	Allocation	Masking	Arms	Primary Outcome
51	Trametinib	Po	small molecule	Targeted agents	Import	Yes	Trametinib combined with dabrafenib is used to treat patients with metastatic NSCLC with BRAF V600 mutations	NSCLC	Solid	Yes	Combination	Yes	2022	Conditional approval	NCT01336634	Advanced-stage Treatment	1-Line	Phase II	Nonrandomized	None	1 arm	ORR
52	Entrectinib	Po	small molecule	Targeted agents	Import	Yes	Indicated for adults and pediatric patients ≥12 years with solid tumors meeting the following criteria: Diagnosed with NTRK gene fusions (excluding acquired resistance mutations); Locally advanced, metastatic, or surgically resectable with severe complications; No satisfactory alternative treatments or failure of prior therapies.	NTRK	Solid	Yes	Combination	Yes	2022	Conditional approval	NCT02097810 &NCT02568267	Advanced-stage Treatment	2-Line & 3-Line	PhaseI& II	Nonrandomized	None	1 arm	ORR
53	Entrectinib	Po	small molecule	Targeted agents	Import	Yes	Indicated for adult patients with locally advanced or metastatic ROS1-positive NSCLC	NSCLC	Solid	Yes	Combination	Yes	2022	Standard approval	NCT02097810 &NCT02568267	Advanced-stage Treatment	1-Line	PhaseI& II	Nonrandomized	None	1 arm	ORR
54	Entrectinib	Po	small molecule	Targeted agents	Import	Yes	Indicated for adults and pediatric patients ≥1 month of age with solid tumors meeting the following criteria: Diagnosed with NTRK gene fusions (excluding acquired resistance mutations); Locally advanced, metastatic, or surgically resectable with severe complications; No satisfactory alternative treatments or failure of prior therapies.	NTRK	Solid	Yes	Combination	No	2024	Conditional approval	NCT02650401 &NCT04589845	Advanced-stage Treatment	2-Line & 3-Line	PhaseI/II & II	Nonrandomized	None	1 arm	ORR
55	Nivolumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC that is EGFR mutation-negative and ALK-negative, who have experienced disease progression or intolerance after prior platinum-based chemotherapy	NSCLC	Solid	Yes	Combination	No	2018	Special approval	NCT02613507	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	OS
56	Nivolumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Indicated as monotherapy for recurrent or metastatic SCCHN patients with PD-L1-expressing tumors (≥1%) and disease progression on or after platinum-based therapy	SCCHN	Solid	Yes	Combination	No	2019	Priority approval	NCT02105636	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	OS
57	Nivolumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Patients with advanced or recurrent gastric or gastroesophageal junction adenocarcinoma who have received two or more prior systemic treatment regimens	GC	Solid	No	Combination	No	2020	Priority approval	NCT02267343	Advanced-stage Treatment	≥3-Line	Phase III	Randomized	Double-blind	2 arms	OS
58	Nivolumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Nivolumab combined with ipilimumab for adult patients with unresectable, previously untreated non-epithelioid malignant pleural mesothelioma	MPM	Solid	No	Combination	No	2021	Conditional approval	NCT02899299	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	≥3 arms	OS
59	Nivolumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Nivolumab with fluoropyrimidine and platinum chemotherapy is for first-line treatment of advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma	GC	Solid	No	Combination	No	2021	Standard approval	NCT02872116	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	≥3 arms	OS
60	Nivolumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Nivolumab combined with fluoropyrimidine and platinum-based chemotherapy is suitable for first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma	EC	Solid	No	Combination	No	2022	Standard approval	NCT03143153	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	≥3 arms	OS
61	Nivolumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Adjuvant treatment for patients with esophageal or gastroesophageal junction cancer who have residual pathology after neoadjuvant chemoradiotherapy and complete surgical resection	EC	Solid	No	Combination	No	2022	Standard approval	NCT02743494	Adjuvant Therapy	/	Phase III	Randomized	Double-blind	2 arms	DFS
62	Nivolumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Nivolumab with platinum-based chemotherapy is for neoadjuvant treatment of resectable NSCLC (tumor ≥4 cm or lymph node positive) in adults	NSCLC	Solid	No	Combination	No	2023	Standard approval	NCT02998528	Neoadjuvant Therapy	/	Phase III	Randomized	None	2 arms	pCR & EFS
63	Nivolumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	For adjuvant treatment of patients with urothelial carcinoma at high risk of recurrence after radical cystectomy	UC	Solid	No	Combination	No	2023	Standard approval	NCT02632409	Adjuvant Therapy	/	Phase III	Randomized	Double-blind	2 arms	DFS
64	Nivolumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	For first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)	CRC	Solid	Yes	Combination	No	2024	Priority approval	NCT04008030	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
65	Nivolumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Nivolumab combined with cisplatin and gemcitabine for first-line treatment in adult patients with unresectable or metastatic urothelial carcinoma	UC	Solid	No	Combination	No	2024	Standard approval	NCT03036098	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS
66	Pembrolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	For the treatment of unresectable or metastatic melanoma after failure of first-line therapy	MEL	Solid	No	Combination	No	2018	Priority approval	NCT02821000	Advanced-stage Treatment	2-Line	PhaseIb	Nonrandomized	None	1 arm	ORR
67	Pembrolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Pembrolizumab with pemetrexed and platinum chemotherapy is for first-line treatment of metastatic non-squamous NSCLC with EGFR and ALK-negative mutations	NSCLC	Solid	Yes	Combination	No	2019	Priority approval	NCT02578680	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
68	Pembrolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Pembrolizumab is indicated as first-line monotherapy for EGFR-negative, ALK-negative, locally advanced or metastatic NSCLC with PD-L1 ≥1%, as approved by the National Medical Products Administration	NSCLC	Solid	Yes	Combination	No	2019	Priority approval	NCT02220894	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS
69	Pembrolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Pembrolizumab combined with carboplatin and paclitaxel is suitable for first-line treatment of patients with metastatic squamous NSCLC	NSCLC	Solid	No	Combination	No	2019	Priority approval	NCT02775435	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS

No.	Generic name	Delivery route	Product type	Mechanism of action	Origin country	Exclusive production	Indication	Classification of Indications	Cancer type	Biomarker	Treatment type	Reimbursed	Year of indication approval	Approval type	Clinical trial	Phase of treatment	Line	Clinical trial phase	Allocation	Masking	Arms	Primary Outcome
70	Pembrolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Pembrolizumab monotherapy is for advanced or metastatic esophageal squamous cell carcinoma with PD-L1 CPS ≥10 in patients who failed first-line treatment, as approved by the National Medical Products Administration	EC	Solid	Yes	Combination	No	2020	Priority approval	NCT02564263	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	OS
71	Pembrolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Pembrolizumab monotherapy is for first-line treatment of metastatic or unresectable recurrent HNSCC with PD-L1 CPS ≥20, as assessed by a validated test	SCCHN	Solid	Yes	Combination	No	2020	Priority approval	NCT02358031	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	≥3 arms	OS
72	Pembrolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Pembrolizumab monotherapy is for first-line treatment of unresectable or metastatic MSI-H or dMMR CRC with wild-type KRAS, NRAS, and BRAF genes	CRC	Solid	Yes	Combination	No	2021	Conditional approval	NCT02563002	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS
73	Pembrolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Pembrolizumab combined with platinum-based and fluoropyrimidine chemotherapy for first-line treatment of locally advanced unresectable or metastatic esophageal/gastroesophageal junction cancer	EC	Solid	No	Combination	No	2021	Standard approval	NCT03189719	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
74	Pembrolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Pembrolizumab monotherapy for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib or chemotherapy containing oxaliplatin	HCC	Solid	No	Combination	No	2022	Standard approval	NCT03062358	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	OS
75	Pembrolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Pembrolizumab combined with chemotherapy as neoadjuvant treatment, followed by pembrolizumab monotherapy as adjuvant treatment for early high-risk PD-L1-positive (CPS ≥20) triple-negative breast cancer (TNBC)	BC	Solid	Yes	Combination	No	2022	Standard approval	NCT03036488	Neoadjuvant Therapy	/	Phase III	Randomized	Double-blind	2 arms	pCR & EFS
76	Pembrolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Monotherapy for adult patients with advanced unresectable or metastatic solid tumors with high microsatellite instability (MSI-H) or defective mismatch repair (dMMR), including colorectal cancer progressing after fluoropyrimidines, oxaliplatin, and irinotecan, and other solid tumors with no satisfactory treatment options	MSI-H/dMMR	Solid	Yes	Combination	No	2023	Conditional approval	NCT02460198 &NCT02628067	Advanced-stage Treatment	2-Line & 3-Line	Phase II	Nonrandomized	None	1 arm	ORR
77	Pembrolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Pembrolizumab with fluoropyrimidine and platinum-based chemotherapy for first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric/gastroesophageal junction adenocarcinoma	GC	Solid	Yes	Combination	No	2023	Standard approval	NCT03675737	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
78	Pembrolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Pembrolizumab combined with gemcitabine and cisplatin for first-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC)	BTC	Solid	No	Combination	No	2024	Standard approval	NCT04003636	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
79	Pembrolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Pembrolizumab with trastuzumab, fluoropyrimidine, and platinum-based chemotherapy for first-line treatment of HER2-positive gastric/gastroesophageal junction adenocarcinoma with PD-L1 expression (CPS ≥1)	GC	Solid	Yes	Combination	No	2024	Standard approval	NCT03615326	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
80	Durvalumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Treatment for unresectable stage III NSCLC patients without progression after platinum-based chemotherapy and concurrent radiotherapy	NSCLC	Solid	No	Combination	No	2019	Standard approval	NCT02125461	Adjuvant Therapy	/	Phase III	Randomized	Double-blind	2 arms	OS
81	Durvalumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Duvaliumab combined with etoposide and carboplatin or cisplatin as first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC)	SCLC	Solid	No	Combination	No	2021	Standard approval	NCT03043872	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	≥3 arms	OS
82	Durvalumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Durvalumab combined with gemcitabine and cisplatin for the first-line treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC)	BTC	Solid	No	Combination	No	2023	Standard approval	NCT03875235	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
83	Atezolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Atezolizumab combined with carboplatin and etoposide for first-line treatment of ES-SCLC patients	SCLC	Solid	No	Combination	No	2020	Standard approval	NCT02763579	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
84	Atezolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Atezolizumab combined with bevacizumab treatment for patients with previously untreated, unresectable hepatocellular carcinoma	HCC	Solid	No	Combination	No	2020	Priority approval	NCT03434379	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS
85	Atezolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	First-line monotherapy for metastatic EGFR- and ALK-negative NSCLC, with PD-L1 positive in ≥50% of tumor cells (TC≥50%) or immune cells covering ≥10% of the tumor (IC≥10%)	NSCLC	Solid	Yes	Combination	No	2021	Conditional approval	NCT02409342	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS
86	Atezolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Atezolizumab with pemetrexed and platinum-based chemotherapy for first-line treatment of metastatic EGFR- and ALK-negative non-squamous NSCLC	NSCLC	Solid	Yes	Combination	No	2021	Standard approval	NCT02657434	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS
87	Atezolizumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Atezolizumab monotherapy for adjuvant treatment of stage II-IIIA NSCLC with PD-L1 TC ≥1% after surgery and platinum-based chemotherapy	NSCLC	Solid	Yes	Combination	No	2022	Standard approval	NCT02486718	Adjuvant Therapy	/	Phase III	Randomized	None	2 arms	DFS
88	Camrelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Treatment of patients with relapsed or refractory classical Hodgkin lymphoma who have received at least second-line systemic chemotherapy with a single agent	HL	Hematoma	No	Combination	Yes	2019	Conditional approval	NCT03155425	Advanced-stage Treatment	≥3-Line	Phase II	Nonrandomized	None	1 arm	ORR
89	Camrelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	For the treatment of advanced hepatocellular carcinoma patients who have previously received sorafenib treatment and/or systemic chemotherapy containing oxaliplatin	HCC	Solid	No	Combination	Yes	2020	Conditional approval	NCT02989922	Advanced-stage Treatment	2-Line	Phase II	Randomized	None	2 arms	ORR

No.	Generic name	Delivery route	Product type	Mechanism of action	Origin country	Exclusive production	Indication	Classification of Indications	Cancer type	Biomarker	Treatment type	Reimbursed	Year of indication approval	Approval type	Clinical trial	Phase of treatment	Line	Clinical trial phase	Allocation	Masking	Arms	Primary Outcome
90	Camrelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Monotherapy for the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma who have experienced disease progression or intolerance to prior first-line chemotherapy	EC	Solid	No	Combination	Yes	2020	Special approval	NCT03099382	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	OS
91	Camrelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Camrelizumab combined with pemetrexed and carboplatin is suitable for first-line treatment of EGFR-negative, ALK-negative, locally advanced or metastatic non-squamous NSCLC that is not amenable to surgery	NSCLC	Solid	Yes	Combination	Yes	2020	Special approval	NCT03134872	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
92	Camrelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	For the treatment of advanced nasopharyngeal carcinoma patients who have experienced disease progression or intolerance after second-line or above chemotherapy	NPC	Solid	No	Combination	Yes	2021	Conditional approval	NCT03558191	Advanced-stage Treatment	≥3-Line	Phase II	Nonrandomized	None	1 arm	ORR
93	Camrelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Camrelizumab combined with cisplatin and gemcitabine for first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma	NPC	Solid	No	Combination	Yes	2021	Priority approval	NCT03707509	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
94	Camrelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Camrelizumab combined with paclitaxel and carboplatin is a first-line treatment for locally advanced or metastatic squamous NSCLC	NSCLC	Solid	No	Combination	Yes	2021	Standard approval	NCT03668496	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
95	Camrelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Camrelizumab combined with paclitaxel and cisplatin for first-line treatment of patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma	EC	Solid	No	Combination	Yes	2021	Standard approval	NCT03691090	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
96	Camrelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Camrelizumab combined with apatinib mesylate for first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma	HCC	Solid	No	Combination	Yes	2023	Standard approval	NCT03764293	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS
97	Tislelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	For the treatment of relapsed or refractory classical Hodgkin lymphoma in patients who have received at least second-line systemic chemotherapy	HL	Hematoma	No	Combination	Yes	2019	Special approval	NCT03209973	Advanced-stage Treatment	≥3-Line	Phase II	Nonrandomized	None	1 arm	ORR
98	Tislelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Treatment for locally advanced or metastatic urothelial carcinoma with high PD-L1 expression after platinum-based chemotherapy failure or progression within 12 months of neoadjuvant/adjuvant chemotherapy	UC	Solid	Yes	Combination	Yes	2020	Special approval	NCT04004221	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
99	Tislelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Tislelizumab combined with paclitaxel and carboplatin is a first-line treatment for unresectable locally advanced or metastatic squamous NSCLC	NSCLC	Solid	No	Combination	Yes	2021	Standard approval	NCT03594747	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	≥3 arms	PFS
100	Tislelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Tislelizumab with pemetrexed and platinum is a first-line treatment for EGFR-negative, ALK-negative, unresectable advanced or metastatic non-squamous NSCLC	NSCLC	Solid	Yes	Combination	Yes	2021	Standard approval	NCT03663205	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
101	Tislelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Indicated for the treatment of hepatocellular carcinoma in patients who have received at least one systemic therapy	HCC	Solid	No	Combination	Yes	2021	Conditional approval	NCT03419897	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
102	Tislelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Monotherapy is indicated for adults with EGFR and ALK-negative, platinum-treated, locally advanced or metastatic NSCLC (non-squamous or squamous) with disease progression or intolerance	NSCLC	Solid	Yes	Combination	Yes	2021	Standard approval	NCT03358875	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	OS
103	Tislelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	For adult patients with unresectable or metastatic advanced solid tumors, including MSI-H or dMMR, with progression after treatment with fluoropyrimidines, oxaliplatin, and irinotecan for colorectal cancer, or other advanced solid tumors with no satisfactory treatment options	MSI-H/dMMR	Solid	Yes	Combination	Yes	2022	Conditional approval	NCT03736889	Advanced-stage Treatment	2-Line & 3-Line	Phase II	Nonrandomized	None	1 arm	ORR
104	Tislelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	For the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma who have progressed or are intolerant to first-line standard chemotherapy	EC	Solid	No	Combination	Yes	2022	Standard approval	NCT03430843	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	OS
105	Tislelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Tislelizumab combined with gemcitabine and cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma	NPC	Solid	No	Combination	Yes	2022	Standard approval	NCT03924986	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
106	Tislelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Tislelizumab combined with fluoropyrimidine and platinum-based chemotherapy for the first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression	GC	Solid	Yes	Combination	Yes	2023	Standard approval	NCT03777657	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
107	Tislelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Tislelizumab combined with paclitaxel and platinum-based drugs or fluoropyrimidine and platinum-based drugs for first-line treatment of unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma	EC	Solid	No	Combination	Yes	2023	Standard approval	NCT03783442	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
108	Tislelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Tislelizumab monotherapy is suitable for the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma	HCC	Solid	No	Combination	Yes	2023	Standard approval	NCT03412773	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS
109	Tislelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Tislelizumab combined with etoposide and platinum-based chemotherapy for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)	SCLC	Solid	No	Combination	Yes	2024	Standard approval	NCT04005716	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS

No.	Generic name	Delivery route	Product type	Mechanism of action	Origin country	Exclusive production	Indication	Classification of Indications	Cancer type	Biomarker	Treatment type	Reimbursed	Year of indication approval	Approval type	Clinical trial	Phase of treatment	Line	Clinical trial phase	Allocation	Masking	Arms	Primary Outcome
110	Tislelizumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Tislelizumab combined with platinum-based chemotherapy as neoadjuvant therapy, followed by monotherapy, for resectable stage II or IIIA NSCLC	NSCLC	Solid	No	Combination	No	2024	Standard approval	NCT04379635	Neoadjuvant Therapy	/	Phase III	Randomized	Double-blind	2 arms	MPR &EFS
111	Sintilimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Treatment of patients with relapsed or refractory classical Hodgkin lymphoma who have received at least second-line systemic chemotherapy with single-agent therapy	HL	Hematoma	No	Combination	Yes	2018	Special approval	NCT03114683	Advanced-stage Treatment	≥3-Line	Phase II	Nonrandomized	None	1 arm	ORR
112	Sintilimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Sintilimab combined with paclitaxel and cisplatin or fluorouracil and cisplatin for first-line treatment of unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma	EC	Solid	No	Combination	Yes	2020	Standard approval	NCT03748134	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
113	Sintilimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Sintilimab with pemetrexed and platinum-based chemotherapy is a first-line treatment for EGFR and ALK-negative, locally advanced or metastatic non-squamous NSCLC not amenable to surgery	NSCLC	Solid	Yes	Combination	Yes	2021	Standard approval	NCT03607539	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
114	Sintilimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Sintilimab with gemcitabine and platinum-based chemotherapy is a first-line treatment for unresectable locally advanced or metastatic squamous NSCLC	NSCLC	Solid	No	Combination	Yes	2021	Standard approval	NCT03629925	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
115	Sintilimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Sintilimab combined with bevacizumab (Daoyoutong®) for the first-line treatment of patients with previously untreated, unresectable or metastatic hepatocellular carcinoma	HCC	Solid	No	Combination	Yes	2021	Priority approval	NCT03794440	Advanced-stage Treatment	1-Line	PhaseII/III	Randomized	None	2 arms	OS
116	Sintilimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Sintilimab combined with fluoropyrimidine and platinum-based chemotherapy for the first-line treatment of unresectable locally advanced, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma	GC	Solid	No	Combination	Yes	2022	Standard approval	NCT03745170	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
117	Sintilimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Sintilimab with bevacizumab, pemetrexed, and cisplatin is for patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have failed EGFR-TKI treatment	NSCLC	Solid	Yes	Combination	Yes	2023	Standard approval	NCT03802240	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	≥3 arms	PFS
118	Ipilimumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	Ipilimumab combined with nivolumab for adult patients with unresectable, previously untreated non-epithelioid malignant pleural mesothelioma	MPM	Solid	No	Combination	No	2021	Conditional approval	NCT02899299	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS
119	Ipilimumab	Iv	monoclonal antibody	Immune regulators	Import	Yes	For the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)	CRC	Solid	Yes	Combination	No	2024	Priority approval	NCT04008030	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
120	Sugemalimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Sugemalimab with pemetrexed and carboplatin for first-line treatment of metastatic EGFR-negative, ALK-negative non-squamous NSCLC; with paclitaxel and carboplatin for metastatic squamous NSCLC	NSCLC	Solid	Yes	Combination	No	2021	Standard approval	NCT03789604	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
121	Sugemalimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Indicated for the treatment of patients with unresectable stage III non-small NSCLC who have not experienced disease progression after platinum-based concurrent or sequential chemoradiotherapy	NSCLC	Solid	No	Combination	No	2022	Standard approval	NCT03728556	Adjuvant Therapy	/	Phase III	Randomized	Double-blind	2 arms	PFS
122	Sugemalimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Single drug for the treatment of adult patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL)	NHL	Hematoma	No	Combination	No	2023	Conditional approval	NCT03595657	Advanced-stage Treatment	2-Line & 3-Line	Phase II	Nonrandomized	None	1 arm	ORR
123	Sugemalimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Sugemalimab combined with fluoropyrimidine and platinum-based chemotherapy drugs for the first-line treatment of unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC)	EC	Solid	No	Combination	No	2023	Standard approval	NCT04187352	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
124	Sugemalimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Sugemalimab with fluoropyrimidine and platinum chemotherapy for first-line treatment of unresectable advanced or metastatic gastric and gastroesophageal junction adenocarcinoma with PD-L1 (CPS ≥ 5)	GC	Solid	Yes	Combination	No	2024	Standard approval	NCT03802591	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
125	Toripalimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Toripalimab is used for the treatment of patients with unresectable or metastatic melanoma who have failed prior systemic therapy	MEL	Solid	No	Combination	Yes	2018	Conditional approval	NCT03013101	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
126	Toripalimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Toripalimab is suitable for the treatment of locally advanced or metastatic urothelial carcinoma that has progressed within 12 months after failure of platinum-based chemotherapy, including neoadjuvant or adjuvant chemotherapy	UC	Solid	No	Combination	Yes	2021	Conditional approval	NCT03113266	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
127	Toripalimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	For the treatment of patients with recurrent/metastatic nasopharyngeal carcinoma who have failed second-line or above systemic therapy	NPC	Solid	No	Combination	Yes	2021	Conditional approval	NCT02915432	Advanced-stage Treatment	≥3-Line	PhaseIb/II	Nonrandomized	None	1 arm	ORR
128	Toripalimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Toripalimab combined with cisplatin and gemcitabine for first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma	NPC	Solid	No	Combination	Yes	2021	Standard approval	NCT03581786	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
129	Toripalimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Toripalimab combined with paclitaxel and cisplatin is suitable for first-line treatment of unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma	EC	Solid	No	Combination	Yes	2022	Standard approval	NCT03829969	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS

No.	Generic name	Delivery route	Product type	Mechanism of action	Origin country	Exclusive production	Indication	Classification of Indications	Cancer type	Biomarker	Treatment type	Reimbursed	Year of indication approval	Approval type	Clinical trial	Phase of treatment	Line	Clinical trial phase	Allocation	Masking	Arms	Primary Outcome
130	Toripalimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Toripalimab with pemetrexed and platinum for first-line treatment of advanced or metastatic EGFR- and ALK-negative non-squamous NSCLC	NSCLC	Solid	Yes	Combination	Yes	2022	Standard approval	NCT03856411	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
131	Toripalimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Toripalimab with chemotherapy for perioperative treatment, followed by adjuvant monotherapy, for resectable stage IIIA-IIIB NSCLC	NSCLC	Solid	No	Combination	Yes	2023	Standard approval	NCT04158440	Adjuvant Therapy	/	Phase III	Randomized	Double-blind	2 arms	MPR & EFS
132	Toripalimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Toripalimab combined with axitinib for first-line treatment of patients with intermediate or high-risk, unresectable or metastatic renal cell carcinoma	RCC	Solid	No	Combination	Yes	2024	Standard approval	NCT04394975	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
133	Toripalimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Toripalimab combined with etoposide and platinum is indicated for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)	SCLC	Solid	No	Combination	Yes	2024	Standard approval	NCT04012606	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
134	Toripalimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Toripalimab combined with paclitaxel for injection (albumin-bound) is indicated for first-line treatment of recurrent or metastatic PD-L1-positive (CPS ≥ 1) triple-negative breast cancer (TNBC) as assessed by a validated test	BC	Solid	Yes	Combination	Yes	2024	Standard approval	NCT03777579	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
135	Serplulimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	For adults with unresectable or metastatic MSI-H solid tumors: colorectal cancer after fluoropyrimidines, oxaliplatin, and irinotecan; gastric cancer after two prior therapies; other solid tumors after one prior therapy, with no alternative options	MSI-H/dMMR	Solid	Yes	Combination	No	2022	Conditional approval	NCT03941574	Advanced-stage Treatment	2-Line & 3-Line	Phase II	Nonrandomized	None	1 arm	ORR
136	Serplulimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Serplulimab combined with carboplatin and albumin-bound paclitaxel is indicated for the first-line treatment of unresectable locally advanced or metastatic squamous NSCLC	NSCLC	Solid	No	Combination	No	2022	Standard approval	NCT04033354	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
137	Serplulimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Serplulimab combined with carboplatin and etoposide is suitable for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)	SCLC	Solid	No	Combination	No	2023	Standard approval	NCT04063163	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
138	Serplulimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Serplulimab combined with fluoropyrimidine and platinum drugs for the first-line treatment of PD-L1 positive, unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (ESCC)	EC	Solid	Yes	Combination	No	2023	Standard approval	NCT03958890	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
139	Penpulimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Indicated for adult patients with relapsed or refractory classical Hodgkin lymphoma who have received at least two lines of systemic chemotherapy	HL	Hematoma	No	Combination	No	2021	Conditional approval	NCT03722147	Advanced-stage Treatment	≥3-Line	Phasel/II	Nonrandomized	None	1 arm	ORR
140	Penpulimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Penpulimab combined with paclitaxel and carboplatin is indicated for first-line treatment of locally advanced or metastatic squamous NSCLC	NSCLC	Solid	No	Combination	No	2023	Standard approval	NCT03866993	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
141	Penpulimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	For the treatment of adult patients with recurrent/metastatic nasopharyngeal cancer who have failed prior second-line or higher systemic therapy	NPC	Solid	No	Combination	No	2024	Standard approval	NCT03866967	Advanced-stage Treatment	≥3-Line	Phase II	Nonrandomized	None	1 arm	ORR
142	Sorafenib	Po	small molecule	Targeted agents	Import	No	For the treatment of unresectable advanced renal cell carcinoma	RCC	Solid	No	Combination	Yes	2006	not available	NCT00073307	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
143	Sorafenib	Po	small molecule	Targeted agents	Import	No	For the treatment of unresectable or metastatic hepatocellular carcinoma	HCC	Solid	No	Combination	Yes	2008	not available	NCT00105443	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
144	Sorafenib	Po	small molecule	Targeted agents	Import	No	For the treatment of locally recurrent or metastatic progressive radioiodine-refractory differentiated thyroid cancer	TC	Solid	No	Combination	Yes	2017	not available	NCT00984282	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	PFS
145	Regorafenib	Po	small molecule	Targeted agents	Import	No	For metastatic colorectal cancer (mCRC) patients previously treated with fluoropyrimidines, oxaliplatin, and irinotecan, and those unsuitable for or previously treated with anti-VEGF or anti-EGFR (RAS wild-type) therapy	CRC	Solid	No	Combination	Yes	2017	Special approval	NCT01103323	Advanced-stage Treatment	≥3-Line	Phase III	Randomized	Double-blind	2 arms	OS
146	Regorafenib	Po	small molecule	Targeted agents	Import	No	Indicated for locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) patients who have previously received imatinib mesylate and sunitinib malate treatment	GC	Solid	No	Combination	Yes	2017	Special approval	NCT01271712	Advanced-stage Treatment	≥3-Line	Phase III	Randomized	Double-blind	2 arms	PFS
147	Regorafenib	Po	small molecule	Targeted agents	Import	No	Indicated for hepatocellular carcinoma (HCC) patients who have previously received sorafenib treatment	HCC	Solid	No	Combination	Yes	2017	not available	NCT01774344	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	OS
148	Lenvatinib	Po	small molecule	Targeted agents	Import	No	Monotherapy is indicated for unresectable hepatocellular carcinoma patients who have not previously received systemic treatment	HCC	Solid	No	Combination	Yes	2018	Special approval	NCT01761266	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS

No.	Generic name	Delivery route	Product type	Mechanism of action	Origin country	Exclusive production	Indication	Classification of Indications	Cancer type	Biomarker	Treatment type	Reimbursed	Year of indication approval	Approval type	Clinical trial	Phase of treatment	Line	Clinical trial phase	Allocation	Masking	Arms	Primary Outcome
149	Lenvatinib	Po	small molecule	Targeted agents	Import	No	Indicated for patients with progressive, locally advanced, or metastatic radioiodine-refractory differentiated thyroid cancer	TC	Solid	No	Combination	Yes	2020	Standard approval	NCT01321554	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
150	Donafenib	Po	small molecule	Targeted agents	Domestic	Yes	Indicated for unresectable hepatocellular carcinoma patients who have not previously received systemic treatment	HCC	Solid	No	Combination	Yes	2021	Priority approval	NCT02645981	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS
151	Donafenib	Po	small molecule	Targeted agents	Domestic	Yes	Indicated for patients with progressive, locally advanced, or metastatic radioiodine-refractory differentiated thyroid cancer	TC	Solid	No	Combination	Yes	2022	Standard approval	NCT03602495	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
152	Trastuzumab	Iv	monoclonal antibody	Targeted agents	Import	No	Indicated for HER2-overexpressing metastatic breast cancer: in combination with paclitaxel or docetaxel, for metastatic breast cancer patients who have not received chemotherapy	BC	Solid	Yes	Combination	Yes	2002	not available	not available	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	TTP
153	Trastuzumab	Iv	monoclonal antibody	Targeted agents	Import	No	Indicated for HER2-overexpressing metastatic breast cancer: as a monotherapy for metastatic breast cancer patients who have received one or more prior chemotherapy regimens	BC	Solid	Yes	Combination	Yes	2002	not available	not available	Advanced-stage Treatment	2-Line & 3-Line	Phase III	Nonrandomized	None	1 arm	ORR
154	Trastuzumab	Iv	monoclonal antibody	Targeted agents	Import	No	Indicated for HER2-positive early breast cancer	BC	Solid	Yes	Combination	Yes	2002	not available	not available	Adjuvant Therapy	/	Phase III	Randomized	None	2 arms	DFS
155	Trastuzumab	Iv	monoclonal antibody	Targeted agents	Import	No	Trastuzumab with capecitabine or 5-FU and cisplatin for HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma patients without prior metastatic treatment	GC	Solid	Yes	Combination	Yes	2012	not available	NCT01041404	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS
156	Apatinib	Po	small molecule	Targeted agents	Domestic	Yes	Monotherapy is indicated for advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma patients who have progressed or relapsed after receiving at least two prior lines of systemic chemotherapy	GC	Solid	No	Combination	Yes	2014	Special approval	NCT01512745	Advanced-stage Treatment	≥3-Line	Phase III	Randomized	Double-blind	2 arms	OS
157	Apatinib	Po	small molecule	Targeted agents	Domestic	Yes	Monotherapy for patients with advanced hepatocellular carcinoma who have failed or were intolerant to at least one prior line of systemic therapy	HCC	Solid	No	Combination	Yes	2020	Standard approval	NCT02329860	Advanced-stage Treatment	2-Line & 3-Line	Phase III	Randomized	Double-blind	2 arms	OS
158	Apatinib	Po	small molecule	Targeted agents	Domestic	Yes	Apatinib combined with carrelizumab injection for first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma	HCC	Solid	No	Combination	Yes	2023	Standard approval	NCT03764293	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS
159	Disitamab Vedotin	Iv	ADC	Targeted agents	Domestic	Yes	For patients with HER2 overexpressing locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two prior systemic chemotherapies	GC	Solid	Yes	Combination	Yes	2021	Conditional approval	NCT03556345	Advanced-stage Treatment	≥3-Line	Phase II	Nonrandomized	None	1 arm	ORR
160	Disitamab Vedotin	Iv	ADC	Targeted agents	Domestic	Yes	Indicated for patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-based chemotherapy and have HER2 overexpression	UC	Solid	Yes	Combination	Yes	2021	Special approval	NCT03809013 &NCT03507166	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
161	Disitamab Vedotin	Iv	ADC	Targeted agents	Domestic	Yes	Disitamab Vedotin combined with toripalimab injection is indicated for perioperative treatment of muscle-invasive bladder cancer	Bladder Cancer	Solid	No	Combination	No	2024	Breakthrough approval	NCT05297552	Neoadjuvant Therapy	/	Phase II	Nonrandomized	None	1 arm	ORR
162	Ramucirumab	Iv	monoclonal antibody	Targeted agents	Import	Yes	Ramucirumab combined with paclitaxel for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma patients who have disease progression during or after fluoropyrimidine- or platinum-containing chemotherapy	GC	Solid	No	Combination	No	2022	Standard approval	NCT01170663	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	OS
163	Ramucirumab	Iv	monoclonal antibody	Targeted agents	Import	Yes	Monotherapy for the treatment of hepatocellular carcinoma patients who have previously received sorafenib treatment and have an alpha-fetoprotein level of ≥400ng/mL	HCC	Solid	No	Combination	No	2022	Standard approval	NCT02435433	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	OS
164	Imatinib	Po	small molecule	Targeted agents	Import	No	Indicated for the treatment of chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML)	LEUK	Hematoma	No	Combination	Yes	2002	not available	not available	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	progression
165	Imatinib	Po	small molecule	Targeted agents	Import	No	Indicated for the treatment of accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML)	LEUK	Hematoma	No	Combination	Yes	2002	not available	not available	Advanced-stage Treatment	1-Line	Phase II	Nonrandomized	None	2 arms	Hematologic response
166	Imatinib	Po	small molecule	Targeted agents	Import	No	Indicated for the treatment of blast crisis Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML)	LEUK	Hematoma	No	Combination	Yes	2002	not available	not available	Advanced-stage Treatment	1-Line	Phase II	Nonrandomized	None	2 arms	Hematologic response
167	Imatinib	Po	small molecule	Targeted agents	Import	No	Indicated for the treatment of adult patients with unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST)	GC	Solid	No	Combination	Yes	2003	not available	not available	Advanced-stage Treatment	1-Line	Phase II	Randomized	None	2 arms	objective responses

No.	Generic name	Delivery route	Product type	Mechanism of action	Origin country	Exclusive production	Indication	Classification of Indications	Cancer type	Biomarker	Treatment type	Reimbursed	Year of indication approval	Approval type	Clinical trial	Phase of treatment	Line	Clinical trial phase	Allocation	Masking	Arms	Primary Outcome
168	Imatinib	Po	small molecule	Targeted agents	Import	No	Imatinib combined with chemotherapy is indicated for the treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in pediatric patients	LEUK	Hematoma	Yes	Combination	Yes	not available	not available	not available	Advanced-stage Treatment	1-Line	Phase III	Nonrandomized	None	≥3 arms	EFS
169	Imatinib	Po	small molecule	Targeted agents	Import	No	Indicated for the treatment of relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adult patients	LEUK	Hematoma	Yes	Combination	Yes	not available	not available	not available	Advanced-stage Treatment	2-Line & 3-Line	Phase II	not available	None	≥3 arms	Hematologic response
170	Imatinib	Po	small molecule	Targeted agents	Import	No	Indicated for the treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα fusion kinase	LEUK	Hematoma	Yes	Combination	Yes	not available	not available	not available	Advanced-stage Treatment	1-Line	Phase II	Nonrandomized	None	1 arm	activity with tumor response
171	Imatinib	Po	small molecule	Targeted agents	Import	No	Indicated for the treatment of adult patients with myelodysplastic syndromes/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements	LEUK	Hematoma	Yes	Combination	Yes	not available	not available	not available	Advanced-stage Treatment	1-Line	Phase II	Nonrandomized	None	1 arm	activity with tumor response
172	Imatinib	Po	small molecule	Targeted agents	Import	No	Indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM) without D816V c-Kit gene mutation or with unknown c-Kit gene mutation	LEUK	Hematoma	Yes	Combination	Yes	not available	not available	not available	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	activity with tumor response
173	Imatinib	Po	small molecule	Targeted agents	Import	No	Indicated for the treatment of unresectable, recurrent, or metastatic dermatofibrosarcoma protuberans (DFSP)	BSTT	Solid	No	Combination	Yes	2010	not available	not available	Advanced-stage Treatment	1-Line	Phase II	Nonrandomized	None	1 arm	activity with tumor response
174	Imatinib	Po	small molecule	Targeted agents	Import	No	Indicated for adjuvant treatment of adult patients with Kit (CD117)-positive GIST who have a significant risk of recurrence after surgical resection. Patients with very low and low recurrence risk should not receive this adjuvant treatment	GC	Solid	Yes	Combination	Yes	not available	not available	NCT00041197	Adjuvant Therapy	/	Phase III	Randomized	Double-blind	2 arms	RFS
175	Sunitinib	Po	small molecule	Targeted agents	Import	No	For advanced renal cell carcinoma (RCC) that cannot be treated with surgery	RCC	Solid	No	Combination	Yes	2007	not available	NCT00083889	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
176	Sunitinib	Po	small molecule	Targeted agents	Import	No	Indicated for gastrointestinal stromal tumors (GIST) in patients who have failed or are intolerant to imatinib mesylate treatment	GC	Solid	No	Combination	Yes	2007	not available	NCT00075218	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	TTP
177	Sunitinib	Po	small molecule	Targeted agents	Import	No	Indicated for adult patients with unresectable, metastatic, well-differentiated, advanced pancreatic neuroendocrine tumors (pNET)	NET	Solid	No	Combination	Yes	2013	not available	NCT00428597	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	PFS
178	Cetuximab	Iv	monoclonal antibody	Targeted agents	Import	No	For RAS wild-type metastatic colorectal cancer: combined with FOLFOX or FOLFIRI for first-line treatment, and with irinotecan after irinotecan-based therapy failure	CRC	Solid	Yes	Combination	Yes	2019	Standard approval	NCT01228734	Advanced-stage Treatment	All Line	Phase III	Randomized	None	2 arms	PFS
179	Cetuximab	Iv	monoclonal antibody	Targeted agents	Import	No	Cetuximab combined with platinum-based chemotherapy and fluoropyrimidine is indicated for first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma	SCCHN	Solid	No	Combination	Yes	2020	Priority approval	NCT00122460	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	OS
180	Cetuximab	Iv	monoclonal antibody	Targeted agents	Import	No	Indicated for the treatment of head and neck squamous cell carcinoma: in combination with radiation therapy for locally advanced disease	SCCHN	Solid	No	Combination	Yes	2022	Standard approval	NCT00004227	Adjuvant Therapy	/	Phase III	Randomized	None	2 arms	Dsease control duration
181	Pucotenlimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	For unresectable or metastatic MSI-H or dMMR advanced solid tumors: including advanced colorectal cancer patients with progression after fluoropyrimidines, oxaliplatin, and irinotecan, and other advanced solid tumors with progression after at least one prior treatment and no satisfactory alternatives	MSI-H/dMMR	Solid	Yes	Combination	No	2022	Conditional approval	NCT03704246	Advanced-stage Treatment	≥3-Line	Phase II	Nonrandomized	None	1 arm	ORR
182	Pucotenlimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Indicated for unresectable or metastatic melanoma patients who have failed prior systemic therapy	MEL	Solid	No	Combination	No	2022	Conditional approval	NCT04749485	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
183	Nilotinib	Po	small molecule	Targeted agents	Import	No	Indicated for adult patients with chronic or accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) who are resistant or intolerant to prior treatment, including imatinib	LEUK	Hematoma	No	Combination	Yes	2009	not available	NCT00109707	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	2 arms	CML-CP; MCyR;
184	Nilotinib	Po	small molecule	Targeted agents	Import	No	Indicated for adult patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML)	LEUK	Hematoma	No	Combination	Yes	2016	not available	NCT00471497	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	≥3 arms	MMR
185	Nilotinib	Po	small molecule	Targeted agents	Import	No	Indicated for the treatment of chronic myelogenous leukemia in children aged 2 years and older	LEUK	Hematoma	No	Combination	Yes	2019	not available	NCT01844765	Advanced-stage Treatment	1-Line & 2-Line	Phase II	Nonrandomized	None	2 arms	MMR
186	Olverembatinib	Po	small molecule	Targeted agents	Domestic	Yes	Indicated for adult patients with chronic or accelerated phase chronic myelogenous leukemia (CML) who are resistant to any tyrosine kinase inhibitor and diagnosed with T315I mutation using a validated testing method	LEUK	Hematoma	Yes	Combination	Yes	2021	Conditional approval	NCT03883087 &NCT03883100	Advanced-stage Treatment	All Line	Phase II	Nonrandomized	None	1 arm	MaHR

No.	Generic name	Delivery route	Product type	Mechanism of action	Origin country	Exclusive production	Indication	Classification of Indications	Cancer type	Biomarker	Treatment type	Reimbursed	Year of indication approval	Approval type	Clinical trial	Phase of treatment	Line	Clinical trial phase	Allocation	Masking	Arms	Primary Outcome
187	Olverembatinib	Po	small molecule	Targeted agents	Domestic	Yes	Indicated for adult patients with chronic phase chronic myelogenous leukemia (CML) who are resistant to and/or intolerant of first- and second-generation tyrosine kinase inhibitors	LEUK	Hematoma	No	Combination	Yes	2023	Breakthrough approval	NCT04126681	Advanced-stage Treatment	≥3-Line	Phase II	Randomized	None	2 arms	EFS
188	Ibrutinib	Po	small molecule	Targeted agents	Import	No	Indicated as monotherapy for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy	NHL	Hematoma	No	Combination	Yes	2017	Priority approval	NCT01646021	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	PFS
189	Ibrutinib	Po	small molecule	Targeted agents	Import	No	Indicated as monotherapy for the treatment of treatment-naïve and relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients	NHL	Hematoma	No	Combination	Yes	2017	Priority approval	NCT01578707	Advanced-stage Treatment	1-Line & 2-Line	Phase III	Randomized	None	2 arms	PFS
190	Ibrutinib	Po	small molecule	Targeted agents	Import	No	Indicated as monotherapy for the treatment of Waldenström's macroglobulinemia patients who have received at least one prior therapy, or as first-line treatment for patients with Waldenström's macroglobulinemia who are not suitable for chemotherapy or immunotherapy	WM	Hematoma	No	Combination	Yes	2018	not available	NCT01614821	Advanced-stage Treatment	1-Line & 2-Line	Phase II	Nonrandomized	None	1 arm	ORR
191	Ibrutinib	Po	small molecule	Targeted agents	Import	No	Ibrutinib combined with rituximab is indicated for the treatment of patients with Waldenström's macroglobulinemia	WM	Hematoma	No	Combination	Yes	2018	not available	NCT02165397	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
192	Zanubrutinib	Po	small molecule	Targeted agents	Domestic	Yes	Indicated for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy	NHL	Hematoma	No	Combination	Yes	2020	Special approval	NCT03206970	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
193	Zanubrutinib	Po	small molecule	Targeted agents	Domestic	Yes	Indicated for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy	NHL	Hematoma	No	Combination	Yes	2020	Special approval	NCT03206918	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
194	Zanubrutinib	Po	small molecule	Targeted agents	Domestic	Yes	Indicated for adult patients with Waldenström's macroglobulinemia (WM) who have received at least one prior therapy	WM	Hematoma	No	Combination	Yes	2021	Conditional approval	NCT03332173	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
195	Zanubrutinib	Po	small molecule	Targeted agents	Domestic	Yes	Indicated as monotherapy for treatment-naïve adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)	NHL	Hematoma	No	Combination	Yes	2023	Standard approval	NCT03336333	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
196	Orelabrutinib	Po	small molecule	Immune regulators	Domestic	No	Indicated for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy	NHL	Hematoma	No	Combination	Yes	2020	Conditional approval	NCT03494179	Advanced-stage Treatment	2-Line	Phase II	Randomized	None	2 arms	ORR
197	Orelabrutinib	Po	small molecule	Immune regulators	Domestic	No	Indicated for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy	NHL	Hematoma	No	Combination	Yes	2020	Conditional approval	NCT03493217	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
198	Orelabrutinib	Po	small molecule	Immune regulators	Domestic	No	Indicated for adult patients with marginal zone lymphoma (MZL) who have received at least one prior therapy	NHL	Hematoma	No	Combination	Yes	2023	Conditional approval	NCT03797456	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
199	Bortezomib	Iv	small molecule	Targeted agents	Import	No	Bortezomib + melphalan + prednisone (MP regimen) for untreated multiple myeloma patients ineligible for high-dose chemotherapy and stem cell transplantation	MM	Hematoma	No	Combination	Yes	2005	not available	NCT00048230	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	TTP
200	Bortezomib	Iv	small molecule	Targeted agents	Import	No	Indicated for the treatment of relapsed multiple myeloma patients who have received at least one prior therapy	MM	Hematoma	No	Combination	Yes	2005	not available	NCT00111319	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	TTP
201	Bortezomib	Iv	small molecule	Targeted agents	Import	No	Indicated for the treatment of relapsed or refractory mantle cell lymphoma (MCL) patients who have received at least one prior therapy	NHL	Hematoma	No	Combination	Yes	2009	not available	NCT00063713	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
202	Bortezomib	Iv	small molecule	Targeted agents	Import	No	Bortezomib, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, is indicated for the treatment of previously untreated adult patients with mantle cell lymphoma (MCL) who are not candidates for hematopoietic stem cell transplantation	NHL	Hematoma	No	Combination	Yes	2018	not available	NCT00722137	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
203	Lenalidomide	Po	small molecule	Immune regulators	Import	No	Lenalidomide in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy	MM	Hematoma	No	Combination	Yes	2013	not available	NCT00056160	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	TTP
204	Lenalidomide	Po	small molecule	Immune regulators	Import	No	Lenalidomide in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have not received prior treatment and are not candidates for transplantation	MM	Hematoma	No	Combination	Yes	2017	Special approval	NCT00689936	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	≥3 arms	PFS
205	Lenalidomide	Po	small molecule	Immune regulators	Import	No	Lenalidomide in combination with rituximab is indicated for the treatment of adult patients with follicular lymphoma grades 1–3a who have received prior treatment	NHL	Hematoma	No	Combination	Yes	2020	Priority approval	NCT01938001	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	PFS-KM

No.	Generic name	Delivery route	Product type	Mechanism of action	Origin country	Exclusive production	Indication	Classification of Indications	Cancer type	Biomarker	Treatment type	Reimbursed	Year of indication approval	Approval type	Clinical trial	Phase of treatment	Line	Clinical trial phase	Allocation	Masking	Arms	Primary Outcome
206	Daratumumab	Iv	monoclonal antibody	Targeted agents	Import	Yes	Monotherapy is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received treatment including proteasome inhibitors and immunomodulatory agents, with disease progression at the last treatment	MM	Hematoma	No	Combination	Yes	2019	Special approval	NCT01985126	Advanced-stage Treatment	≥3-Line	Phase II	Randomized	None	1 arm	Overall Response
207	Daratumumab	Iv	monoclonal antibody	Targeted agents	Import	Yes	Daratumumab combined with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, is indicated for the treatment of adult patients with multiple myeloma who have previously received at least one line of therapy	MM	Hematoma	No	Combination	Yes	2021	Priority approval	NCT02136134	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	PFS
208	Daratumumab	Iv	monoclonal antibody	Targeted agents	Import	Yes	Daratumumab combined with lenalidomide and dexamethasone, or with bortezomib, melphalan, and prednisone, is indicated for the treatment of newly diagnosed multiple myeloma adult patients who are not candidates for autologous stem cell transplantation	MM	Hematoma	No	Combination	Yes	2021	Standard approval	NCT02195479	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
209	Blinatumomab	Iv	monoclonal antibody	Targeted agents	Import	Yes	Indicated for the treatment of adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia	LEUK	Hematoma	No	Combination	No	2020	Conditional approval	NCT02013167	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	OS
210	Blinatumomab	Iv	monoclonal antibody	Targeted agents	Import	Yes	Indicated for the treatment of pediatric patients with relapsed or refractory CD19-positive precursor B-cell acute lymphoblastic leukemia	LEUK	Hematoma	Yes	Combination	No	2022	Conditional approval	NCT02393859	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	EFS
211	Zimberelimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Indicated for adult patients with relapsed or refractory classic Hodgkin lymphoma who have received at least two lines of systemic chemotherapy	HL	Hematoma	No	Combination	Yes	2021	Conditional approval	NCT03655483	Advanced-stage Treatment	≥3-Line	Phase II	Nonrandomized	None	1 arm	ORR
212	Zimberelimab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Indicated for patients with relapsed or metastatic cervical cancer who have failed platinum-based chemotherapy and are PD-L1 positive (CPS≥1)	CC	Solid	Yes	Combination	Yes	2023	Conditional approval	NCT03972722	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
213	Rituximab	Iv	monoclonal antibody	Targeted agents	Import	No	Indicated for previously untreated CD20-positive stage III-IV follicular non-Hodgkin lymphoma patients, to be used in combination with chemotherapy	NHL	Hematoma	Yes	Combination	Yes	2000	not available	NCT00140582	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
214	Rituximab	Iv	monoclonal antibody	Targeted agents	Import	No	Indicated for the treatment of relapsed or chemotherapy-resistant follicular lymphoma	NHL	Hematoma	No	Combination	Yes	2000	not available	NCT00004179	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	Response to treatment
215	Rituximab	Iv	monoclonal antibody	Targeted agents	Import	No	CD20-positive diffuse large B-cell lymphoma (DLBCL) should be treated in combination with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) for 8 cycles	NHL	Hematoma	Yes	Combination	Yes	2000	not available	NCT00499018	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	DFS
216	Rituximab	Iv	monoclonal antibody	Targeted agents	Import	No	Monotherapy is used for maintenance treatment of follicular lymphoma patients who have achieved complete or partial remission after rituximab combined with chemotherapy	NHL	Hematoma	No	Combination	Yes	2019	Standard approval	NCT00140582	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
217	Rituximab	Iv	monoclonal antibody	Targeted agents	Import	No	Rituximab combined with fludarabine and cyclophosphamide (FC) is used for the treatment of previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL) patients	LEUK	Hematoma	No	Combination	Yes	2019	Standard approval	NCT00281918	Advanced-stage Treatment	1-Line & 2-Line	Phase III	Randomized	None	2 arms	PFS
218	Polatuzumab Vedotin	Iv	ADC	Targeted agents	Import	Yes	Polatuzumab Vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone is indicated for the treatment of previously untreated adult patients with diffuse large B-cell lymphoma (DLBCL)	NHL	Hematoma	No	Combination	Yes	2023	Standard approval	NCT03274492	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
219	Polatuzumab Vedotin	Iv	ADC	Targeted agents	Import	Yes	Polatuzumab Vedotin combined with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for hematopoietic stem cell transplantation. Conditional approval was based on complete response rates and duration of response for relapsed or refractory DLBCL	NHL	Hematoma	No	Combination	Yes	2023	Conditional approval	NCT02257567	Advanced-stage Treatment	2-Line	Phase II	Randomized	None	2 arms	ORR
220	Brentuximab Vedotin	Iv	ADC	Targeted agents	Import	Yes	Indicated for the treatment of adult patients with CD30-positive lymphoma: relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)	NHL	Hematoma	No	Combination	Yes	2020	Priority approval	NCT00866047	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
221	Brentuximab Vedotin	Iv	ADC	Targeted agents	Import	Yes	Indicated for the treatment of adult patients with CD30-positive lymphoma: relapsed or refractory classical Hodgkin lymphoma (cHL)	HL	Hematoma	No	Combination	Yes	2020	Priority approval	NCT00848926	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR
222	Brentuximab Vedotin	Iv	ADC	Targeted agents	Import	Yes	Indicated for adult patients with CD30-positive primary cutaneous anaplastic large cell lymphoma (pcALCL) or mycosis fungoides (MF) who have previously received systemic therapy	NHL	Hematoma	Yes	Combination	Yes	2021	Standard approval	NCT01578499	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	ORR
223	Chidamide	Po	small molecule	Targeted agents	Domestic	Yes	Indicated for adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who have received at least one prior systemic chemotherapy	NHL	Hematoma	No	Combination	Yes	2014	Special approval	NCT05833724	Advanced-stage Treatment	2-Line	Phase II	Nonrandomized	None	1 arm	ORR

No.	Generic name	Delivery route	Product type	Mechanism of action	Origin country	Exclusive production	Indication	Classification of Indications	Cancer type	Biomarker	Treatment type	Reimbursed	Year of indication approval	Approval type	Clinical trial	Phase of treatment	Line	Clinical trial phase	Allocation	Masking	Arms	Primary Outcome
224	Chidamide	Po	small molecule	Targeted agents	Domestic	Yes	Chidamide + aromatase inhibitors is indicated for postmenopausal HR-positive, HER2-negative locally advanced or metastatic breast cancer patients with recurrence or progression after endocrine therapy	BC	Solid	Yes	Combination	No	2019	Priority approval	NCT02482753	Advanced-stage Treatment	≥3-Line	Phase III	Randomized	Double-blind	2 arms	PFS
225	Abiraterone	Po	small molecule	Targeted agents	Import	No	Abiraterone, in combination with prednisone or prednisolone, is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC)	PCa	Solid	No	Combination	Yes	2015	Standard approval	NCT00638690	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
226	Abiraterone	Po	small molecule	Targeted agents	Import	No	Abiraterone acetate, in combination with prednisone or prednisolone, is indicated for the treatment of newly diagnosed high-risk metastatic endocrine-sensitive prostate cancer, including patients who have not received endocrine therapy or have received endocrine therapy for no more than 3 months	PCa	Solid	No	Combination	Yes	2018	Priority approval	NCT01715285	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
227	Apalutamide	Po	small molecule	Targeted agents	Import	No	Indicated for the treatment of adult patients with high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC)	PCa	Solid	No	Combination	Yes	2019	Priority approval	NCT01946204	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	MFS
228	Apalutamide	Po	small molecule	Targeted agents	Import	No	Indicated for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC)	PCa	Solid	No	Combination	Yes	2020	Priority approval	NCT02489318	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
229	Enzalutamide	Po	small molecule	Targeted agents	Import	No	Indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic and have not received chemotherapy after failure of androgen deprivation therapy	PCa	Solid	No	Combination	Yes	2019	Priority approval	NCT01212991	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	OS
230	Enzalutamide	Po	small molecule	Targeted agents	Import	No	Indicated for adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis	PCa	Solid	No	Combination	Yes	2020	Priority approval	NCT02003924	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	MFS
231	Enzalutamide	Po	small molecule	Targeted agents	Import	No	Indicated for metastatic hormone-sensitive prostate cancer (mHSPC)	PCa	Solid	No	Combination	Yes	2024	Standard approval	NCT02677896	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	rPFS
232	Darolutamide	Po	small molecule	Targeted agents	Import	Yes	Indicated for the treatment of adult patients with high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC)	PCa	Solid	No	Combination	Yes	2021	Priority approval	NCT02200614	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	MFS
233	Darolutamide	Po	small molecule	Targeted agents	Import	Yes	Darolutamide in combination with docetaxel is indicated for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC)	PCa	Solid	No	Combination	Yes	2023	Standard approval	NCT02799602	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS
234	Olaparib	Po	small molecule	Targeted agents	Import	No	Monotherapy is indicated for the maintenance treatment of adult patients with platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have achieved complete or partial response after platinum-based chemotherapy	OC&TC&PC	Solid	No	Combination	Yes	2018	Special approval	NCT01874353	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	PFS
235	Olaparib	Po	small molecule	Targeted agents	Import	No	Indicated for the maintenance treatment of adult patients with germline or somatic BRCA-mutated advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have achieved complete or partial response after first-line platinum-based chemotherapy	OC&TC&PC	Solid	Yes	Combination	Yes	2019	Priority approval	NCT01844986	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	PFS
236	Olaparib	Po	small molecule	Targeted agents	Import	No	Indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who carry germline or somatic BRCA mutations (gBRCAm or sBRCAm) and have previously failed treatment, including with a novel endocrine therapy	PCa	Solid	Yes	Combination	Yes	2021	Conditional approval	NCT02987543	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	rPFS
237	Olaparib	Po	small molecule	Targeted agents	Import	No	Olaparib in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who are homologous recombination repair-deficient (HRD-positive) and have achieved a complete or partial response to first-line platinum-based chemotherapy combined with bevacizumab	OC&TC&PC	Solid	No	Combination	Yes	2022	Standard approval	NCT02477644	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	OS
238	Trastuzumab Emtansine	Iv	ADC	Targeted agents	Import	Yes	Adjuvant treatment for breast cancer: Monotherapy is indicated for HER2-positive early breast cancer patients who have residual invasive disease after receiving neoadjuvant therapy with taxane combined with trastuzumab	BC	Solid	Yes	Combination	Yes	2020	Priority approval	NCT01772472	Adjuvant Therapy	/	Phase III	Randomized	None	2 arms	IDFS
239	Trastuzumab Emtansine	Iv	ADC	Targeted agents	Import	Yes	Metastatic breast cancer treatment: Monotherapy is indicated for HER2-positive, unresectable locally advanced or metastatic breast cancer patients who have received treatment with taxane and trastuzumab. The patient should meet one of the following conditions: previously received treatment for locally advanced or metastatic breast cancer, or experienced disease recurrence within 6 months after adjuvant treatment or during the course of adjuvant therapy	BC	Solid	Yes	Combination	Yes	2021	Standard approval	NCT00829166	Advanced-stage Treatment	≥3-Line	Phase III	Randomized	None	2 arms	OS & PFS

No.	Generic name	Delivery route	Product type	Mechanism of action	Origin country	Exclusive production	Indication	Classification of Indications	Cancer type	Biomarker	Treatment type	Reimbursed	Year of indication approval	Approval type	Clinical trial	Phase of treatment	Line	Clinical trial phase	Allocation	Masking	Arms	Primary Outcome
240	Pertuzumab	Iv	monoclonal antibody	Targeted agents	Import	No	Indicated for adjuvant treatment in HER2-positive early breast cancer patients with high recurrence risk, in combination with trastuzumab and chemotherapy	BC	Solid	Yes	Combination	Yes	2018	Standard approval	NCT01358877	Adjuvant Therapy	/	Phase III	Randomized	Double-blind	2 arms	IDFS
241	Pertuzumab	Iv	monoclonal antibody	Targeted agents	Import	No	Indicated for neoadjuvant treatment in HER2-positive, locally advanced, inflammatory, or early breast cancer patients (with tumors >2 cm or lymph node-positive), in combination with trastuzumab and chemotherapy, as part of the overall treatment plan for early breast cancer	BC	Solid	Yes	Combination	Yes	2019	Priority approval	NCT02586025	Neoadjuvant Therapy	/	Phase III	Randomized	Double-blind	2 arms	tpCR
242	Pertuzumab	Iv	monoclonal antibody	Targeted agents	Import	No	Pertuzumab, in combination with trastuzumab and docetaxel, is indicated for HER2-positive patients with metastatic disease who have not previously received HER2-targeted treatment or chemotherapy for metastatic or unresectable locally recurrent breast cancer	BC	Solid	Yes	Combination	No	2019	Priority approval	NCT00567190	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
243	Trastuzumab Deruxtecan	Iv	ADC	Targeted agents	Import	Yes	Monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received one or more HER2-targeted therapies	BC	Solid	Yes	Combination	Yes	2023	Priority approval	NCT03529110	Advanced-stage Treatment	≥3-Line	Phase III	Randomized	None	2 arms	PFS
244	Trastuzumab Deruxtecan	Iv	ADC	Targeted agents	Import	Yes	Monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC1+ or IHC2+/ISH-) breast cancer who have previously received at least one systemic therapy during the metastatic disease phase, or who experienced disease recurrence within 6 months after adjuvant chemotherapy or during the course of adjuvant chemotherapy	BC	Solid	Yes	Combination	Yes	2023	Standard approval	NCT03734029	Advanced-stage Treatment	2-Line	Phase III	Randomized	None	2 arms	PFS
245	Pyrotinib	Po	small molecule	Targeted agents	Domestic	Yes	Pyrotinib in combination with capecitabine is indicated for the treatment of HER2-positive, recurrent or metastatic breast cancer patients who have not received or have previously received trastuzumab. Prior to the use of pyrotinib, patients should have received anthracycline or taxane-based chemotherapy	BC	Solid	Yes	Combination	Yes	2018	Special approval	NCT02422199	Advanced-stage Treatment	2-Line	Phase II	Randomized	None	2 arms	ORR
246	Pyrotinib	Po	small molecule	Targeted agents	Domestic	Yes	Pyrotinib in combination with trastuzumab and docetaxel is indicated for neoadjuvant treatment of HER2-positive early or locally advanced breast cancer patients	BC	Solid	Yes	Combination	Yes	2022	Conditional approval	NCT03588091	Neoadjuvant Therapy	/	Phase III	Randomized	Double-blind	2 arms	ORR
247	Pyrotinib	Po	small molecule	Targeted agents	Domestic	Yes	Pyrotinib in combination with trastuzumab and docetaxel is indicated for the treatment of HER2-positive, advanced-stage, recurrent or metastatic breast cancer patients who have not previously received anti-HER2 therapy	BC	Solid	Yes	Combination	Yes	2023	Priority approval	NCT03863223	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
248	Abemaciclib	Po	small molecule	Targeted agents	Import	Yes	Abemaciclib in combination with aromatase inhibitors is indicated as initial endocrine therapy for postmenopausal HR-positive, HER2-negative, locally advanced or metastatic breast cancer patients	BC	Solid	Yes	Combination	Yes	2020	Priority approval	NCT02246621	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
249	Abemaciclib	Po	small molecule	Targeted agents	Import	Yes	Abemaciclib in combination with fulvestrant is indicated for HR-positive, HER2-negative, locally advanced or metastatic breast cancer patients who have progressed after previous endocrine therapy	BC	Solid	Yes	Combination	Yes	2020	Priority approval	NCT02107703	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	PFS
250	Abemaciclib	Po	small molecule	Targeted agents	Import	Yes	Abemaciclib in combination with endocrine therapy (tamoxifen or aromatase inhibitors) is indicated for adjuvant treatment of HR-positive, HER2-negative, lymph node-positive, high-risk early breast cancer adult patients with Ki-67 ≥ 20%	BC	Solid	Yes	Combination	Yes	2021	Standard approval	NCT03155997	Adjuvant Therapy	/	Phase III	Randomized	None	2 arms	IDFS
251	Dalpiciclib	Po	small molecule	Targeted agents	Domestic	Yes	Dalpiciclib in combination with fulvestrant is indicated for patients who have experienced disease progression after prior endocrine therapy	BC	Solid	No	Combination	Yes	2021	Priority approval	NCT03927456	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	PFS
252	Dalpiciclib	Po	small molecule	Targeted agents	Domestic	Yes	Indicated for patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer: to be used in combination with an aromatase inhibitor as initial endocrine therapy.	BC	Solid	Yes	Combination	Yes	2023	Standard approval	NCT03966898	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
253	Ribociclib	Po	small molecule	Targeted agents	Import	Yes	Indicated for use in combination with an aromatase inhibitor as initial endocrine therapy for premenopausal or perimenopausal women with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer. When using endocrine therapy, it should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist	BC	Solid	Yes	Combination	Yes	2023	Standard approval	NCT02278120	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
254	Ribociclib	Po	small molecule	Targeted agents	Import	Yes	Indicated for use in postmenopausal women with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine therapy	BC	Solid	Yes	Combination	Yes	2023	Standard approval	NCT01958021	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	PFS
255	Denosumab	Iv	monoclonal antibody	Immune regulators	Import	No	Indicated for the treatment of unresectable or surgically resectable bone giant cell tumors that could cause severe functional impairment, including adult patients and adolescents with skeletal maturity (defined as at least one mature long bone and body weight ≥ 45kg)	BSTT	Solid	No	Combination	Yes	2019	Priority approval	NCT00680992	Advanced-stage Treatment	1-Line	Phase II	Nonrandomized	None	1 arm	ORR

No.	Generic name	Delivery route	Product type	Mechanism of action	Origin country	Exclusive production	Indication	Classification of Indications	Cancer type	Biomarker	Treatment type	Reimbursed	Year of indication approval	Approval type	Clinical trial	Phase of treatment	Line	Clinical trial phase	Allocation	Masking	Arms	Primary Outcome
256	Denosumab	Iv	monoclonal antibody	Immune regulators	Import	No	Indicated for the prevention of bone-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma	MM	Hematoma	No	Combination	Yes	2020	Standard approval	NCT00321464 &NCT01345019	Adjuvant Therapy	/	Phase III	Randomized	Double-blind	2 arms	noninferiority of SRE
257	Nimotuzumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Nimotuzumab in combination with radiotherapy is indicated for the treatment of stage III-IV nasopharyngeal carcinoma with positive EGFR gene expression	NPC	Solid	Yes	Combination	Yes	2008	not available	not available	Advanced-stage Treatment	1-Line	Phase II	Randomized	None	2 arms	ORR
258	Nimotuzumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Nimotuzumab in combination with gemcitabine is indicated for the treatment of K-Ras wild-type locally advanced or metastatic pancreatic cancer	PC	Solid	Yes	Combination	No	2023	Standard approval	NCT00561990	Advanced-stage Treatment	2-Line	PhaseIIb/IIIa	Randomized	Double-blind	2 arms	OS
259	Nimotuzumab	Iv	monoclonal antibody	Immune regulators	Domestic	Yes	Nimotuzumab in combination with concurrent chemoradiotherapy is indicated for the treatment of locally advanced head and neck squamous cell carcinoma	SCCHN	Solid	No	Combination	Yes	2024	Standard approval	not available	Advanced-stage Treatment	1-Line	Phase III	Randomized	None	2 arms	PFS
260	Niraparib	Po	small molecule	Targeted agents	Import	No	Indicated for the maintenance treatment of adult patients with platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, following platinum-based chemotherapy achieving a complete or partial response	OC&TC&PC	Solid	No	Combination	Yes	2019	Special approval	NCT01847274	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	PFS
261	Niraparib	Po	small molecule	Targeted agents	Import	No	Indicated for the maintenance treatment of adult patients with advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have achieved a complete or partial response after first-line platinum-based chemotherapy	OC&TC&PC	Solid	No	Combination	Yes	2020	Priority approval	NCT02655016	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	PFS
262	Fluzoparib	Po	small molecule	Targeted agents	Domestic	Yes	Indicated for the treatment of platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with germline BRCA mutations who have received at least second-line chemotherapy	OC&TC&PC	Solid	Yes	Combination	Yes	2020	Special approval	NCT03509636	Advanced-stage Treatment	≥3-Line	Phaselb	Nonrandomized	None	1 arm	ORR
263	Fluzoparib	Po	small molecule	Targeted agents	Domestic	Yes	Indicated for maintenance treatment of platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in adult patients who have achieved a complete or partial response after platinum-based chemotherapy	OC&TC&PC	Solid	No	Combination	Yes	2021	Priority approval	NCT03863860	Advanced-stage Treatment	2-Line	Phase III	Randomized	Double-blind	2 arms	PFS
264	Candonilimab	Iv	monoclonal antibody	Targeted agents	Domestic	Yes	Indicated for the treatment of recurrent or metastatic cervical cancer in patients who have previously failed platinum-based chemotherapy	CC	Solid	No	Combination	Yes	2022	Conditional approval	NCT04380805	Advanced-stage Treatment	2-Line	PhaseIb/II	Nonrandomized	None	1 arm	ORR
265	Candonilimab	Iv	monoclonal antibody	Targeted agents	Domestic	Yes	Candonilimab in combination with XELOX (oxaliplatin and capecitabine) is indicated for first-line treatment of unresectable locally advanced, recurrent, or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma	GC	Solid	No	Combination	No	2024	Standard approval	NCT05008783	Advanced-stage Treatment	1-Line	Phase III	Randomized	Double-blind	2 arms	OS

Table S4. Excluded Non-anticancer Indications and A List of Car-T cell Therapies

Hematologic tumor drugs	
No.	**Drug Name**
1	Thalidomide
2	Equecabtagene Autoleucel
3	Axicabtagene Ciloleucel
4	Relmacabtagene Autoleucel

Table S5. List of Excluded Novel Single-indication Anti-cancer Drugs for Indications and Clinical Trials

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	NCT	Clinical trial phase	Allocation	Masking	Arms
1	1	Gefitinib	1	2004	For use in locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitive mutations in the epidermal growth factor receptor (EGFR) gene	Single	NCT00322452	Phase III	Randomized	None	2 arms
9	5	Dacomitinib	1	2019	Monotherapy for first-line treatment of advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation	Single	NCT01774721	Phase III	Randomized	None	2 arms
17	9	Befotertinib	1	2023	For treating adults with advanced NSCLC harboring EGFR T790M mutation who have progressed on or after EGFR-TKI therapy	Single	NCT03861156	Phase II	Nonrandomized	None	1 arm
20	11	Alectinib	1	2018	For the treatment of patients with locally advanced or metastatic NSCLC who are ALK-positive	Single	NCT02075840	Phase III	Randomized	None	2 arms
25	14	Brigatinib	1	2022	For the treatment of patients with locally advanced or metastatic NSCLC who are ALK-positive	Single	NCT02737501	Phase III	Randomized	None	2 arms
36	18	Endostatin	1	2005	Combined with vinorelbine/cisplatin chemotherapy regimen for the treatment of newly diagnosed or relapsed stage III–IV NSCLC patients	Single	Not available	Not available	Not available	Not available	Not available
52	23	Savolitinib	1	2021	For adults with advanced metastatic NSCLC with MET exon 14 mutation who progressed or are intolerant to platinum-based chemotherapy	Single	NCT02897479	Phase II	Nonrandomized	None	1 arm
53	24	Glumetinib	1	2023	For the treatment of locally advanced or metastatic NSCLC with MET exon 14 skipping mutation	Single	NCT04270591	Phase Ib/II	Nonrandomized	None	1 arm
63	28	Mobocertinib	1	2023	For adults with advanced NSCLC harboring EGFR exon 20 insertion mutation who progressed during or after platinum-based chemotherapy	Single	NCT02716116	PhaseI & II	Nonrandomized	None	1 arm
151	41	Adebrelimab	1	2023	Combined with carboplatin and etoposide for first-line treatment of patients with extensive-stage small cell lung cancer	Single	NCT03711305	Phase Ⅲ	Randomized	Double-blind	2 arms
188	52	Avapritinib	1	2021	For the treatment of adult patients with unresectable or metastatic GIST harboring PDGFRA exon 18 (including D842V) mutations	Single	NCT02508532	Phase I	Nonrandomized	None	1 arm
189	53	Ripretinib	1	2021	For the treatment of adult patients with advanced GIST who have received three or more tyrosine kinase inhibitors, including imatinib	Single	NCT03353753	Phase III	Randomized	Double-blind	2 arms
190	54	Surufatinib	1	2020	For the treatment of unresectable advanced or metastatic non-pancreatic G1/G2 non-functional neuroendocrine tumors	Single	NCT02588170	Phase III	Randomized	Double-blind	2 arms
194	56	Fruquintinib	1	2018	Monotherapy for mCRC patients who have received chemotherapy and are unsuitable for anti-VEGF or anti-EGFR (RAS wild-type) therapies	Single	NCT02314819	Phase III	Randomized	Double-blind	2 arms
195	57	Envafolimab	1	2021	For the treatment of adult patients with unresectable or metastatic MSI-H/dMMR advanced solid tumors, including: Advanced colorectal cancer that progressed after fluoropyrimidine, oxaliplatin, and irinotecan treatment; Other advanced solid tumors that progressed with no alternative options	Single	NCT03667170	Phase II	Nonrandomized	None	1 arm
196	58	Larotrectinib	1	2022	For adult and pediatric patients with solid tumors confirmed to have non-resistant NTRK fusions, who have locally advanced/metastatic disease or high surgical risk, and no satisfactory alternative treatment	Single	NCT02122913/NCT02637687/NCT02576431	Phase I/II	Nonrandomized	None	1 arm
199	60	Pemigatinib	1	2022	For adult patients with advanced cholangiocarcinoma who have received systemic therapy and tested positive for FGFR2 fusions/rearrangements	Single	NCT02924376	Phase II	Nonrandomized	None	1 arm
200	61	Dasatinib	1	2011	For the treatment of adult patients with Ph+ CML in the chronic, accelerated, or blast phase who are resistant or intolerant to imatinib	Single	NCT00123474	Phase III	Randomized	None	≥3 arms
206	64	Flumatinib	1	2019	For the treatment of adult patients with Ph+ CML in the chronic phase	Single	NCT02204644	Phase III	Randomized	None	2 arms
222	69	Carfilzomib	1	2021	With dexamethasone for adults with relapsed/refractory multiple myeloma after two or more treatments	Single	NCT03029234	Phase III	Nonrandomized	None	1 arm
223	70	Ixazomib	1	2018	With lenalidomide and dexamethasone for adults with multiple myeloma after at least one prior treatment	Single	NCT01564537	Phase III	Randomized	Double-blind	2 arms
227	72	Pomalidomide	1	2020	Pomalidomide + dexamethasone for adults with relapsed/refractory multiple myeloma after ⩾2 treatments and progression within 60 days	Single	NCT01311687	Phase III	Randomized	None	2 arms

No.	Drug No.	Generic name	Indication No.	Year of indication approval	Indication	Single/Multiple Indications	NCT	Clinical trial phase	Allocation	Masking	Arms
231	74	Selinexor	1	2021	With dexamethasone for adults with relapsed/refractory multiple myeloma resistant to proteasome inhibitor, immunomodulator, and anti-CD38 antibody	Single	NCT02336815	Phase II	Nonrandomized	None	1 arm
232	75	Gilteritinib	1	2021	For adults with relapsed/refractory AML confirmed to have FLT3 mutation by validated testing	Single	NCT02421939	Phase III	Randomized	None	2 arms
233	76	Venetoclax	1	2020	With azacitidine for newly diagnosed AML adults ineligible for intensive induction chemotherapy due to comorbidities or age ⩾75	Single	NCT02993523	Phase III	Randomized	Double-blind	2 arms
234	77	Ivosidenib	1	2022	For adults with relapsed/refractory AML with an IDH1 mutation	Single	NCT02074839	Phase II	Nonrandomized	None	1 arm
244	81	Ripertamab	1	2022	For newly diagnosed adults with CD20+ DLBCL and IPI 0-2, in combination with standard CHOP chemotherapy	Single	NCT02772822	Phase III	Randomized	Single-blind	2 arms
245	82	Zuberitamab	1	2023	For adults with CD20+ diffuse large B-cell lymphoma, in combination with standard CHOP chemotherapy	Single	NCT03485118	Phase III	Randomized	Double-blind	2 arms
246	83	Obinutuzumab	1	2021	In combination with chemotherapy for newly diagnosed stage II with large tumors, stage III, or stage IV follicular lymphoma, followed by obinutuzumab maintenance after partial remission	Single	NCT01332968	Phase III	Randomized	None	2 arms
252	86	Inotuzumab Ozogamicin	1	2021	For adults with relapsed/refractory precursor B-cell acute lymphoblastic leukemia	Single	NCT01564784	Phase III	Randomized	None	2 arms
255	88	Linperlisib	1	2022	For adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies	Single	NCT04370405	Phase II	Nonrandomized	None	1 arm
256	89	Duvelisib	1	2022	For adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies	Single	NCT01882803	Phase II	Nonrandomized	None	1 arm
257	90	Ruxolitinib	1	2017	For adults with intermediate- or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF), to treat disease-related splenomegaly or symptoms	Single	NCT00952289	Phase III	Randomized	Double-blind	2 arms
258	91	Mogamulizumab	1	2022	Indicated for relapsed/refractory Sézary syndrome or advanced (Stage III/IV) mycosis fungoides in adults who have received systemic therapy	Single	NCT01728805	Phase III	Randomized	None	2 arms
259	92	Siltuximab	1	2021	Indicated for the treatment of adult patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative	Single	NCT01024036	Phase II	Randomized	Double-blind	2 arms
260	93	Pazopanib	1	2017	For first-line and post-cytokine therapy treatment of advanced renal cell carcinoma (RCC)	Single	NCT00334282	Phase III	Randomized	Double-blind	2 arms
261	94	Axitinib	1	2015	For adult patients with advanced renal cell carcinoma (RCC) who have progressed following prior treatment with one tyrosine kinase inhibitor (TKI) or cytokine therapy	Single	NCT00678392	Phase III	Randomized	None	2 arms
271	99	Rezvilutamide	1	2022	Indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with high tumor burden	Single	NCT03520478	Phase III	Randomized	None	2 arms
283	104	Inetetamab	1	2020	Indicated for the treatment of HER2-positive metastatic breast cancer (MBC) in combination with vinorelbine in patients who have previously received one or more prior chemotherapy regimens	Single	Not Available	Phase III	Randomized	None	2 arms
284	105	Lapatinib	1	2013	For HER2-overexpressing advanced or metastatic breast cancer (MBC), in combination with capecitabine, previously treated with anthracyclines, taxanes, and trastuzumab	Single	NCT00078572	Phase III	Randomized	None	2 arms
288	107	Neratinib	1	2020	For adult patients with HER2-positive early breast cancer, following enhanced adjuvant therapy after trastuzumab-based treatment	Single	NCT00878709	Phase III	Randomized	Double-blind	2 arms
289	108	Palbociclib	1	2018	For HR+/HER2- locally advanced or metastatic breast cancer (MBC) in postmenopausal women, in combination with an aromatase inhibitor (AI) as first-line endocrine therapy	Single	NCT01740427	Phase III	Randomized	Double-blind	2 arms
297	112	Sacituzumab Govitecan	1	2022	Indicated for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic therapies, with at least one for metastatic disease	Single	NCT01631552	Phase II	Nonrandomized	None	1 arm
298	113	Vemurafenib	1	2017	Indicated for the treatment of unresectable or metastatic melanoma with BRAF V600 mutation-positive status	Single	NCT01006980	Phase III	Randomized	None	2 arms
299	114	Sonidegib	1	2021	Indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) who are not candidates for surgery or radiation, or who have recurrent disease following surgery or radiation therapy	Single	NCT01327053	Phase II	Randomized	Double-blind	2 arms
309	119	Pamiparib	1	2021	Indicated for the treatment of patients with relapsed, advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer harboring a germline BRCA mutation, who have received two or more prior lines of chemotherapy	Single	NCT03333915	PhaseI/II	Nonrandomized	None	1 arm